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Introduction: Cardiovascular diseases remain a major cause of morbidity and mortality worldwide. There is a 
large number of patients who suffer from myocardial infarction (MI). However, the a hearts of majority of 
patients who survive an MI will undergo substantial changes that will lead to heart failure (HF). The aim of this 
work is to characterise post ischaemic cardiac remodelling in two different experimental models using rats and 
pigs. A clinical study was also planned to identify acute changes in the blood metabolome of patients undergoing 
primary percutaneous coronary intervention (PPCI) following ST elevation myocardial infarction (STEMI) and 
correlate with long term recovery. The obtained information will help in identifying targets for therapeutic 
interventions, which can reduce the likelihood of adverse cardiac remodelling, and therefore heart failure.   
Methods: Adult rats undergoing left anterior descending (LAD) coronary artery ligation and pigs with LAD 
coronary artery balloon occlusion were used in this work. SHAM operated rats and healthy pigs were used as 
control. After initiation of cardiac injury, the animals were monitored for 4 weeks before termination. Cardiac 
injury and function 4 weeks after interventions were assessed using echocardiography and cardiac proteins 
release in pigs. Hearts and blood samples were extracted and collected. Nuclear magnetic resonance 
spectroscopy was used to assess metabolic profile of blood and cardiac tissues. Cardiac energy metabolites were 
measured using high performance liquid chromatography. Cardiac protein and phospho-protein quantification 
were carried out using liquid chromatography tandem mass spectrometry. Histological analyses of infarcted and 
control hearts were conducted using light and electron microscopies to 
detect ultrastructural differences.  Ethical application and protocol for the clinical study were granted.  
Results: Post ischaemic cardiac remodelling in rodent and porcine hearts was associated with increased cardiac 
fibrosis and wall thickening of small to medium size arterioles. Ultrastructural analysis showed characteristics of 
ongoing structural remodelling in the extracellular matrix and the presence of fibroblasts and telocytes. There 
was disruption to mitochondrial cristae density and distribution. No significant changes were detected in cardiac 
energetics in infarcted and control tissues of rats and pigs. Proteomics and phosphoproteomics analyses 
revealed evidence of sustained oxidative stress and inflammation, in addition decrease of mitochondrial 
respiration and metabolism proteins, modification to calcium cycling, z disc and selected extracellular matrix 
proteins and collagen subtypes.  There was increase in certain metabolites with post ischaemic remodelling, 
mainly ketone bodies in rodents and porcine blood, and taurine in porcine cardiac tissues.  The clinical study was 
suspended due to Covid-19 pandemic. 
Conclusion: Post ischaemic cardiac remodelling is associated with substantial cellular, molecular and metabolic 
changes in rodent and porcine models of cardiac injury. Importantly, the increase in blood ketone bodies in both 
models, in addition to decreased porcine blood taurine level could potentially be investigated furthermore in 
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1.1 Overall impact of cardiovascular diseases 
 
Cardiovascular diseases (CVDs) are a leading cause of death globally, with an estimate of 17.9 million lives lost 
each year due to CVDs (World Health Organizition WHO). Ischaemic heart disease (IHD) and other diseases like 
stroke account for most of CVD deaths. In the United Kingdom, it has been estimated that 27% of deaths each 
year (nearly 160,000 deaths) is caused by or related to cardiovascular diseases (British Heart Foundation). 
Patients who survive previous heart attack will most likely suffer from deleterious sequela, i.e., Heart Failure, 
which will dramatically affect quality of life and increase risk of sudden cardiac death. As for 2019, there were 
around 900,000 patients who survived an episode of myocardial infarction and are living with heart failure 
(British Heart Foundation). Whereas several heterogenous aetiologies are attributed to heart failure, ischaemic 
heart disease, however, remains the most common cause (Vedin, Lam et al. 2017). Unfortunately, despite the 
recent advancements in reperfusion strategies such as percutaneous coronary intervention (PCI) and coronary 
artery bypass grafting (CABG) surgery, reperfusion substantially exacerbates the initial ischaemic injury, which 
manifests in decreased cardiac function and expansion of the infarct size in patients with coronary artery disease 
(CAD). Therefore, expansion of the current knowledge involving the pathophysiological changes contributing 
toward development of heart failure will assist in identifying new targets, designing new therapeutic 
interventions and modulating disease progression. 
This introduction will review basic knowledge and advances in our understanding of myocardial structure and 
metabolism in health and during ischaemia reperfusion injury (IRI). Additionally, this introduction will address 
key concepts related to cardiac remodelling following acute myocardial infarction (MI) and the use of 








1.2 Myocardial structure and metabolism 
1.2.1 Structure 
Mammalian cardiovascular system consists of heart which continuously pumps blood into pulmonary and 
systemic circulation through blood vessels. The heart itself consists of two atria and two ventricles, separated 
by muscular septum and valves as illustrated in figure 1.1. All the heart chambers contract and relax in a well-
coordinated manner to facilitate blood pumping into lungs or other organs. Right atrium receives deoxygenated 
blood from superior and inferior vena cavae, whereas oxygenated blood is carried through pulmonary veins into 
left atrium. During cardiac diastole, passive filling of blood into right and left ventricles from right and left atria 
occurs through tricuspid and mitral valves, respectively. Atria contract simultaneously to eject blood into right 
and left ventricles at the end of diastole, which takes around two thirds of the cardiac cycle. During systole, 
however, right ventricle ejects deoxygenated blood through pulmonary valve to pulmonary artery. Concurrently, 
left ventricle contracts against aortic valve, ejecting blood into the systemic circulation through via the aorta.  
Moreover, the heart function is tightly regulated through central neurological and endocrine mechanisms as 
well as regional autoregulatory responses to achieve homeostasis (Dampney 2016).  
 
The heart wall is made of three distinct layers: innermost endothelial layer, i.e., endocardium, intermediate 
muscular layer of myocardium and an outermost layer called epicardium. The pericardium consists of serous 
and fibrous layers, which surrounds the heart for protection and lubrication from pericardial fluid in the 
pericardial cavity. Myocardium constitutes the bulk of heart wall and contains cardiomyocytes, in which their 
structural arrangement is inseparable from their main contractile function. Cardiomyocytes occupy majority of 
cardiac volume (70–85%) and are arranged in in criss-crossing fashion, therefore reducing the longitudinal axis 
of the chamber to generate the maximum force to pump the blood out (Zhou and Pu 2016). As seen in figure 
Figure 1.1 The heart and its champers, and the side box showing different layers of cardiac wall. Adapted from 
Lumenlearning courses website. 
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1.2, the cardiac tissue include a variety of non-cardiomyocytes cells in addition to cardiomyocytes including 
smooth muscle cells (SMC), endothelial cells, fibroblasts, pericytes, and immune cells, e.g. macrophages, mast 
and T cells, and cardiac progenitor cells (Takeda and Manabe 2011). Spindle-shaped fibroblasts mediate fibrotic 
response and produce interstitial collagen, proteoglycans, and proteases. Endothelial cells play central role in 
release of growth factors and active substances modulating vascular tone, coagulation and inflammatory 
responses (Esper, Nordaby et al. 2006). Noncardiomyocytes normally resides in the heart stroma, however, 
massive infiltration of immune cells and fibroblasts occurs following cardiomyocytes death to mediate repair 
(Hinglais, Heudes et al. 1994). Electron micrographs of these different types of cells with their characteristic 
morphology are listed in table 1.1. Nonetheless, since adult cardiomyocytes are terminally differentiated, they 

































Table 1.1 Characteristics, function, and electron micrographs of selected cardiac connective tissue cells. 
 
 Cell Characteristics and function Electron micrograph Image Source 
Fibroblast Elongated cells of branched 
cytoplasm, elliptical nucleus with 
abundant rough endoplasmic 













Elongated spindle shape cells, 
involved in vascular remodelling and 
control lumen diameter of blood 
vessels. 
SMC, smooth muscle cell 
(Sciencephoto) 
Telocyte Stromal cells with dichotomous 
pattern of elongated extensions 
called telopdes, up to hundreds of 
microns in length. Involved in 
intercellular signalling and 
regeneration. 
TC, telocyte; Tp, telopodes 




Cells lining blood vessels, and 
endocardium and mediates various 
biological responses related to 




et al. 2015) 
Pericyte Their cellular extensions wrap 
around endothelial cells to control 
capillary blood flow. 
P., pericyte 
(Slideshare) 
Macrophage Antigen presentation, phagocytosis 











Cardiac myocyte is striated, branched, multi- nucleated cell where the nuclei are centrally located, however, like 
other striated skeletal muscle, each cell is composed of many fibres called myofibrils which contain functional 















Sarcomere, the fundamental contractile unit of the myocyte, is primarily made up of parallel overlapping 
arrangement of thick filaments, myosin, and thin actin filaments, as well as other structural protein elements 
(Farah and Reinach 1995). Figure 1.4 illustrates the areas and lines recognised within a sarcomere. A band 
(anisotropic) spans the length of the whole thick filaments. I band (isotropic) is the section which contains only 
thin filaments that are bound to z discs at the end of each sarcomere. An individual sarcomere, therefore, spans 















Figure 1.3 Longitudinal section of porcine myocardium stained with eosin and haematoxylin (H&E) stain, 








Cardiomyocytes must contract simultaneously for effective pumping, and this requirement is mediated through 
intercalated discs, which are located at the end of cardiomyocytes. These highly organized structures play an 
important role in intercellular signalling and simultaneous electrical coupling and contraction. As a result, cardiac 
myocytes work together as a single functional unit, or syncytium (Manring, Dorn et al. 2018).  
Intercalated discs, as illustrated in figure 1.5, are made of three components: gap junctions, desmosomes as well 
as adherens junctions. Adherens junction directly link the contractile proteins in one cardiomyocyte to the 
neighbouring cells, thus transmitting the contractile force from cardiomyocyte to the other (Tepass, Truong et 
al. 2000). Intermediate filaments in each myocyte are connected through desmosomes to filaments in other 
cells. As a result, desmosomes provide an essential robust structure to allow cardiomyocytes to withstand the 
force generated during cardiac cycle (Delmar 2004). The gap junctions, consisting of connexin proteins, act like 
tunnels allowing ions influx to be transmitted from one cardiomyocyte to another rapidly, therefore allowing 
simultaneous propagation of electrical stimuli to trigger cardiac contraction (Rohr 2004).  
 
1.2.2 Excitation-Contraction coupling  
Excitation- Contraction (E-C) coupling is an energy dependant process linking electrical signal that results in 
action potential to myocyte contraction. Contractile apparatus consumes more than two thirds of hydrolysed 
myocardial ATP, while the remaining is used to keep ion balance, namely by sarcoplasmic reticulum Ca2+-ATPase 
and the sarcolemmal Na+/K+-ATPase, in addition to various enzymatic activities (Solaini and Harris 2005, Maack 
and O'Rourke 2007). Calcium cycling is central in mediating the coupling between excitation and contraction. 
In the mammalian hearts, E-C coupling is a calcium dependant process. Calcium influx triggers further release of 
SR calcium, and together result in transient rise of calcium which a central role in mediating interaction between 
actin and myosin necessary for contraction. Therefore, calcium transient must be tightly controlled through its 
release and recycling back to sarcoplasmic reticulum (Bers 2002). 
 
Figure 1.5 Schematic and electron micrograph of intercalated disc structure in cardiomyocyte. Gap junction consists of 
connexin proteins, fascia adherens junctions in cardiomyocytes are made of N-cadherin, and desmosomes of desmoglein 




Excitation occurs by autonomous generation of action potential in specialized cells in the sinoatrial (SA) node, 
acting as pacemaker of the heart, which is transmitted throughout the atria until it reaches the atrioventricular 
(AV) node. Action potential is then transmitted through conduction system by bundle of His, then through the 
widely distributed Purkinji fibres to the ventricles traveling down to t-tubule to reach cardiomyocytes. Because 
of gap junctions, membrane depolarisation diffuses rapidly and simultaneously to all neighbouring cells. Action 













Ventricular cardiomyocyte has a resting membrane potential nearly of -90 mV (Wright 2004), this is due to 
selective membrane permeability to potassium ions via inward rectifying potassium channels. At this stage, 
membrane potential is at phase 4.   
As rapid depolarisation occurs as a result of voltage gated Na+ channels opening, the membrane potential 
increases leading to an upstroke in membrane potential (phase 0) from rapid influx of sodium into cells with its 
electrochemical gradient (Reuter and Beeler 1969). Early repolarisation (phase 1) is mediated by inactivation of 
voltage gated Na+ channels when the membrane potential reaches positive value, in addition to an outward 
current of K+ and Cl- (Luo and Rudy 1994). However, in phase 2 there is a plateau in membrane potential due to 
a balance between influx of calcium, through L-type Ca2+ channels which open when the potential is higher than 
-40 mV, and the slow efflux of potassium via delayed rectifier K+ channels (Orkand and Niedergerke 1964). 
However, when membrane potential becomes below -40 mV, marking phase 3, delayed rectifier potassium 
channels remain open, driving repolarisation and a drop in membrane potential toward its resting value (-90 
Figure 1.6 Changes in action potential (phases are indicated by numbers (0 - 4) among different areas of the heart 




mV). These channels close when the resting membrane potential is achieved at phase 4, when only inward 














Depolarization-activated opening of calcium channels results in calcium influx as illustrated in figure 1.8. This 
slight increase in intracellular calcium ions triggers ryanodine receptors (RyR) on sarcoplasmic reticulum (SR) to 
release even further stored calcium (Bers, Lederer et al. 1990, Lee and Michalak 2010), the net result is a greater 
increase in cytosolic Ca2+ transient, from 0.1 µM to 1 µM (Bers 2002). This effect is known as calcium induced 
calcium release (CICR) which is the driving signal for cardiomyocyte contraction (Fabiato and Fabiato 1975). 
Calcium exerts its action through its binding to troponin C, to activate a conformation changes in troponin T and 
I proteins to displace tropomyosin protein from actin, facilitating myosin-actin binding (Bing, Fraser et al. 1997). 
Figure 1.7 Ventricular membrane potential (in voltage). Numbers from 0 to 4 denote phases of action potential 
production. From (Walker and Spinale 1999) 
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Calcium release and uptake is a highly controlled process. There are several mechanisms to regulate intracellular 
calcium concentration, including phosphorylation as well as inactivation of ryanodine receptors opening by 
calsequestrins. These proteins are detached from ryanodine receptors in a relaxed state, i.e. when intraluminal 
calcium concentration is high (Stevens, Terentyev et al. 2009). However, once ryanodine receptors are triggered 
by the influx of calcium through L-type Ca2+ channels, they release stored calcium. When intraluminal calcium 
levels are decreased, calsequestrin interacts with ryanodine receptors to block their opening, and subsequently 




Relaxation and cross bridge cycle 
Myosin has 3 main parts: head to which actin binds, in addition to neck and tail, whereas actin filaments are 
helical structures of two interwoven globular actin subunits. In a relaxed state, myosin heads are bound to ATP 
and myosin binding sites on actin are covered by tropomyosin, hindering the myosin-actin interaction. 
Tropomyosin interacts with Troponin complex by troponin T, which binds to troponin I and C proteins (Yasui, 
Fuchs et al. 1968). When intracellular Ca2+ level increases, calcium binds to troponin C leading to conformational 
changes which force tropomyosin displacement by troponin I and T (Dong, Jayasundar et al. 2007). This leaves 
myosin heads vacant to bind with actin. ATP hydrolysis to ADP and Pi occurs on myosin head where conversion 
of chemical to mechanical energy occurs. When phosphate group is released from myosin head, this results in a 
power stroke to allow myosin to slide over actin filament, forming a cross-bridge interaction between the two 
Figure 1.8 Excitation contraction coupling and CICR from sarcoplasmic reticulum (SR). AP action potential, NCX 
(Na+ /Ca2+ exchanger), RyR (ryanodine receptors). From (Bers 2002) 
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filaments (Huxley and Hanson 1954). Hydrolysis of ATP molecules therefore leads to shortening of I bands, as z 











ADP is released from myosin head which, in turn, is released from actin. ATP binds to myosin head to undergo 
hydrolysis for the next cycle. Calcium is pumped back to SR through sarcoplasmic reticulum Ca2+ ATPase (SERCA), 
sarcolemmal Na+/Ca2+ exchanger as well as plasmalemmal Ca2+-ATPase (PMCA)(Bers, Lederer et al. 1990, Maack 
and O'Rourke 2007). When intracellular calcium level falls, it dissociates from troponin C, allowing tropomyosin 











Figure 1.9 Actin and myosin filaments during cardiomyocyte contraction and relaxation. From (Lodish H 2000) 
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1.2.3 Cardiac metabolism 
    1.2.3.1 Energy production  
 
ATP, a molecule with high energy phosphate bonds is constantly demanded as a prerequisite to maintain cardiac 
contraction and cellular integrity. Cardiac energy pool constitutes of ATP (~ 5 μmol/g wet wt) in addition to 
phosphocreatine (~ 8 μmol/g wet wt) serving as a buffer system for ATP transport(Beer, Seyfarth et al. 2002). 
Oxidative phosphorylation produces 90% of cardiomyocytes ATP pool (Mootha, Arai et al. 1997). Other sources 
being GTP formation from Krebs cycle and ATP production from glycolysis.  Figure 1.10 is an overview of 
metabolic pathways to utilise main substrates in cardiomyocytes.  
Figure 1.10 Summary of metabolic pathways to utilise various substrates in the cardiomyocyte. CPT I and II; carnitine 
palmitoyltransferases I and II, FAT/CD 36; fatty acid translocase Cluster of Differentiation CD 36, PDH; pyruvate 
dehydrogenase, PDK; pyruvate dehydrogenase kinase, GLUT; 1/4 glucose transporter type 1/4, ACC; acetyl CoA carboxylase, 
MCD; malonyl CoA decarboxylase, SCOT; succinyl-CoA:3-oxoacid-CoA-transferase, βOHB; β-hydroxybutyrate, BDH, βOHB 
dehydrogenase; MPC; (mitochondrial pyruvate carrier), MCT; monocarboxylate transporters, LDH; Lactate dehydrogenase 
From (Karwi, Uddin et al. 2018).  
Under normoxic conditions, heart utilises fatty acids (FA) through β-oxidation as the primary source of energy, 
as nearly 60% of ATP production comes from FA oxidation (Doenst, Nguyen et al. 2013). Other substrates include 
glucose (which contributes to 30% of ATP production), amino acids (10%) and occasionally lactate and ketone 
bodies (Schutz 1995). Therefore, the heart can upregulate and use several pathways to meet its high energy 
demands in different physiological conditions, establishing a versatile cardiac metabolism or what is known as 
metabolic flexibility.  Fatty acids, which could be found as free fatty acids that are circulating in blood or released 
from lipoprotein containing triglycerides, are converted by β-oxidation in the mitochondria into acetyl-CoA to 
enter Krebs (or TCA/Citric acid) cycle (Lopaschuk, Ussher et al. 2010), while glucose could undergo into the 
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anaerobic glycolysis in the cytosol, producing 2 pyruvate molecules and 2 ATP molecules. Then pyruvate enters 
Krebs cycle, and electron transport chain (ETC) in the mitochondria, where oxygen is used as electron acceptor 
and the resulting proton current is used to synthesise ATP by F0/F1 ATP synthase (Lopaschuk, Ussher et al. 2010).  
1.2.3.2 Substrates used by cardiomyocytes for energy production 
 
Glucose 
Glucose availability depends on either transportation of exogenous glucose into cardiomyocytes mainly via 
insulin dependent glucose transporter type 4 (GLUT 4) and type 1 (GLUT 1) or through breakdown of stored 
cardiac glycogen (Fischer, Thomas et al. 1997, Abel 2004). Once in the cytosol, glucose is phosphorylated to by 
hexokinase to glucose-6‐phosphate (G-6-P). Phosphorylated glucose can be used in glycogen synthesis or enter 
several metabolic pathways including glycolysis, and Pentose Phosphate Pathway (PPP), for pyrimidine and 
purine synthesis, as well as Hexosamine Biosynthetic Pathway (HBP) for synthesis of proteoglycans and other 
glycation end products (Tran and Wang 2019). Initial utilisation of one molecule of glucose by a series of enzymes 
through glycolytic pathway generates 2 pyruvate molecules, 2 Nicotinamide Adenine Dinucleotide Hydrogen 











Figure 1.11 Glycolytic pathway for glucose metabolism. PDH; pyruvate dehydrogenase, GLUT 1/4; glucose transporter type 
1/4, PK; pyruvate Kinase, HK; Hexokinase, GAPDH; glyceraldehyde-3- phosphate dehydrogenase; PFK 1 and 2; ATP-
dependent phosphofructokinase 1 and 2, PK; pyruvate kinase, LDH; lactate dehydrogenase, ALT; alanine aminotransferase. 
From (Tran and Wang 2019) 
This process occurs regardless of oxygen availability in the cytosol (anaerobic glycolysis); however, its ATP yield 
is not sufficient to maintain the contractile machinery. Therefore, pyruvate can be further utilised by aerobic 
respiration once it has been transported into mitochondrial matrix, where it is converted by pyruvate 
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dehydrogenase into acetyl-CoA to feed Krebs cycle (Patel and Korotchkina 2006). Regulation of PDH activity 
depends on availability of acetyl-CoA and NADH as they exert product inhibition effect. In addition, pyruvate 
dehydrogenase is regulated by PDH kinase (inhibits PDH through phosphorylation) and PDH phosphatase 
(activation through dephosphorylation)(Holness and Sugden 2003). Glucose has phosphate to oxygen (P/O) ratio 
of 2.58, which makes it the most energy efficient substrate; as 6 oxygen molecules are needed to oxidise one 
molecule of glucose, producing in total 31 ATP (Karwi, Uddin et al. 2018).  
Fatty acids  
Heart utilises free fatty acids (FFA) that are bound to albumin or released from triglycerides (TAG), which are 
found in chylomicron or Very Low Density Lipoproteins (VLDL) (Hauton, Bennett et al. 2001). Fatty acids could 
be either diffused into the cytosol or transported by fatty acid translocase (Cluster of Differentiation CD 36)(van 
der Vusse, van Bilsen et al. 2000). Esterification of fatty acid to long chain fatty acyl Coenzyme A by fatty acyl 
CoA synthase takes place in cytosol. This step is necessary to facilitate triglyceride synthesis (cardiac TAG reserve) 
or, alternatively, direct shuttle of the vast majority of fatty acyl CoA into mitochondria. The later occurs through 
carnitine shuttle system by carnitine palmitoyltransferases (CPT I and II). CPT I enzyme converts long chain fatty 
acyl CoA into long chain acylcarnitine to be transported through outer mitochondrial membrane (OMM). 
Carnitine acylcarnitine translocase on the inner mitochondrial membrane (IMM) transfers acylcarnitine into 
mitochondrial matrix, where CPT II converts them back into long chain fatty acyl CoA to be utilised via β-











Regulation of this shuttle system, and β-oxidation, depends on malonyl CoA, made from acetyl-CoA 
carboxylation by acetyl-CoA carboxylase. Whenever there is excess acetyl-CoA, it is converted into malonyl CoA 
(which indicates an increased rate of β-oxidation). Malonyl CoA consequently inhibits CPT I, decreasing long 
chain fatty acyl CoA transport across mitochondrial membranes (McGarry, Mannaerts et al. 1977). 
Figure 1.12 Carnitine shuttle pathway. CPT I and II; carnitine palmitoyltransferases I and II, LACS; Long fatty acyl 
CoA synthase. From (Qu, Zeng et al. 2016) 
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 β-oxidation is the sequential derivation of acetyl-CoA (two carbon units) from fatty acyl CoA. Acetyl-CoA then 
enters TCA cycle, which yields NADH, reduced flavin adenine dinucleotide (FADH2), which are used to generate 
ATP during mitochondrial oxidative phosphorylation (Cotter, Schugar et al. 2013). In terms of energy efficiency, 
β-oxidation of a typical FA molecule such as palmitate produces 105 ATPs per 23 oxygen molecules, with P/O 
ratio of 2.33, making it less energy efficient that glucose. Nonetheless, in terms of the theoretical amount of ATP 
molecules produced by two carbons unit utilisation, fatty acids supersede any other myocardial substrates 
(Karwi, Uddin et al. 2018). 
Ketone bodies  
Ketone bodies are synthesised by liver during prolonged fasting or starvation, and can be oxidised to enter TCA 
cycle. Acetoacetate, β-hydroxybutyrate (βOHB) are predominant the ketone bodies circulating in blood, while 
acetone which is easily eliminated by breath(Cotter, Schugar et al. 2013). Cardiomyocytes utilise only ketone 
bodies in a proportional manner to their delivery since heart lacks the ability to produce ketones, however, it is 
considered the highest ketones consumer per unit of mass (Young, McNulty et al. 2002). Oxidation of βOHB 
takes place in the mitochondria by phosphatidylcholine-dependent βOHB dehydrogenase into acetoacetate, 
thensuccinyl-CoA:3-oxoacid-CoA-transferase (SCOT) converts acetoacetate into acetoacetyl-CoA. Finally, 
acetoacetyl-CoA is converted by acetyl-CoA acetyltransferase into acetyl-CoA, as shown in figure 1.13, which can 













Figure 1.13 Ketone Body oxidation pathway. SCOT; succinyl-CoA:3-oxoacid-CoA-transferase, βOHB; β-hydroxybutyrate, 
BDH1; βOHB dehydrogenase, AcAc,; Acetoacetate, AcAc-CoA; Acetoacetate-CoA, PDH; Pyruvate dehydrogenase.  From 
(Cotter, Schugar et al. 2013) 
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Lactate and amino acids  
Amino acids have minor contribution to ATP production under normal condition, but this could be greatly 
challenged during cardiac ischaemia. Unlike lactate, amino acids can be involved in energy production under 
hypoxic or anoxic conditions, without vastly decreasing cellular pH levels, through conversion into TCA 
intermediates and participation in substrate-level phosphorylation. Aspartate, asparagine, and the branched 
chain amino acids (BCAAs) in addition to glutamate and glutamine can be all converted TCA cycle intermediates. 
As shown in figure 1.14, glutamate (from glutamine conversion) can be transaminated into α-ketoglutarate, a 
Krebs cycle intermediate, by glutamate-dehydrogenase, leading to production of a single molecule of GTP and 
one NADH, through conversion of α-ketoglutarate to succinate (Mudge, Mills et al. 1976). Asparagine and 
aspartate can be converted to oxaloacetate, wheras alanine, on the other hand, is interconvertible with pyruvate 
(Drake, Sidorov et al. 2012). Pyruvate oxidation results in three NADH and one GTP.  
 
Lactate, a by-product of glucose metabolism, is produced in the heart when it is lacking adequate oxygenation 
to carry on aerobic glycolysis. Lactate dehydrogenase converts pyruvate to lactate, oxidising NADH to NAD+, 
which will be recycled in anaerobic glycolysis reaction to produce 2 ATP molecules(Berg, Tymoczko et al. 2010).  
Pyruvate + NADH + H+ → lactate + NAD+ 




 1.2.3.3 TCA cycle and oxidative phosphorylation  
 
As illustrated previously in figure 1.14, acetyl-CoA is combined with oxaloacetate, forming citrate by citrate 
synthase. Citrate undergoes several consecutive reactions that end up in oxaloacetate formation, to start 
another cycle. Therefore, one TCA cycle decarboxylates acetyl-CoA into CO2 and results in 3 NADH, 1 FADH2 and 
1 ATP molecule.  Since this cycle is fundamental in energy production, its pool of intermediates can be 
replenished from other metabolites through different collateral metabolic pathways, what is known as 
anaplerosis (Des Rosiers, Labarthe et al. 2011). An example of anapleric reaction is the conversion of glutamate 
to α-ketoglutarate as described earlier in the previous section. Electron donors NADH and FADH2 subsequently 
undergo oxidative phosphorylation in the electron transport chain to contribute for ATP production through ATP 
synthase.  
There are four complexes in the Electron Transport Chain (ETC) located on the inner mitochondrial membrane 
as seen in figure 1.15, which work together to shuffle electrons from one to another, facilitating coupling of 
energy to create a proton gradient. Complex I (NADH-quinone oxidoreductase), which accepts NADH as electron 
donor, pumps protons from the matrix into inter membrane space to initiate proton gradient. However, complex 
II (succinate dehydrogenase) only accepts electron from FADH2. Both complex I and II transfer their electrons to 
Coenzyme Q (CoQ), which moves electrons to complex III (ubiquinol-cytochrome c oxidoreductase) to pump 
further protons. Complex III then passes its electrons to Cytochrome C, which mediates electrons transfer to 
complex IV (cytochrome c oxidase). In addition to pumping protons, the later uses oxygen as final electron 
acceptor. The proton gradient created throughout the chain is used by F0/F1 ATP synthase to phosphorylate 
ADP to ATP (chemiosmosis) as protons flow back to the matrix. In general, four protons are required to produce 
a single ATP molecule (Saraste 1999). The ATP produced is then exported from mitochondria in exchange for 
ADP by adenine nucleotide translocase (ANT) found in the mitochondrial inner membrane (Wheaton and 
Chandel 2011).  
Figure 1.15 Schematic of Electron Transport Chain (ETC) in mitochondria. Redox centres numbers are denoted by numbers 
I to VI. ATP synthase is essential for ATP synthesis, also known as complex V, although it is not part of ETC. Q, Coenzyme Q 
(CoQ), C Cytochrome C. From (McEwen, Sullivan et al. 2011) 
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Both sustained ischaemia and ischaemia followed by reperfusion trigger series of cellular changes including Ca2+ 
loading and oxidative stress, which lead to mitochondrial permeability transition pore (mPTP) opening and death 
by necrosis or/and apoptosis (Hausenloy and Yellon 2013). Figure 1.16 is a summary of key changes associated 
with IRI. Ischaeamia reperfusion injury not only results in infarct size expansion, but also cardiac arrhythmia, 
myocardial stunning (post ischaemic contractile dysfunction), microvascular obstruction or lethal injury (Krug, 
De Rochemont et al. 1966, Hearse and Tosaki 1987, Kloner, Bolli et al. 1998).  
 
Figure 1.16 Illustration of molecular and metabolic changes following acute myocardial ischaemia (A) and reperfusion (B) 
injury. G 6-P; Glucose 6-phosphate, OXPHOS; oxidative phosphorylation, NCX; the sodium-calcium exchanger, mNCX; 
mitochondrial sodium-calcium exchanger, NHE; Na+/H+ exchanger, MPTP; mitochondrial permeability transition pore, ROS; 
reactive oxygen species. From (Ramachandra, Hernandez-Resendiz et al. 2020). 
1.3.2 Ischaemia 
 
Cessation or reduction of blood flow in a coronary artery by a thrombus or embolus will deprive cardiomyocytes 
from blood oxygen and nutrients, i.e., ischaemia. However, in most clinical settings, attempts to restore blood 
flow and achieve tissue reperfusion with coronary catheterisation, for example, will eventually exacerbate the 
ischaemic injury. During ischaemia, the oxygen-deprived myocytes switch from oxidative phosphorylation, the 
primary source to generate ATP for contraction, to anaerobic glycolysis due to decreased ETC complexes and 
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ATP synthase activity (Rouslin 1983). In these circumstances, cardiomyocytes will rely heavily on glucose to 
produce energy. However, NAD+ must be abundant to keep anaerobic glycolysis going. Consequently, pyruvate 
is converted to either alanine or, most likely, lactate by lactate dehydrogenase (Taegtmeyer 1994). 
 
 1.3.2.1 Metabolic and ionic disturbances 
 
Since anaerobic glycolysis is extremely inefficient to provide adequate levels of ATP (2 ATP molecules per one 
glucose, versus 31 in aerobic respiration), it results in dysfunctional ATP-dependant ion transporters activity and 
consequently intracellular electrolytes imbalance, which halts myocytes contractility and cellular integrity. Lactic 
acid concentration increases hence, accumulation of protons in the cytoplasm, i.e. decrease in intracellular pH. 
The increase in intracellular H+ will lead to Na+ accumulation by the action of sarcolemmal Na+/H+ exchanger, 
which is activated to eliminate the excess protons in the cytoplasm. This step, however, leads to Ca2+ 
accumulation by the activated Na+/Ca2+ exchanger (NCX), as the excess sodium cannot be removed by ATP-
dependant Na+/K+ ATPase (due to ATP deprivation) (Avkiran and Marber 2002). Eventually, elevated intracellular 
Ca2+, along with ATP depletion causes impaired cardiac contractility (rigor hypercontacture), alterations in 
membrane potentials, all of which are implicated in cardiomyocytes death.  
1.3.2.2 Cardiomyocytes and Mitochondrial swelling 
 
With prolonged ischaemia and ATP depletion, there is a disruption in ion balance, as the increase in intracellular 
sodium results in osmotic discrepancies in cardiomyocytes, leading to cellular swelling and reduced contractile 
responsiveness, and no reflow phenomenon if reperfusion occurs (Garcia-Dorado, Andres-Villarreal et al. 2012). 
Although acidic environment maintains mPTP stability initially, with extended duration of ischaemia the influx 
of calcium through calcium uniporters into mitochondria triggers mPTP to open, and this provokes mitochondrial 
swelling, releasing pro-apoptotic enzymes to drive cardiomyocytes to apoptosis (Parlakpınar, Örüm et al. 2013). 
 1.3.3 Reperfusion 
 
Although it is an apparent necessity needed to limit further injury, blood flow restoration after prolonged 
ischaemia can lead to precipitation of initial damage caused by ischaemia itself. Reperfusion reintroduces oxygen 
to the ischaemic tissues, however, this paradoxically provokes excessive reactive oxygen species (ROS) formation 
by the defective ETC complexes (complex I and complex III), also known as ‘Oxygen Paradox’. ROS results in 
disruption of sarcolemma, lipid peroxidation, proteins, and nucleic acids damage. Calcium ions accumulate due 
to NCX activity, low activity of Ca2+-ATPases (SERCA & sarcolemma), disruption in plasma membranes, 





1.3.3.1 Ca2+ loading  
 
Another element involved in reperfusion injury is the rapid washout of protons via Na+/H+ exchanger to restore 
pH values. Sarcolemmal Na+/H+ exchanger retains its activity contributing to increased Na+ levels, which 
consequently stimulates an increase in calcium influx through NCX. The inhibitory effect of cellular acidity on 
mPTP is reduced, which potentiates their susceptibility for opening as they become more permeable to ROS with 
increased calcium loading (Thind, Agrawal et al. 2015).  
1.3.3.2 Reactive Oxygen Species (ROS)  
 
Reactive oxygen species are chemicals derived from oxygen molecules (Taverne, Bogers et al. 2013) that are 
synthesised naturally as by-products during oxidative phosphorylation, or through enzymatic reactions carried 
out by certain enzymes such as xanthine oxidase (endothelial cells) and NAD(P)H oxidase (neutrophils)(Droge 
2002). ROS include free radicals, e.g., superoxide (O2•-), and hydroxyl radicals (OH•), which are characterised by 
their unpaired free electrons, that is responsible for high chemical reactivity. In addition, there are hydrogen 
peroxide (H2O2)and peroxynitrite (ONOO−), however these chemicals lack the unpaired electron, consequently 
they only exert oxidising effects (Droge 2002). Imbalance between ROS synthesis and removal  creates a state 
of oxidative stress (Dhalla, Temsah et al. 2000), which leads deleterious effects on cellular membrane through 
lipids peroxidation, in addition to proteins oxidation and DNA damage (Moris, Spartalis et al. 2017).  
The main source of O2•- in most tissues is derived nonenzymatically from mitochondrial ETC. It is estimated that 
1-2% of electrons could be leaked to oxygen during electron shuffle from redox centres(Turrens 2003). 
Enzymatic ROS production comes from NAD(P)H oxidases in macrophages and neutrophils (to aid in phagocytic 
activities), xanthine oxidases, and endothelial nitric oxide synthase (eNOS).  
 Superoxide can undergo several reactions resulting in H2O2, OH• and peroxynitrite production. Superoxide 
Dismutase converts superoxide to hydrogen peroxide, which also could be produced from several oxidases. 
Although H2O2 is not a radical, it has high reactivity as it is a precursor for hypochlorous acid (HOCl-), as well as 
hydroxyl radical. When H2O2 interacts with reduced metal ion, it decomposes leading to OH- formation through 
Fenton reaction. Alternatively, H2O2 interaction with O2•-  through Harbar-Weiss reaction also produces hydroxyl 








Hydroxyl radical along with peroxynitrite, which is formed from superoxide reaction with nitric oxide, are 
considered the most reactive species. They induce cellular damage through free chain radial protein oxidation 
and lipid peroxidation, which consequently alters membrane permeability and stability through disruption of 
phospholipid bilayer integrity (Turrens 2003) as demonstrated in figure 1.18. 
 
Figure 1.18 Deleterious effect of reactive oxygen species on various cellular targets.From (Dhalla, Temsah et al. 2000) 
Figure 1.17 Reactions of reactive oxygen species production and removal. NO, nitric oxide, NOS, NO synthase, SOD, 
superoxide dismutase. From (Taverne, Bogers et al. 2013) 
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1.3.3.3 Antioxidant defence mechanisms  
 
Both enzymatic and nonenzymatic defence mechanisms exist intra- and extracellularly to neutralise ROS 
immediately. Superoxide is converted into H2O2 and O2•-  by SOD, which is found in the heart in two isofroms, 
mitochondrial Mn-SOD and cytoplasmic Cu/Zn- SOD (Freeman and Crapo 1982). Catalase (in peroxisomes) and 
glutathione peroxidase hydrolyse H2O2 into water and oxygen. Glutathione peroxidase (GPx) is particularly 
important in the heart as it uses abundantly available reduced glutathione (2GSH) in the cytoplasm as a redox 
buffer to catalyse the reaction:  
H2O2 + 2 GSH → 2 H2O + GSSG 
Reduced glutathione provides protons to cell membrane lipids to maintain them reduced, which helps in cardiac 
protection specifically during IRI(Curello, Ceconi et al. 1985, Cheung, Wang et al. 2000). Glutathione reductase 
uses NADPH to covert GSSG to 2GSH, which maintains antioxidant activity of GPx. Therefore, an imbalance 
between the oxidised and reduced glutathione (GSH : GSSG ratio) is considered as indicator of the oxidative 
state in the cells(Curello, Ceconi et al. 1987). Other antioxidant proteins include thioredoxin, peroxiredoxin and 
glutaredoxins. They function as electron donors and maintain redox state through H2O2 mediated signal 
transduction (Hanschmann, Godoy et al. 2013, Netto and Antunes 2016) 
Nonenzymatic scavenging mechanisms also exist to reduce the effect of ROS and limit lipid peroxidation, these 
are present intracellularly such as ubiquinone (Coenzyme Q) and vitamin E (α-tocopherol), and extracellularly 
such as vitamin C (Dhalla, Temsah et al. 2000). 
1.3.3.4 Mitochondria permeability transition pores (mPTP)  
 
Ions and solutes movements across mitochondria, the cellular powerhouses, must be tightly regulated.  Outer 
mitochondria membrane is permeable to solutes up to 5kDa, whereas inner mitochondrial membrane has 
relative impermeability under normal physiological conditions. Although the exact molecular nature is not fully 
elaborated, the mitochondrial permeability transition pores are to thought be complex proteinaceous entities 
consisting of the voltage dependent anion channel (VDAC), adenine nucleotide translocase (ANT), phosphate 
carrier (PiC), spastic paraplegia 7 (SPG7), and components of the ATP, i.e. synthase oligomycin sensitivity 
conferring protein (OSCP) (Briston, Roberts et al. 2017). Cyclophilin D (Cyp-D), matrix protein that meditates 
increased pores sensitivity to Ca2+ through binding with PiC and ANT, triggering pores formation (Halestrap 2009). 
Dysregulation of cytoplasmic Ca2+ levels, and mitochondrial calcium overload in addition to oxidative stress 
during IRI induce pores opening (Haworth and Hunter 1979), which occurs more prominently during early 
minutes of reperfusion (Griffiths and Halestrap 1995). Pores formation and opening results in osmotic-induced 
mitochondrial swelling, oxidative phosphorylation uncoupling, rupture and eventually release of apoptotic 
enzymes (Crompton 1999). The cardioprotective effects of mPTP inhibition by cyclosporin A, which inhibits CyP-
D binding to PiC and ANT complex, were shown to decrease pores sensitivity to increased Ca, and consequently 
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lead to reduction in infarct size after IRI (Hausenloy, Duchen et al. 2003).  Figure 1.19 is an illustration of 











Figure 1.19 Schematic of mPTP opening during ischaemia reperfusion injury. ANT, adenine nucleotide translocase; HK, 
hexokinase; CK, creatine kinase; MIM, mitochondrial inner membrane; CyP-D, cyclophilin D; MOM, mitochondrial outer 
membrane; Pi, inorganic phosphate; PBR, peripheral benzodiazepine receptor; SOD, superoxide dismutase; VDAC, voltage-
dependent anion channel. Adapted from (Hernandez-Resendiz, Buelna et al. 2012)  
       1.3.3.5 mPTP as a target for protection against IRI  
 
Since there are several key players involved in mediating ischaemia reperfusion injury to the heart, there were 
also different approaches to protect the heart, especially during cardiac surgeries when aortic cross clamping 
and declamping are needed, which result in global cardiac ischaemia reperfusion injury (Beyersdorf 2009), or in 
the events of myocardial infarction, in which minimising damage that occurs during reperfusion remains the top 
priority. Cardioprotective interventions and drugs work on specific cellular and molecular targets. Cyclosporin A 
(as discussed earlier in section 1.3.3.4) and Sanglifehrin A inhibit CyP- D peptidyl-prolyl cis-trans isomerase 
(PPIase) activity, which is shown to decrease cardiac injury through a decrease in mPTP opening, particularly 
during early reperfusion (up to 15 min after ischaemia )(Hausenloy, Duchen et al. 2003), as used in reperfused 
isolated rat heart after induced ischaemia (Clarke, McStay et al. 2002, Xie and Yu 2007). While other drugs such 
as propofol, GABAA agonist and a scavenger of free radicals, have shown cardioprotective effects when infused 
with cardioplegic solution in in porcine model undergoing cardiopulmonary bypass (CPB)(Lim, Halestrap et al. 
2005), and decreased calcium-induced mPTP opening in  isolated Langendorff perfused rat hearts during 
reperfusion (Javadov, Lim et al. 2000). 
Additionally, there are interventions aiming to decrease impact of ischaemic insult while conferring a varying 
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prior an extended ischaemic period, halts mPTP opening through decreasing oxidative stress or Ca2+ overload, 
or both, in different experimental models (Murry, Jennings et al. 1986, Javadov, Clarke et al. 2003). Observed 
changes in signalling pathways, as a result of ischaemic preconditioning, involved pro-survival kinases activation, 
such as PKB (Akt), ERK1/2) and PKC through phosphorylation (Armstrong, Downey et al. 1994, Hausenloy, Tsang 
et al. 2005). Similarly, these cycles of brief ischaemic periods could be applied in a remote region away from the 
heart, for example a peripheral limb, prior to a prolonged cardiac ischaemic insult, as these cycles would still 
trigger cardioprotective effects. This is known as Remote ischaemic preconditioning (RIPC) and it possibly 
involves a systemic interplay of neural and humoral mediators that convey stress signals to the myocardium 
during ischaemic periods (Gho, Schoemaker et al. 1996). Other modalities include ischaemic postconditioning, 
in which cycles of ischaemia are introduced after a major ischaemic insult, such as myocardial infarction, which 
result in decrease in infarct size and preservation of endothelial function in a dog model (Zhao, Corvera et al. 
2003). Finally, there is temperature preconditioning, in which cycles of hypothermia (optimally at 26 °C) are 
induced, instead of brief ischaemia, before a lethal ischaemic insult. Effects of temperature preconditioning are 
linked to reduction in oxidative stress and mPTP inhibition (Khaliulin, Clarke et al. 2007, Khaliulin, Halestrap et 
al. 2011).  
 
1.4 Cardiac remodelling following acute myocardial infarction 
 
The concept of post infarction ventricular remodelling was first emphasised in 1985 by Pfeffer et. al who 
examined the causes of left ventricular dilation, and disrupted myocardial function following coronary artery 
ligation in rodent models (Pfeffer, Pfeffer et al. 1985). Consequently, remodelling was described as a complex 
alteration in the topography and architecture occurring acutely or chronically and involves infracted and non-
infarcted zones of the ventricle (Pfeffer and Braunwald 1990). However, the established evidence a decade later 
demonstrated that remodelling is not only confined to the structural aspects, but the term also expands to 
include the molecular, cellular and extracellular alterations, that will clinically manifest as changes in size, shape 
and function of the heart (Cohn, Ferrari et al. 2000). Indeed, it is a culmination of physical configuration that is 
driven by a combination of myocytes apoptosis, hypertrophy, fibrosis and myofibroblasts proliferation (Konstam, 
Kramer et al. 2011). That is why the current emphasis on the inseparable bio-mechanical nature of cardiac 
remodelling remains the guide to comprehend and address this intricate and ongoing process. Patients suffering 
from acute myocardial infarction undergo percutaneous coronary intervention (PCI) or coronary artery bypass 
graft (CABG) surgery to restore coronary flow, however, that will inevitably subject them to ischaemia 
reperfusion injury, which deleteriously increase the infarct size, and potentially worsen, remodelling. In 
conclusive prospect, cardiac remodelling could be thought as defined as the molecular, cellular and extracellular 
alterations that manifests clinically as changes in cardiac shape, size, and function a result of certain pathological 















                             Figure 1.20 Phases of post ischaemic remodelling. From (Prabhu and Frangogiannis 2016) 
 
1.4.1 The role of inflammation in post infarct remodelling 
 
The necrotic myocytes during ischaemia and reperfusion release damage-associated molecular patterns (DAMP) 
such as ATP, mitochondria DNA (mtDNA) (Birdsall, Green et al. 1997).  DAMPs bind to pattern recognition 
receptor, e.g. Toll-like receptor (TLR), located on the innate immune cells in the parenchyma, as well as the 
infiltrating white blood cells, to initiate a group of inflammatory mediators (such as cell adhesion molecules, pro 
inflammatory cytokines and chemokines) (Prabhu and Frangogiannis 2016). Pro-inflammatory cytokines (IL-1, 
IL-6, TNF-α) and chemokines (monocyte chemoattractant protein-1 MCP, chemokine ligand 5 CCL5) upregulate 
endothelial cell adhesion molecule synthesis (Kumar, Ballantyne et al. 1997, Frangogiannis 2007), and at the 
same time, induce leukocyte integrins expression. This interaction between endothelial and leukocytes 
adhesions molecule results in leukocyte rolling, strong adhesion and extravasation of neutrophils into the 
infarcted area (Frangogiannis 2008). Neutrophils are initially recruited to clear dead myocytes and cellular debris 
at the site of infarct, marking the beginning of acute inflammation. Neutrophils degrade and resolve the 
extracellular matrix (ECM) through secretion of proteases, neutrophil NAPPH oxidase induced ROS release. 
Monocytes are later recruited by chemokines from neutrophils, and are sequentially activated into M1 
proinflammatory type macrophages, which are characterized by their function to phagocytose cellular debris.  
Once matrix fragments and cellular debris clearance is completed, the inflammatory response is inhibited, and 
the previously activated neutrophils undergo apoptosis and clearance by macrophages (Chen and Frangogiannis 
2013). Additionally, macrophages and lymphocytes release inhibitory mediators to supress pro-inflammatory 
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signals, e.g. and transforming growth factor-β (TGF-β( and interleukin (IL)-10 (Nahrendorf, Swirski et al. 2007). 
Proliferative phase is stimulated by a molecular switch to type M2 macrophages that promote fibroblasts and 
endothelial infiltration, collagen deposition by fibroblast, myofibroblasts proliferation and matrix reorganisation, 
all of which are prominent characteristics of the proliferative phase (Willems, Havenith et al. 1994, Troidl, 
Möllmann et al. 2009). During this phase, extracellular matrix network is dynamically modulated, and directly 
orchestrates the cellular function and phenotype. Phagocytosis of cellular fragments found in the infarcted area 
initiates a provisional matrix formation, which is made up mainly by fibrin and fibronectin. The crucial role of 










Figure 1.21 The role of fibroblast in mediating inflammatory response. IL-1, interleukin 1, TLR, Toll-Like Receptor, TNF-α, 
Tumor Necrosis Factor α, MMPs, Matrix Metalloproteases. From  (Chen and Frangogiannis 2013). 
Endothelial cells proliferation and adherence, labelled by αvβ3integrins form new microvessels (angiogenesis) as 
shown in the Figure 1.22, occur during this phase. Finally, scar condensation and maturation continue while the 
fibroblasts undergo apoptosis and neovessels regress. The triggers driving reparative cells apoptosis are not yet 
fully understood, however, removal of fibrogenic growth factors, initiating inhibitory signals which hinders TGF-
β and angiotensin II signalling, in addition to elimination of proteins in the matrix, could altogether lead to 
suppression of proliferation and a reduction of synthetic function of the fibroblasts in the extracellular matrix 
(Prabhu and Frangogiannis 2016). The resulting outcome is a highly crossed linked scar that replaces the dead 
myocytes and is progressively modulated as a result of increased wall stress (Willems, Havenith et al. 1994, Troidl, 













Figure 1.22 Angiogenesis PET. 68Ga-NODAGA-E[c(RGDyK)]2 (RGD) positron emission topography PET (top row, bright colour) 
and stress PET (bottom row, showing the occlusion) before and after one week (1W) and one month (1M) of induced 
myocardial infarction (LAD coronary artery occlusion in minipigs). Labelling using αvβ3integrins. From (Rasmussen, Follin et 
al. 2016) 
 
Recent evidence demonstrated that post myocardial infarction inflammation could potentiate the ischaemic 
myocardial injury via inflammatory derived cell death or programmed necrosis (necroptosis) mediated by pro-
inflammatory cytokines for example IL-1α, IL-6, TNFα (Gao, Liu et al. 2011, Seropian, Toldo et al. 2014), however, 
the detrimental roles of inflammation and oxidative stress must be thoroughly addressed in animal models and 
patients suffering from chronic ischaemia and/or ischaemia reperfusion injury, since a comprehensive 
understanding of roles of the inflammation and oxidative stress in adverse post-infarction LV remodelling are 
yet to be fully understood. 
1.4.2 Manifestations of post ischaemic cardiac remodelling 
 
The major features of cardiac remodelling following acute myocardial infarction are infarct expansion, extension 
of the infarct to the neighbouring non-ischaemic region as well as the compensated hypertrophy and dilatation 
of remote myocardium (Cheng, Nguyen et al. 2006). Once the cardiomyocytes are dead due to an ischaemic 
injury, a subsequent impairment of the contractile force of the diseased heart creates an increased level of strain 
on the infarct during the ongoing repair process, leading to elongation and thinning of ventricular wall (Opie, 
Commerford et al. 2006). Moreover, cardiomyocytes contraction in the border zone will be ultimately 
diminished by the abnormal workload and the increased end diastolic pressure, consequently, these hostile 
conditions drive an apoptotic cell death response in that area (Narula, Dawson et al. 2000), whereas the remote 
myocardium displays an adaptive eccentric hypertrophy (Konstam, Kramer et al. 2011). Not only heart 
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configuration is distorted, but these changes will often precipitate the initial myocardial injury, leading to a 
progressive deterioration in the left ventricular performance, and indefinitely, heart failure.   
1.4.3 Molecular and metabolic aspects of post ischaemic cardiac remodelling  
 
Better understanding of the key changes that draw a link between the initial ischaemic insult and end stage 
heart failure necessitates a comprehensive study of cardiac remodelling following acute and chronic ischaemia 
at different, yet highly integrated, perspectives. For this reason, combining and interpreting several different -
omics platforms such as genomics, proteomics and metabolomics is invaluable approach to comprehend an 
inclusive network of the several pathways involved in disease progression and development at several time 
points. For instance, a porcine model of ischaemia/reperfusion injury was used by Binek et. al to follow the 
differential cardiac protein expression from early reperfusion (120 minutes) up to 7 days and reported an 
increase expression of proteins involved in ribosomes, vesicle-mediated protein transport, in addition to 
collagen and ECM proteins in the ischaemic area. In contrast to mitochondrial and metabolism proteins which 
were significantly diminished (Binek, Fernández-Jiménez et al. 2017). In this regard, many studies have examined 
the different metabolic profiles in various cardiovascular diseases, including heart failure of different aetiologies. 
It has been shown that the failing heart displays an impairment of fatty acid oxidation (Lai, Leone et al. 2014), 
as well as lactate and ketone body accumulation (Stanley, Recchia et al. 2005), suggesting a disruption to 
mitochondrial function, in addition to a decrease in essential and nonessential amino acid metabolism (Ussher, 
Elmariah et al. 2016). Many of the metabolomic studies were notably carried out on patients who often suffer 
from other co-morbidities or metabolic diseases, reflecting a possible source of heterogeneity, which makes 
interpretation of metabolomics results quite challenging. 
1.5 Experimental models of myocardial infarction 
 
Although there is extensive research investing post MI remodelling in patients, these studies have several 
limitations which include inability to control disease progression, and unavailability of tissue samples at suitable 
time points. Therefore, it is critical to use animal models to understand the progression of disease and identify 
targets for therapeutic interventions. Experimental animal models used to study acute sustained ischaemia or 
acute ischaemia and reperfusion are quite varied ranging from small rodents to dogs and pigs (Camacho, Fan et 
al. 2016).  Preclinical models (ex-vivo, in-vivo and in-vitro) used to study myocardial infarction in rodents and 
mice, which include whole animal, isolated perfused heart, and isolated cardiomyocytes (figure 1.23).  
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Figure 1.23  Schematic representation of experimental models of MI. Reproduced from (Kumar, Kasala et al. 2016). 
In-vivo large animal models are divided into open chest or closed chest models(Kumar, Kasala et al. 2016). Rat 
hearts with surgically induced MI and heart failure have been extensively used including in our lab (Khaliulin, 
Halestrap et al. 2014). Percutaneous left anterior descending artery balloon occlusion in pigs is also a popular 
model for studying heart failure after acute MI and is used largely for investigating therapeutic interventions 
(Laguens, Cabeza Meckert et al. 2002, Champagne, Su et al. 2003, Jansen of Lorkeers, Gho et al. 2015, Malka, 
Meerkin et al. 2015, Collantes, Pelacho et al. 2017). Unlike the rodent heart, hearts of pigs, sheep and dogs are 
very similar to human hearts. Therefore, their use to study interventions prior to clinical trials is very important.  
Unfortunately, large animals used to study MI tend to be normal animals unlike mice which can be diseased 
(chemically induced or genetically modified). Moreover, both mice and humans have a completed proteome 
database available whilst this is not yet applicable for large animals. One important difference between rodents 




Figure 1.24 Shape and size of infarcts following LAD ligation in mouse, rat and pig heart. IVS, interventricular septum. 
Image from (Yen and Hsieh). 
 
1.5.1 Relevance of animal models to human cardiovascular disease  
 
Extrapolation of results obtained from animal models of ischaemic heart disease requires careful assessment of 
advantages and drawbacks of each model. Small animals like mice, and to a lesser degree rat, provide transgenic 
disease models that could assist in monitoring changes of the diseased heart over their relatively short life span. 
Nevertheless, key physiological differences in heart rate, being faster in small mammals (e.g.  rat resting heart 
rate ranging from 330 to 480 beats per min) as well as basal metabolic rate should be always considered during 
interpretation and translation of the obtained data into clinically relevant study designs (Milani-Nejad and 
Janssen 2014).  In this regard, despite being labour intensive and costly, large animal models are, however, of 
great value to studies investigating cardiac remodelling at the structural and functional levels and in clinically 
relevant settings.   
1.5.2 Rodent model of post ischaemic cardiac remodelling following acute sustained ischaemia 
 
In early 1980s, experimental work on rodents was performed to create MI model via coronary artery ligation 
(Goldman and Raya 1995). Rat model of MI is considered comparable to human with CAD disease, specifically in 
terms of pathophysiology and progression toward heart failure following reperfusion (Wayman, McDonald et al. 
2003). Due to their availability, lower husbandry costs compared to large animal models, in addition to shorter 
life span, rats provide an excellent model to study the myocardial changes following myocardial infarction. 
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1.5.3 Porcine model of post ischaemic cardiac remodelling following ischaemia reperfusion injury             
                                                                                                                                                                                                                                                                                                                                                                                                                                       
The use of porcine model in cardiovascular research has gained wide acclaim recently due to the anatomical and 
physiological similarities between human and pig hearts (Spannbauer, Traxler et al. 2019), including energy 
consumption, left ventricular wall tension and presence of right-dominant coronary vasculature (Kumar, Kasala 
et al. 2016, Silva and Emter 2020). This great advantage facilitated the translation of numerous therapeutic 
interventions and devices from small animal models to patients. However, the lack of developed collateral 
coronary circulation in pigs remains one of the major limitations that challenge the use of this model as a 
substitute to human heart to study ischaemic heart diseases (Seiler, Stoller et al. 2013). A porcine heart can be 
always seen as “young heart” for this reason. Nevertheless, the high rate of mortality due to fatal arrhythmias 
in pigs during surgical induction of ischaemia and/or reperfusion remains an issue for many research centres 
(Spannbauer, Traxler et al. 2019). In general, the ongoing use of porcine model in cardiovascular diseases 
facilitated the enhancement of surgical techniques and animal care, all of which aim to advance implementation 
of this model to test several preclinical therapeutic interventions. 
 
  1.6 Clinical studies and cardiac remodelling post MI 
 
Ischaemic heart disease (IHD) is the most common cause of heart attack. However, not all patients die after a 
heart attack, as it is estimated that 1.4 million people living in the UK who have survived an event of myocardial 
infarction and a significant number of these patients (estimated at 900,000 people) end up with heart failure 
(British Heart Foundation annual report 2019). Heart attacks are a consequence of atherosclerosis of the 
coronary arteries which renders areas of the myocardium ischaemic. Sustained deprivation of cardiomyocytes 
of oxygen and metabolites results in disruption to intracellular metabolic and ionic homeostasis, Ca2+ loading 
and cardiomyocyte death. However, timely reperfusion of the ischaemic zone (PPCI), can salvage some of the 
myocardium but can also cause reperfusion injury. Cardiomyocytes are terminally differentiated and therefore 
are unable to replace the dead ones. Subsequently, the damaged myocardium undergoes a state of cleaning and 
repair helped by apoptosis and the migration of inflammatory cells to the infarcted area (Zimmer, Bagchi et al. 
2019)). In addition to structural changes, cardiac remodelling also includes metabolic, molecular and cellular 
alterations (Pfeffer and Braunwald 1990, Cohn, Ferrari et al. 2000). Given the intensive functional demands of 
the myocardium and the associated gradual inflammatory response, apoptosis, hypertrophy, myofibroblasts 
proliferation and fibrosis, theses will ultimately lead to heart failure (Konstam, Kramer et al. 2011). Heart failure 
will dramatically affect quality of life and increase risk of sudden cardiac death.  
Although there is good understanding of the pathophysiological mechanisms behind ischaemia and reperfusion 
injury (acute response), little is known about the processes leading to subsequent heart failure (chronic 
response). More importantly, the link between acute injury and characteristics of heart failure (e.g., onset and 
intensity) is not yet fully explained. Understanding and identifying the underlying triggers of heart failure early 
after an ischaemic injury and recognition of early disease signs will help in the design of targeted therapeutic 
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interventions. Since both acute injury and subsequent chronic remodelling involve metabolic alterations, 
metabolites are exceedingly being targeted to assess the progression of heart failure to help in prevention, 
diagnosis, and therapy(Barba, Andres et al. 2019, Cresci, Pereira et al. 2019). This approach in particular is more 
likely to improve the prediction of heart failure thus adding key clues that could be considered in addition to 
other established risk factors (e.g., age, sex, low-density and high-density lipoprotein cholesterol, triglycerides, 
diabetes, body mass index, blood pressure, kidney function, smoking, and MI prior to or during follow-
up)(Stenemo, Ganna et al. 2019).  
A limited number of clinical studies have attempted in recent years to investigate the changes in blood 
metabolome in several heart diseases such as hypertrophy, coronary artery disease, diabetic cardiomyopathy, 
heart failure, atrial fibrillation and resynchronization therapy (McKirnan, Ichikawa et al. 2019, Muller, Heckmann 
et al. 2019, Pouralijan Amiri, Khoshkam et al. 2019, Sowton, Griffin et al. 2019, Stenemo, Ganna et al. 2019, 
Zhong, Liu et al. 2019, Zhou, Sun et al. 2019, Zhu, Fulati et al. 2019). There are also recent studies that have 
reported changes in the metabolome in ST-segment elevation myocardial infarction STEMI patients(Kohlhauer, 
Dawkins et al. 2018, Goulart, Santos et al. 2019). However, work looking at changes in metabolome throughout 
early stages of infarction and during chronic remodelling to heart failure is very limited (Chen, Song et al. 2019). 
Studies of this kind tend to focus on either acute or chronic phases using heterogenous population of patients 
(sex, age, etc.) who have other diseases with metabolic impact (e.g., diabetes and kidney disease). More 
importantly, such studies should take in consideration the role of early changes in biomarkers and their ability 
















1.7 Hypothesis  
 
Post ischaemic cardiac remodelling following acute sustained ischaemia or ischaemia reperfusion injury in adult 
heart occurs at the functional, structural, molecular, and metabolic levels and that investigating these changes 
will help in identifying pathways and biomarkers that can be targeted to mitigate the deleterious effects of 
remodelling. 
1.8 Aims and objectives  
 
1- Investigate and characterise post ischaemic cardiac proteomic, metabolic, and structural (alterations that occur 
using the following experimental models:  
a. Rodent model of ischaemia-induced infarction by LAD coronary artery ligation. 
b. Porcine model of ischaemia reperfusion injury.  
2- Identify chronic changes in blood constituents that occur following infarction in both models. 
3- Monitor alterations in cardiac function, blood metabolites and markers of cardiac injury in a selected group of 

















































2.1 Materials  
    2.1.1 Chemicals and reagents 
 
Agar Scientific (Essex, UK) 
Glutaraldehyde solution (25 %) 
Bio-Rad (Hertfordshire, UK) 
Precision Plus Protein™ All Blue Standards 
Quick Start™ Bradford 1 x Dye Reagent 
BOC Healthcare (Surrey, UK) 
95 % oxygen/5 % carbon dioxide medical gas mixture 
BOC Industrial Gases (Surrey, UK) 
Liquid nitrogen 
Fisher Scientific UK Ltd (Leicestershire, UK) 
D-glucose anhydrous 
Magnesium sulphate (MgSO4·7H2O) 
Sodium chloride (NaCl) 68 
Sodium dodecyl sulphate (SDS) 
Merck (New Jersey, USA) 
Magnesium chloride (MgCl2) 
Roche (Sussex, UK) 
cOmplete, EDTA-free protease inhibitor cocktail tablets 
PhosSTOP phosphatase inhibitor cocktail tablets 
Sigma-Aldrich™ (Dorset, UK) 
Albumin from bovine serum (BSA) 
Calcium chloride solution (1 M) (CaCl2)  
Chelerythrine Chloride 
Ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA) 
Folin and Ciocalteu’s phenol reagent 




Nonidet™ P 40 substitute solution 
Phosphate buffered saline (PBS) tablets 
Sodium deoxycholate 
Sodium hydroxide (NaOH) 
VWR International Ltd (Leicestershire, UK) 
4-(2-Hydroxyethyl) piperazin-1-ylethanesulphonic acid (HEPES) 
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Di-sodium hydrogen phosphate (Na2HPO4) 
Hydrochloric acid fuming (37 %) (HCl) 
Potassium chloride (KCl) 
Potassium dihydrogen phosphate (KH2PO4) 




























Hrebs-Henseleit (KH) buffer 
The chemicals used to prepare KH buffer are listed in table 2.1. 
Table 2.1 Concentration of chemicals in KH buffer. pH =7.4, solution was equilibrated with 95% O2-5% CO2. 










The chemicals used to make cardioplegia solution are listed in table 2.2. 
 
Table 2.2 Concentration of chemicals in cardioplegia solution. Same pH as above. 
 



















2.2 Animals breeding, handling, care & ethics 
 
   2.2.1 Rats 
 
Wistar Han male rats, weighing from 220 to 240 g, were provided and delivered by Charles River (Margate, UK). 
Upon arrival, the animals were placed at University of Bristol animal unit. Animals care and handling were in 
accordance with Home office guidance (Scientific Procedures) Act of 1986 and the 3R rules (Refinement, 
Reduction and Replacement). Rats were given ad libitum access to food and water.  
   2.2.2 Pigs 
 
Four months old female Yorkshire (large white) pigs, weighing 58-64 kg, were kept at the Translational 
Biomedical Research Centre (TBRC), University of Bristol in accordance with the United Kingdom Animal 
(Scientific Procedures) Act, 1986 and the reduction component of the 3Rs (Refinement, Reduction and 
Replacement). Diet and nutrition were provided by TBRC team throughout the duration of experiment. A week 
before the procedure, pigs were given daily a single dose of Aspirin (75 mg), and the night prior to surgical 
procedure, pigs were starved for 8 hours but allowed a continuous access of water.  
 
2.3 Experimental procedures 
 
   2.3.1 In-vivo Left Anterior Descending (LAD) artery ligation in rodents 
 
All procedures conform to the Directive 2010/63/EU of the European Parliament and the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health (National Research Council 
Committee for the Update of the Guide for the and Use of Laboratory 2011). Ethical approval was obtained from 
University of Bristol, and project licence was granted from Home Office under project licence PPL 30/3448, held 
by Dr. Andrew James. 
Adult Wistar male rats were allocated into either SHAM (n = 5) or LAD ligation group (n = 5). Surgical procedures 
were performed by Dr. Simon Bryant in animal care unit, University of Bristol and I observed the surgery. 
      2.3.1.1 Anaesthetic drugs  
 
Table 2.3 includes a list of anaesthetic drugs and their dosage, function and route of administration in LAD 
coronary artery ligation procedure for rodents. Induction of anaesthesia was achieved by injecting 
medetomidine HCl and ketamine HCl mixture into intraperitoneal space. Followed by Buprenorphine HCl 
subcutaneous injection to start analgesia and surgery. Finally, Atipamezole was used as a reverse agent to 





 Table 2.3 List of anaesthetic drugs used in LAD coronary artery ligation procedure in rats. 
 
     2.3.1.2 Surgical procedure  
 
After ensuring adequate anaesthesia, level of responsiveness was assessed by rear foot reflexes. The rats were 
intubated via endotracheal tube and ventilated with small animals respirator (Harvard Apparatus) at 250 ± 10 
ml flow volume/min. Heat mat was placed under each rat to maintain the body temperature at 37°C throughout 
the sugery and recovery. A 3 cm longitudinal left parasternal thoracotomy incision was created from 3rd 
intercostal space. In LAD group, a coated braided polyester round needle 6-0 was used to occlude and tie LAD 
coronary artery. In SHAM operated rats, no LAD artery occlusion occurred. The surgical incision was closed using 
4-0 Vicryl on a cutting needle.  
 
       2.3.1.3 Recovery and monitoring 
 
Rats received recovery inside a recovery chamber (Vet Tech Solutions Ltd) where they were ventilated with room 
air, given glucose saline and followed closely up to 2 hours. All the operated animals survived after the surgery 
and kept under daily close monitoring and observation at Animal Services Unit, University of Bristol for four 
weeks after the day of surgery. At the end of the experiment, the rats were culled according to Schedule 1 killing 
method by stunning and cervical dislocation. 
 
   2.3.2 Percutaneous Balloon occlusion of proximal left anterior descending (LAD) artery in pigs 
 
Animal procedures were undertaken at the University of Bristol Translational Biomedical Research Centre (TBRC) 
in accordance with the United Kingdom Animal (Scientific Procedures) Act, 1986, under project licence PPL 
7008975, held by Prof. Raimondo Ascione. TBRC team carried out the intervention, led by Dr. Tom Johnson and 
Drug  Dose per 100 g (of rat body weight) Function  Route 
Medetomidine HCl (1 
mg/ml) and Ketamine HCl 
(100mg/ml) 
125 µl of medetomidine:ketamine 
2:3 ratio. 
Induction Intraperitoneal 
Buprenorphine HCl (0.3 
mg/ml) 
17 µl Analgesia Subcutaneous 






Dr. Domenico Bruno. Four months old female Yorkshire (n=4, weights 62.3 kg ± 5.55 kg) underwent 60-minute 
closed-chest balloon catheter inflation to occlude the proximal left anterior descending (LAD) coronary artery.  
 
    2.3.2.1 Anaesthetic drugs  
 
Table 2.4 includes a list of anaesthetic drugs and their dosage, function and route of administration in LAD 
coronary artery occlusion procedure for pigs. 
Table 2.4 Dose and route of administration of anaesthetic drugs used in LAD coronary artery occlusion procedure in pigs. 
 
 Anaesthesia was delivered and maintained by veterinary anaesthetists and TBRC team in Langford campus, 
University of Bristol.  
     2.3.2.2 Surgical procedure  
 
The pigs underwent closed chest percutaneous balloon occlusion of proximal LAD coronary artery for 60 minutes 
to induce MI. The mean pressure of occlusion inside the artery was 10.6 atmospheric pressure (atm). Deflation 
of balloon to achieve reperfusion and animal recovery followed. Amiodarone (300mg) and magnesium (8 mg) 
were administered through a central line at the time of MI induction and over 4 hours as a measure to decrease 
the possibility of fatal ventricular arrhythmia. Cardiopulmonary resuscitation (CPR) was performed in case of 
lethal arrhythmia. CMR and cTnI measurement methods were used to assess cardiac injury after four weeks, 
and are described fully in appendix. 
   2.3.2.3 Recovery and monitoring 
 
All the operated animals were kept under daily intensive monitoring and observation at TBRC, University of 
Bristol for four weeks from the day of intervention before termination. 
   2.3.2.4 Control Group 
 
Control group was chosen from healthy four months old pigs were (n=4) from abattoir, Langford Campus for 
veterinary sciences, University of Bristol 
Drug  Dose  Function  Route 
Dexmedetomine 15 mcg/kg Sedation Intramuscular 
Ketamine 10 mg/kg Induction Intramuscular 
Propofol 1 mg/kg Induction Intravascular 
Isoflorane (2%) Maintenance Inhalation 
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2.3.3 Tissue collection, preparation, and storage 
 
    2.3.3.1 Rats 
 
Animals were culled according to Schedule 1 killing methods by stunning and cervical dislocation. Hearts were 
extracted and rapidly transferred into ice-cold KH buffer. Each heart was cannulated into Langendorff system 
through the aorta and perfused at speed of 10 ml/min for 5 minutes with KH solution then switched to 
cardioplegia solution by syringe pump. 
Tissues from apex, right and left atrium were collected, transferred to cryotubes (Thermo Fisher Scientific, UK) 
and immediately snap frozen in liquid nitrogen and stored at - 80 °C. Perfusion then switched to electron 















   2.3.3.2 Pigs 
 
Cardiac tissues collected from infarcted region from left ventricle from LAD group (four weeks after surgical 
procedure) and left ventricle from control were transferred immediately into cryotubes, snap frozen in liquid 
nitrogen and stored at -80°C freezers. 
Additionally, tissues from left ventricle of control as well as infracted area of left ventricle in LAD group were 
placed in 4% paraformaldehyde solution, kept at 4°C for 24 hours and sent for tissue processing and embedding 
the following day.  
            
 
 
Figure 2.1 Isolated Langendorff perfused rat heart extracted after 4 weeks after LAD coronary artery ligation. 
Surgical knot outlined in blue arrow. The right panel shows how selected parts of the heart that were 
collected for different purposes. Following perfusion with cardioplegia, left and right atria and the apex were 
collected for molecular studies. Sections for histology were taken after perfusion with fixative. 
Proteomics / 
metabolomics 





 2.4 Methods 
 
 2.4.1 Proteomics and phosphoproteomics 
 
    2.4.1.1 Protein extraction  
 
Tissues from pigs or rats were defrosted but kept on ice and weighed for wet weight. This was followed by the 
addition of 10 µl RIPA buffer cocktail per 1 mg of tissue wet weight. RIPA buffer cocktail was prepared in 200ml 
1X PBS. The following were added to the PBS: 1% (v/v) Nonidet P-40 detergent, 0.5% (w/v) Sodium deoxycholate 
and 0.1% (w/v) Sodium dodecylsulphate. On the day of the experiment, protease and phosphatase inhibitors 
were added, these were mini, EDTA-free protease inhibitor cocktail tablets and phosphatase inhibitor cocktail 
tablets PhosSTOP (Roche, UK). 
Up to 20 Zirconium oxide beads (1.4mm) were added as appropriate to the tissues immersed in RIPA buffer 
cocktail in 0.5 ml soft tissue homogenizing CK 14 tubes (Precellys 24), then each tube was placed in the tissue 
homogenizer (Bertin technologies, France) at 4°C for 10 seconds, repeated twice at the maximum speed with 5 
second break. Tubes containing the homogenised tissues were left in icebox on the shaker for 30 minutes, before 
centrifugation at 10,000 x g for 10 minutes at 4°C. The supernatant was pipetted and kept in Eppendorf tubes at 
-80°C for further quantification using Bradford assay. The pallet contained cellular debris and, therefore, was 
discarded. 
 
    2.4.1.2 Protein estimation using Bradford assay  
 
Bradford assay was used to quantify proteins content in the samples prepared in the previous section. First, the 
samples were diluted three times with distilled water (5 μl sample to 10μl of distilled water) to fit in standard 
curve range. 5 μl of the diluted samples were then pipetted into LP4 tubes in duplicates and 5 μl of RIPA buffer 
as a blank. Bovine Serum Albumin (BSA) stock solution 5 mg/ml was used to prepare protein standard curve by 
pipetting a duplicate of 1, 2, 3, 4 and 5μl into LP4 tubes. Followed by addition of 3ml of Bradford reagent to 
every single tube plus an empty one serving as standard blank. All the tubes were vortexed and incubated for 
15 minutes at room temperature.  The light absorbance was measured at 595nm using spectrophotometer. 
Average absorbance of each BSA concentration was calculated and used to plot the standard curve. The curve 





















Protein concentration of 2mg/ml was prepared by diluting the protein extract with double distilled water, based 
on Bradford protein quantification method. Protein identification was performed using Tandem Mass Tagging 
(TMT) (ThermoFisher Scientific, UK) and reverse phase nano-liquid chromatography (RP nano-LC MS/MS) using 
a LTQ-Orbitrap Velos mass spectrometer at the University of Bristol Proteomics Facility (ThermoFisher Scientific, 
UK), run by Dr. Kate Heesom. 
    2.4.1.3 Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) setup 
 
Proteins of each sample were digested and processed into amino acids, which were labelled using TMT. Each 
TMT label consists of a cleavable linker region, and NH2 Reactive group, which allows efficient amine-specific 
binding to peptides, a Mass Normaliser, which is used to ensure the overall mass of each tag is constant despite 
the differing reporter groups, in addition to a Mass Reporter group (R), that specifically binds to each sample in 
a single run (labelled as 126, 127, 128, 129, 130 and 131) (Abdul-Ghani, Heesom et al. 2014). The linker region 
is cleaved during LC-MS/Ms followed by fragmentation using Collision Induced Dissociation (CID), which releases 
the Mass Reporter group. This allows the detection of different reporter ions ranging 126-131 Da as they cluster 
at the low mass end of each LC-MS/MS spectra to indicate the relative abundance of each peptide by sample, 
as illustrated in figure 2.3. 
 

























Protein amount in rats (µg) 
Figure 2.2 Standard curve calculated using the Bradford assay in rats (above) and pigs (below). Absorbance was 
measured at 595 nm. 




























    
2.4.1.4 Phosphoproteins identification  
 
Phosphopeptide enrichment technique to quantify and determine phosphopetides in the samples was 
performed through running the tagged samples through a titanium dioxide (TiO2) column. Unlike the non-
phosphorylated peptides, the phosphopeptides in these samples bind to the column, this step was followed by 
elution and analysis in LC-MS/MS (Abdul-Ghani, Heesom et al. 2014). 
   2.4.1.5 Proteomics and phosphoproteomics data analysis 
 
Proteins levels were processed using Proteome discoverer software 2.1 (ThermoFisher Scientific, UK) as the 
sample normalized abundance values by setting the Normalization Mode parameter of the “Peptide and Protein 
Quantifier” node in Proteome discoverer to either Total Peptide or Specific Protein Amount. Proteins and 
phosphosites of low confidence rate were excluded from analysis. 
Proteomics data were transferred from Proteome discover to be analysed using Microsoft Excel 2016. After 
correction of each individual sample to the pooled sample, abundance of proteins in each group was displayed 
as mean and standard error of the mean (SEM). F-test for variance followed by Unpaired student’s t-test were 
used to determine statistical significance (p < 0.05) between 2 groups. Data were illustrated as Fold Change 
(mean LAD abundance/ mean SHAM or Control abundance). Panther GO database was used to classify molecular 
function of proteins. Pathway analysis was completed using Ingenuity Pathway analysis (IPA) software (QIAGEN, 
USA) against rodent and human databases for porcine data (using Uniport ID system). 
 Figure 2.3 (Right and Left): The tandem mass tag reagents. Right: Structure of the amine-reactive TMT Reagents. A) 
Functional regions of the reagent structure. B) Structures ofTMT10plex reagent with 13C and 15N heavy isotope 
positions (red asterisks) Left: Scheme for MS experiments using TMT Isobaric Mass Tagging Reagents. In this experiment, 
protein extracts are reduced, alkylated and digested overnight. Samples are labelled with the TMT Reagents and then 
mixed before sample fractionation. Labelled samples are analysed by high resolution Orbitrap LC-MS/MS right before 




Phosphosites analysis followed same pattern as proteome data, in addition to Proteome Discoverer program to 
identify the exact phosphorylation site(s) of each phosphoprotein. 
 
 2.4.2 High Performance Liquid Chromatography (HPLC) 
 
    2.4.2.1 Samples preparation 
 
Frozen tissues, as described in (section 2.3.3), were crushed using a pestle and mortar in liquid nitrogen. The 
resulting tissue powder was immediately moved into perchloric acid (PCA) containing LP3 tube (4.8% perchloric 
acid (PCA) made by addition of 8 ml of 60% PCA to 100ml distilled water and cooled to 4°C. The tubes were 
weighed before and after addition of the tissue powder to obtain wet tissue weight. The mixture was vortexed 
(Rotamixer 7871, Hook & Tucker Instruments) and centrifuged at 4°C, 4000 g for 10 minutes using Allegra 21R 
centrifuge (Beckman Coulter, UK). The supernatant was neutralised by mixing with equal volume of 0.44 M K2CO3 
(400 µl). The mixture was then centrifuged again at 4°C, 4000 g for 10 minutes. The supernatant was collected, 
aliquoted and stored at -20 °C freezer for HPLC analysis while the pellet, potassium perchlorate and debris, was 
discarded. 
   2.4.2.2 HPLC apparatus 
 
The high-performance liquid chromatography (HPLC) instrumentation consists of a solvent module pump 
(Beckman System Gold 125), an autosampler (Beckman System Gold 507e, Beckman Coulter Ltd, UK), a 
separation column, and a detector (Beckman System Gold 166, Beckman Coulter Ltd, UK). All the samples were 
run by Hua Lin. The machine operates through two phases, stationary and mobile phase. Standards or samples 
were first injected by autosampler to the separation column, which is termed stationary phase, then a high-
pressure pump forces the eluent solution through the column, i.e., mobile phase. A chromatographic material 
is used for compounds separation, in which the absorbance was recorded by a detector that is wired to computer 














2.4.2.3 Metabolites Analysis 
 
A 3 μm octadecyl silane Hypersil column (150 mm x 4.6 mm) was used as the separation column (Thermo 
Scientific, UK). The elution of metabolites is dependent on the composition of the mobile phase, 
which contained two eluents. Eluent A (150 mM KH2PO4 and 150 mM KCl, set at pH 6.0 with KOH) and eluent B 
(eluent A with 15 % (v/v) HPLC grade acetonitrile added) and a low-pressure gradient mixing device was used 
to ensure a well-controlled composition of the mobile phase.   
At different time points, the amount of eluent B changed linearly as seen in table 2.5. The 
column temperature was maintained at 17-19 °C and the absorption was measured at 254 nm.  
 
Table 2.5 Mobile phase composition at selected time points.  
 
Time (min) Flow speed (mL ∙ min-1) Eluent A (%) Eluent B (%) 
0 0.9 100 0 
0.1 0.9 97 3 
3.0 0.9 91 9 
7.0 0.9 0 100 
8.5 0.9 100 0 
 
10 μL of standard samples or 20 μL of tissue extract were injected into HPLC system and bound to the 
column. ATP, ADP, AMP, GTP, GDP, GMP, IMP, xanthine, hypoxanthine, β-NAD, inosine and adenosine were 
measured.  According to the mobile phase composition, each of these metabolites were eluted at different 









2.4.2.4 HPLC Data analysis 
 
The signals generated from HPLC were displayed as chromatograms using OpenLab Software (Aligent, USA). The 
samples chromatograms were compared to the standards to identify peaks of each metabolite (Figure 2.5). Data 
analysis was completed by measuring area under curve and adjusting the values to samples recorded weights. 
Concentration of metabolites is derived from the corrected values, and statistical analysis is done by comparing 










2.4.3 Nuclear Magnetic Resonance (NMR) 
 
   2.4.3.1 NMR apparatus 
 
NMR spectroscope (700 MHz Bruker AVANCE HD, Bruker BioSpin GmbH, Germany) in School of Chemistry at 
University of Bristol, consists mainly of liquid handling robots, sample holder placed within a magnet (14 Tesla) 
that is wired with radiofrequency (RF) pulse transmitter and receiver. Once the signal is obtained and detected 
from RF receiver, it is amplified and strengthened by a recorder that transforms the spectrum for analysis. Figure 







Figure 2.5 Chromatographs for cardiac energetics from one of the samples, measured using high-performance 

















   2.4.3.2 Samples preparation for NMR  
 
       2.4.3.2.1 Blood 
 
Blood samples taken from rats (baseline and 4 weeks after LAD ligation) or pigs (4 weeks after LAD occlusion and 
control) were collected into EDTA tubes, centrifuged at 2000 g for rats samples (1000 g for pigs) for 10 minutes, 
and the resultant plasma was placed into Eppendorf tubes and stored in -80°C freezer until the day of the 
experiment. Samples (~0.5ml each) were then transferred to School of Chemistry-University of Bristol on dry ice 
for metabolites analysis using Nuclear Magnetic Resonance spectroscopy (NMR), run by Dr. Matt Goodwin. Once 
defrosted, plasma is transferred into 1.7 mm CryoProbe and dissolved with NMR buffer (1 PBS tablet, 0.16 g 
Trimethylsilylpropanoic acid (TSP), 0.2 g sodium azide NaN3 in 170 ml type I water and 20 ml deuterium oxide 
(D2O), adjusted to pH 7.4) and kept at 4°C during running. 
                    
       2.4.3.2.2 Myocardial tissue extract 
 
Same extraction method, that was used in section (2.4.2.1) using PCA extraction, was also used in NMR study to 
detect cardiac tissue metabolites from both rodent and porcine models.  
Figure 2.6 NMR experiment workflow. A schematic diagram of Nuclear Magnetic Spectroscopy. Plasma is mixed with NMR 
buffer, transferred into cryoprobe (tubes) and placed inside NMR magnet. A radiofrequency generator detects the 
radiofrequency signals of each sample, which are recorded, transformed and processed into NMR spectrum. (own work) 
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   2.4.3.3 Running samples in NMR spectroscope 
 
NMR depends on the quantum mechanical properties of the nucleus of the atom, specifically spinning and 
electrical charge. 1H-NMR uses external magnetic field that is exposed toward hydrogen nuclei of biomolecules, 
therefore the energy is transferred to a higher level and vice versa, when magnetic field is removed. The energy 
transfer occurs at a wavelength that is recorded and interpreted based on the known properties of each 
molecules, since the intra-molecular magnetic field is specific depending on the type, number of hydrogen nuclei 
and their interactions within one single molecule (Watkins, Jenkins et al. 2017). Figure 2.7 shows a 
representation of 1H-NMR spectrum. 
 
 
  2.4.3.4 NMR Data analysis 
 
1H-NMR spectra were Fourier-transformed using Bruker TopSpin software (Bruker, Germany), 1D-1H Carr–
Purcell–Meiboom–Gill (CPMG) pulse sequence was used for data analysis using MestReNova software (Mnova, 
MestReNova Research SL, Spain) . 
 
Samples were referenced against Trimethylsilylpropanoic acid (TSP) at concentration of 4.6 mM, which had a 
chemical shift value of 0. Chemical shifts reference for selected metabolites were obtained using Human 
Metabolome Database (HMDB) and Chenomix metabolites library (Chenomix Inc., Alberta, Canada) and through 
searching the available literature (Soininen, Kangas et al. 2009) as seen in figure 2.8. Targeted metabolomics 
was used to determine differences between groups. Peaks areas generated from Mnova files were annotated 
to their corresponding metabolites, and the average of each metabolite was compared between the two groups 
(LAD vs. SHAM or control) using unpaired student’s t-test for pigs (and paired student’s t-test for rat samples). 
Figure 2.7 1-Dimension (1D) 1H-NMR spectrum generated by 700 MHz spectrometer. Some metabolites were annotated 
based on their chemical shifts (ppm). (own work) 
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Statistically significant p value is set to < 0.05. Fold change is calculated by dividing mean metabolites values in 
intervention group (LAD) by the corresponding ones at the baseline or control.  
 
2.4.4 Light Microscopy   
 
 2.4.4.1 Tissue processing and embedding  
  
    2.4.4.1.1 rats 
 
Fixed tissues from rat hearts were prepared by Dr Erin O'Callaghan. Mid sections of rat hearts were submerged 
in 50 mM PBS/EDTA for 5 minutes then switched to 10% formaldehyde solution for 2 minutes, and left in 4% 
formaldehyde solution at room temperature overnight. Tissues were transversely sliced and washed with PBS 
buffer twice and kept at 4°C for one day. Slices were later transferred to 30% sucrose in PBS. At this stage, the 
samples are floating on the surface, once they sink, indicating that sucrose had fully penetrated the tissues, they 
were oriented and embedded in OCT (Optimal Cutting Temperature) compound media using a piece of wood 
placed on dry ice before suspending tissues on the surface of Liquid Nitrogen until frozen. The samples were 




Fixed tissues were collected and proceed for sectioning. Scientific Cryostar NX50 Cryostat machine 
(Thermofisher Scientific, UK) was used to cut the OCT embedded tissue. First, the machine was cooled to -20 °C. 
The samples were transferred from - 80°C freezer on dry ice and left in the cryochamber to equilibrate with 
chamber temperature. Second, OCT freezing compound was added to specimen chunk to stick the sample on it, 
and when the chunk is placed on cryobar, the compound became frozen. The slices were cut at thickness of 8 
microns, anti-roll glass was used to prevent rolling of slices during cutting (Figure 2.9). Polysaline slides 
Figure 2.8 1D 1H-NMR spectrum of human plasma. From  (Soininen, Kangas et al. 2009) 
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(Thermofisher Scientific, UK) were used to adhere to the slices briefly after sectioning. Each glass slide was placed 
to air dry for 5 minutes before bringing it back to cutting chamber. Slides were either placed in acetone for 5 












   2.4.4.1.2 pigs 
 
Ventricular tissues were taken from left ventricle from both control and LAD groups. Samples were preserved in 
4% paraformaldehyde solution at 4°C, for 24 hours and then transferred to PBS buffer to be washed and 
preserved until processing in tissue processor (ThermoFisher Scientific ExcelsiorTM AS Tissue Processor). Each 
sample was cut to appropriate size of cassette and placed in tissue processer for gradual dehydration using 
ethanol, substituting water content in tissues, to allow for paraffin infiltration. Samples were embedded in 
paraffin blocks using Thermo Scientific™ HistoStar™ Embedding Workstation. Metal moulds were used in 
embedding by adding a layer of paraffin wax, followed by placing the sample in the desired orientation for 
cutting, topped with another layer of paraffin and then the plastic cassette. The moulds were cooled before 




Paraffin blocks were cooled on ice block, cardiac tissues were cut at 3-micron thickness using Thermo Scientific™ 
Shandon™ Finesse™ 325 Manual Microtome. Each section was placed in water path before it is placed into 
microscope slides (Superfrost, Thermo-scientific, UK) and left to dry in an oven at 37°C overnight. 
 
 
Section after cutting at 8 micron 
thickness 
A bloc containing heart embedded in 
OCT compound (white). 




Tissue preparation before staining  
Rat slides prepared from cryosectioning were transferred on dry ice and placed in coplin jar and submerged with 
acetone solution for 5 minutes at -20 °C for further fixation. Then slides were transferred to PBS solution. At this 
stage, tissues are rehydrated and ready to start staining protocol. 
Paraffin-embedded slides prepared from porcine hearts were rinsed with histoclear solutions before staining to 
dissolve wax and rehydrate tissues as listed in table 2.6. 
 
Table 2.6 List of histoclear solutions and duration in preparation for staining. 
 
Solution Duration 
Clearene 1 5 minutes 
Clearene 2 5 minutes 
Clearene 3 5 minutes 
100 % industrial methylated spirits (IMS) 3 minutes 
95 % IMS 3 minutes 
70 % IMS 10 minutes 
Distilled water Until staining 
 
Finally, once slides are in distilled water, they are ready for the staining protocol. 
 
 
  2.4.4.2 H&E Staining 
 
Haemtoxylin is a basic dye used to stain acidic structures in the cells (e.g. DNA, RNA) in blue to purple colour, 
whereas its counterstain, eosin, stains basic acidophilic elements of the cells such as cytoplasm and proteins 
with pink (Titford 2005). H&E staining is especially helpful when studying architecture and organisation of cells 





















Rehydrated slides (in water or PBS) are first stained with haematoxylin dye to stain nuclei in reddish-purple 
colour, which is enhanced by addition of weak alkaline. Then, eosin is added to stain different cellular 
components in pink. Porcine tissues were rinsed, dehydrated with alcohol and finally placed in clearene and 
mounted with Thermo Scientific™ DPX Mounting Media. A cover slip was placed to cover the specimen, and 
slides were dried in fume hood overnight.Rat tissues were airdried at the end of staining and then transferred 
into clearene and mounted in the same manner as porcine samples. 
  2.4.4.3 EVG Staining  
 
EVG stain uses iron-haematoxylin compound to stain elastin, which is found in elastic fibres in dark purple. Van 
Gieson’s stain, a counterstain, is used as contrast. The result of this stain is appearance of elastic fibres and 
nuclei with dark purple colour, collagen in red and other components in yellow or orange. EVG stain is used to 
study blood vessels since they are rich in elastic fibres. Figure 2.11 is a representative image of EVG stain from 
porcine heart.  
 
Figure 2.10 Representative mage of H&E stain from porcine heart. Scale bar set to 10 micron. 



















Rehydrated slides were transferred into 1% oxalic acid, rinsed in water. Slides were rinsed in 70% IMS and 
stained in Miller’s stain for 1 hour. This was followed by another rinse in 70% IMS and water. Then they were 
stained with the counterstain, Van Gieson’s stain, before rinsing and dehydration in alcohol (for porcine samples) 
and cleared in clearene and mounted with mounting media. Similarly, rodent samples were airdried and placed 
straight into clearene solution and mounted with Thermo Scientific™ DPX Mounting Media. 
 
Auto staining  
H&E and EVG staining were done using the auto-stainer (Thermo Scientific™ Varistain™ 24-4 Automatic Slide 
Stainer) which contains 24 compartments, 14 of which are used in the H&E staining, whereas 18 are used in the 
EVG staining. Running time for H&E and EVG staining were 51 min and 2 hours, respectively.   
Rat samples were treated similar to porcine samples, with exception of acetone fixation before placing slides 
into machine, and no gradual hydration and dehydration steps occurred. After staining, slides were mounted 
with Thermo Scientific™ DPX Mounting Media and left to air-dry in hood. 
  2.4.4.4 Masson’s Trichrome 
 
This stain involves three colours to differentiate three components: Collagen in blue, nuclei in black and 
cytoplasm and muscle fibres in red. Massan’s Trichrome is therefore used to study collagen fibres in skin and 
muscles, as seen in figure 2.12. 
Figure 2.11 Representative image of EVG stain from porcine heart. Scale bar set to 10 micron. Blue 





















For porcine samples, nuclei were first stained with Mayor’s Haematoxylin for one minute, washed with running 
tap water for 10 minutes and rinsed in distilled water. Cardiomyocytes were stained with Biebrich scarlet acid 
fushsin solution (3 ml glacial acetic acid, 2.4 gm of Biebrish scarlet, 0.3 gm of acid fuchsin, and 300 ml distilled 
water) for 15 minutes, rinsed in distilled water followed by the differentiation step in phosphomolybdic-
phosphotungstic acid solution (25 gm of 5% phosphomolybdic acid, 25 gm of 5% phosphotungstic acid, and 1000 
ml distilled water) for another 15 minutes until the collagen appears colourless. Slides were placed in aniline 
blue solution (2.5 gm aniline blue, 1 ml glacial acetic acid, and 100 ml distilled water) for two minutes and in 1% 
acetic acid for 5 minutes. Finally, slides were dehydrated with 95% ethyl alcohol, and 100% ethyl alcohol, cleared 
quickly in xylene and mounted resinous medium.   
 
Rat samples, however, had a different staining protocol. Masson’s Trichrome stain was prepared by placing 
acetone-fixed slides in tap water first, then left in Wiegert’s Iron haematoxylin (made up of equal volumes of 
Wiegert’s A +B solutions) for 8 minutes. The slides were moved to tap water for blueing, and then, differentiation 
in 1% acid alcohol, followed by blueing in Scott’s water and quick rinse in distilled water. The slides were stained 
in Masson’s red solution for 30 seconds and rinsed in distilled water. They were treated in 1% phosphomolybdic 
acid for 2 minutes and rinsed again in distilled water. Colour intensity of the red stain was checked at this stage 
to confirm adequate staining of myocytes. Slides were placed quickly (less than 2 seconds) in 25% Masson’s blue 
solution and rinsed immediately in distilled water, and finally 1% acetic acid for 1 minute. Slides were to air dry, 
then dehydrated and cleared in histoclear solutions before mounting with mounting medium.  
 
Figure 2.12 Representative image of Masson’s trichrome stain from porcine heart. Scale bar set to 10 





  2.4.4.5 Image acquisition and analysis 
 
Image Procapture software 2.1 was used to acquire images for different sections of H&E, EVG and Masson’s 
Trichrome stain under light microscope (Olympus BX40 Microscope and QImaging QICAM Fast 1394 digital 
camera).   
Different magnification at 1.25, 4, 10, 20 and 100X were obtained using different microscopic lenses. Images 
were coded before analysis, and ImageJ software (Fiji) was used to adjust scale and colour threshold to quantify 
fibrosis and arteriolar wall thickness.  
 
2.4.5 Electron Microscopy 
 
2.4.5.1 Samples processing, embedding and sectioning 
 
Left ventricular tissues from comparative groups (intervention and control or SHAM) in rodent and porcine 
hearts were sent to EM to study cellular ultrastructure and changes in mitochondrial morphometry in different 
subpopulations (subsarcolemmal, interfibrillar and perinuclear). 
 
After perfusion with cardioplegia as described in section (2.3.3.1), tissues from rat were perfused with EM 
fixative solution (0.1 M phosphate buffer + 1% glutaraldehyde + 1% paraformaldehyde + 0.5 mM CaCl2 and 1.7 
mM D-glucose anhydrous) for 2-3 min at rate of 1ml/min. Then tissues were cut and placed in phosphate buffer 
(76.76 mM HNa2O4P, 22.5 mM NaH2PO4.2H2O, and 100 ml distilled water; pH = 7.4) for an hour, then samples 
were washed and preserved in PBS buffer at 4°C, cut into small cubes before processing. Porcine tissues, 
however, were only preserved in 4% paraformaldehyde solution at 4°C, for 24 hours and then transferred into 
PBS buffer and cut into small cubes before EM processing. This fixation process is not normally used for EM, 
however, it was adopted to overcome technical issues with EM perfusion in porcine hearts. 
2.4.5.2 Tissue processing  
 
Porcine and rodent fixed heart samples were sent for processing at Wolfson Bioimaging facility, University of 
Bristol by Gini Tilly. Hearts were placed in 1 % (w/v) OsO4 in phosphate buffer for 90 min for post-fixation. This 
was followed by a wash in phosphate buffer (3 times, 10 minutes each) and distilled water. Samples were stained 
in 3 % (w/v) uranyl acetate in distilled water for 30 min in dark room, followed by rinse in distilled water for 10 
minutes. Samples were dehydrated in 70%, 80% and 90% ethanol for 10 minutes in each solution, then rinsed 
in propylene oxide (3 times, 10 minutes each) before storage in sealed container overnight. Tissues were 
preserved in EPON epoxy resin for 24 hours, followed by embedding in EPON epoxy resin and polymerise at 
60 °C for 48-72 hours. Finally, tissues were cut into different blocks and stained finally with uranyl acetate and 





2.4.5.3 Image acquisition  
 
The EM sections were examined and captured with a Tecnai 12 bioTWIN transmission electron microscope (EI, 




















2.4.5.4 Data Analysis 
 
The obtained images were used to measure sarcomere length (micron), mitochondrial morphometry (length, 
width, perimeter), area and circularity, and aspect ratio (length: width) using ImageJ software.  
IBM SPSS software was used to analyse different measurements using student’s t-test and compare between 
the control (or SHAM) and LAD group. One-way anova was used to compare between different mitochondrial 








Figure 2.13 An image of T12 electron microscope. CCD = charge-coupled device. From(Littlejohns, 
University of et al. 2013) 
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2.6 Patients protocol and requirements for metabolomics study 
 
As explained in chapter 1, metabolomics is a relatively new omic application with great potential of identifying 
biomarkers of disease. Progression from acute cardiac injury following interventions (e.g., PPCI) to heart failure 
involves gradual remodelling (e.g., metabolic, molecular and structural) in infarcted and non-infarcted areas of 
the heart with inflammatory response (adaptive and innate) playing a central role in remodelling. These changes 
are likely to be reflected in changes in blood metabolites of patients which will reflect different steps of 
remodelling from acute (ischaemia/reperfusion) to chronic stage (heart failure). However, despite intense 
recent work involving measuring the metabolome, this has produced very little to identify early biomarker 
associated with progression to heart failure. Heterogeneity of patients including those with co-morbidities that 
a metabolic impact (diabetes, kidney disease, etc.) is likely to be responsible.  
The proposed pilot study aims to monitor alterations in the blood metabolome of STEMI patients (n=30) with 
no major associated disease that would impact upon the metabolome (e.g., diabetes, disease of the kidney, liver 
and peripheral vasculature). This will ensure the blood metabolome (acutely and chronically) will largely reflect 
the changes associated with cardiac remodelling. This project intends to assess changes and variations of left 
ventricular function and cardiac remodelling among STEMI patients using echocardiography soon after in-
hospital treatment with Primary Percutaneous Coronary Intervention (PPCI) and 4-6 weeks later. Blood 
metabolome will be measured and detected with NMR and High-Performance Liquid Chromatography, which 
are available at the University of Bristol.  
This preliminary study will identify metabolite(s) that correlate/predict the inflammatory response and 
progression to heart failure. The biomarker(s) are likely to be linked mostly to cardiac changes. The next step 
will expand on this by monitoring the identified metabolites in different populations of patients with different 
co-morbidities and characteristics. The trial will include more collection of samples, MRI will be deployed to 
monitor cardiac function to identify relationships between biomarkers and disease progression in patients with 
different co-morbidities.  
 
Study design  
The proposed pilot study will measure the blood metabolome in patients undergoing emergency PCI for STEMI 
at the time of presentation, 48 hours as part of routine standard clinical treatment, and 4-6 weeks later to assess 
remodelling and functional parameters. Additionally, cardiac function will be assessed at these intervals using 
echocardiography. Apart from blood collection during the chronic stage, all steps are part of current standard 
clinical care treatment in cardiac coronary care. The data will be collected over a 12months duration. In order 
to obtain a normal metabolome for reference, blood will be collected from age matched normal subject. 
 
Study Population 
This pilot study will include adult patients undergoing emergency PCI for STEMI resulting from left main coronary 
artery. Patients having any of the following will be excluded: diabetes mellitus; chronic kidney disease; lung 
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disease; previous MI; previous PCI; previous CABG; hypertension; peripheral vascular disease; cerebrovascular 
disease; valvular heart disease; heart failure. 
The obtained data will be analysed to look for any correlation between certain metabolomic profiles and degree 
of left ventricular dysfunction. If any biomarkers are identified this could be used to help risk stratify patients at 
risk of adverse remodelling and heart failure with reduced ejection fraction. Information gained will be used to 
design interventions to prevent adverse remodelling and cardiac fibrosis which is associated with high rates of 
morbidity and mortality. Copy of full protocol, including eligibility criteria and requirement, and ethics 









































Post ischaemic cardiac remodelling in rat model of 
























    3.1.1 Overview 
 
The use of rodents as preclinical model to study ischaemic heart diseases has been established for a long time 
using a variety of surgical and non-surgical methods. Bagdon et al first developed a non-surgical chemical 
intervention to induce MI in rat heart through sequential subcutaneous administration of isoproterenol, a non-
selective β adrenoreceptor agonist (Zbinden and Bagdon 1963). Others have used cauterisation applied to apical 
epicardium create focal lesions of necrosis (Adler, Camin et al. 1976), however, the most common and widely 
accepted technique is coronary artery ligation, to induce regional myocardial necrosis in a rat heart, which was 
first introduced by Pfeffer et al in 1979.  
Pfeffer group used left anterior descending coronary artery ligation procedure to investigate the relationship 
between infarct size and ventricular performance, and the role of captopril, an angiotensin-converting enzyme 
inhibitor, in modulating the course of LV remodelling in hearts with medium to large infarcts (Pfeffer, Pfeffer et 
al. 1979). This work established a foundation for several modified versions of the technique (for example, no 
heart exteriorisation, temporary instead of permanent coronary artery ligation) that are still used today as a 
classical model of MI in rodents. This procedure can be coupled with electrocardiography (ECG) and 
echocardiography, as a validation of the cardiac injury instantly, and to assess LV functional parameters and 
remodelling. It important to take in consideration that all these mentioned models involve normal hearts. 
Alternatively, other studies have used transgenic mice, particularly those fed high-fat diet, as they showed 
evidence of atherosclerosis and myocardial infarction (Chase 2007). However, these mice also have limitations, 
including uncertainty regarding onset of infarction. Although these techniques are extensively employed to 
evaluate and determine effectiveness of various cardioprotective therapeutic interventions, it must be noted 
that each has its own drawbacks and limitations, all of which must be considered carefully as attempts to mimic 
and study cardiovascular diseases (Patten and Hall-Porter 2009).  
    3.1.2 Integrated studies in small animal models of myocardial infarction 
 
Ischaemic heart disease has complex and inherent nature that involves crosstalk of multiple underlying 
mechanisms. Therefore, employment of system biology studies (including -omics studies) to trace imminent or 
consequent changes in the hearts during ischaemia and/or ischaemia reperfusion injury, both in clinical and 
animal models, provides wider and more inclusive prospects. The data obtained systemically using -omics 
technologies from several molecular levels at different time points could be collectively integrated to establish 
the major cellular pathways that result in substantial alterations in cardiac function and structure after acute 
myocardial injury. 
 Whilst some studies focused on specific pathophysiological aspects involved in myocardial damage such as 
inflammation and fibrosis (Frantz, Bauersachs et al. 2009, Prabhu and Frangogiannis 2016, Talman and Ruskoaho 
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2016), oxidative stress (Byrne, Grieve et al. 2003, Grieve and Shah 2003) and microvascular obstruction 
(Hamirani, Wong et al. 2014, Yu, Kalogeris et al. 2019) as disease modifying targets, others have used proteomic-
metabolomic studies to identify possible mechanisms implicated in acute MI  (White, Cordwell et al. 2005, Kim, 
Lee et al. 2006, Basak, Varshney et al. 2015). For example, Bai et al found significant perturbation in certain 
myocardial metabolic pathways such as lipid and amino acid metabolism, as well as proteins involved in vascular 
smooth muscle contraction and gap junction signalling, as measured from rat hearts 24 hours after LAD coronary 
artery ligation procedure (Bai, Sun et al. 2020). White et al reported marked upregulation in many functional 
protein groups, notably stress response proteins (Heat Shock Protein 27 kDa, Alpha B-Crystallin) and redox 
regulatory proteins (e.g. NADH Ubiquinone Oxidoreductase proteins) using isolated and perfused rabbit heart 
model of ischaemia reperfusion injury (White, Cordwell et al. 2005). Others have conducted metabolomics study 
in mice 8 weeks after MI, and demonstrated a decrease in metabolites related to lipid and energy metabolism, 
and an increase in indices of oxidative stress, such as oxidised glutathione (Sansbury, DeMartino et al. 2014). 
Nonetheless, a comprehensive approach that involves integration of -omics technologies with the observed 
alterations at the cellular and subcellular levels, such as mitochondria, to investigate and characterise the 
ongoing post ischaemic cardiac remodelling weeks after MI is highly needed.  
Therefore, chapter 3 aims to characterise modifications resulted from chronic MI-induced cardiac remodelling 
in rat model following LAD coronary artery ligation in the myocardium and blood. Molecular changes manifested 
as altered expression in cardiac proteomics and phosphoproteomis, integrated with cardiac and systemic 
metabolomics, in addition to assessment of cardiac cellular and subcellular components, were all presented to 
provide novel mechanistic aspects that could be translated as potential therapeutic targets to prevent adverse 
















The techniques and methods used in this chapter are fully described in materials and methods chapter (chapter 
2). In summary, 10 Wistar male rats (Charles River), weighing from 220 to 240 g, were used in this study. The 
animals were divided into SHAM or LAD group (n=5 per group). Additionally, a separate group of Wistar Rats 
(n=4) had also LAD coronary artery ligation surgery and were only used for collecting blood and histology 
samples. These were carried out by Dr. Erin Callaghan (Bristol Medical School). 
    3.2.1 Experimental procedure 
 
Details of surgery and anaesthesia are mentioned in detail in section (2.3.1). Briefly, after adjusting the dose to 
rat total body wight, induction of anaesthetise was achieved with intraperotineal injection of medetomidine and 
ketamine, while buprenorphine was used to maintain analgesia throughout the procedure. After intubation and 
ventilation with a respirator, rats body temperature was kept at 37 °C throughout the surgery and during 
recovery. Left longitudinal parasternal thoracotomy incision was made, and for LAD group, a suture was used to 
occlude LAD coronary artery. Whereas in SHAM operated rats, no LAD coronary artery occlusion occurred. The 
surgical wound was closed, and the rats were injected with atipamezole, placed in a chamber for recovery 
afterward and monitored closely for 2 hours. All operated animals survived after the surgery and kept under 
daily close monitoring and observation at Animal Services Unit, University of Bristol for four weeks after. 
        3.2.1.1 Heart extraction and perfusion 
 
Four weeks after surgery, SHAM and LAD rats (n=5) were culled according to Schedule 1 by stunning and cervical 
dislocation. Hearts were extracted and immediately immersed into ice cold KH buffer. Hearts were cannulated 
into Langendorff apparatus and perfused with KH buffer for 5 minutes, followed by cardioplegia solution for 
another 5 minutes. Tissues from apex, right and left atrium were collected and immediately snap frozen in liquid 
nitrogen for storage at -80 °C. Perfusion was then switched to EM fixative solution for 4 minutes.  
For the additional group of LAD rats, blood samples were obtained using tail cannulation prior to surgery, and 4 
weeks after ligation, just before termination. Blood samples were collected into EDTA tubes kept on ice until 
centrifugation at 1000 g for 10 minutes. The resultant plasma was collected into 0.5 ml Eppendorf tubes and 
stored at -80 °C.  Extracted hearts were submerged in PBS/EDTA solution prepared for OCT embedding for 
histology.  
    3.2.2 Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) 
  
Apical myocardial tissues from both group (n=5) were homogenised for protein extraction in RIPA buffer with 
protease and phosphatase inhibitors, followed by quantification using Bradford essay, and then the extracted 
samples were sent for Proteomics facility at University of Bristol, to be analysed using Liquid Chromatography 
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Tandem Mass Spectrometry (LC-MS/MS) to detect changes in proteins and phosphoproteins as described in 
detail in section (2.4.1). 
  3.2.3 High Performance Liquid Chromatography (HPLC) 
 
Apical, right and left atrial tissues from both group (n=5) were crushed with pestle and mortar for metabolites 
extraction using PCA and neutralised with K2CO3. The tissue extract was sent for HPLC analysis to determine 
cardiac energetics in apex, left and right atria from each group as described in section (2.4.2). 
  3.2.4 Nuclear Magnetic Resonance (NMR) 
 
Blood samples taken from rats prior to surgery and 4 weeks after LAD coronary artery ligation were collected 
into EDTA tubes, centrifuged at 1000 g for 10 minutes, and the plasma was transferred into Eppendorf tubes 
and stored in -80 °C freezer until later use. Plasma samples and tissue extracts (section 2.3.3.1) were then 
transferred to School of Chemistry, University of Bristol on dry ice for blood metabolites analysis using Nuclear 
Magnetic Resonance spectroscopy (NMR). Full method is described in section (2.4.3).  
Spike-in experiment 
Spike-in experiment of acetone and arginine involves injecting a small of pure metabolite sample into plasma 
and re-running NMR spectra. Overlapping of the spiked sample signal with the original un-spiked one at the 
exact chemical shift (ppm) confirms the presence of the metabolite(s). Therefore, 1.25 mM acetone and 2 mM 
Arginine in PBS buffer were injected separately into a pooled sample of rat plasma. Spectra of original plasma 
were first acquired using 700 MHz spectrometer. Then the spectra of metabolites in PBS buffer were recorded 
and compared against the spectra of plasma and metabolites mixture. 
  3.2.5 Light Microscopy  
 
Heart tissues from LAD rats (n=4) and a group of control from healthy adult rats (n=4) were fixed and OCT 
embedded and prepared for cryosectioning, and staining with H&E, EVG and Masson’s trichrome. Full details 
regarding these techniques are found in section (2.4.4). 
  3.2.6 Electron Microscopy 
 
Left ventricular tissues from SHAM and LAD rats (n=5) were fixed with EM fixative solution and sent for Wolfson 
Bioimaging facility for processing, EPON epoxy resin embedding, sectioning, and staining with uranyl acetate 
and lead citrate to study post ischaemic cardiac remodelling at ultrastructural structural level. Full details 




 3.3 Results 
 
  3.3.1 Effect of LAD coronary artery ligation on gross rodent cardiac morphology 
 
Hearts extracted from rats in SHAM and LAD groups were perfused in the Langendorff mode to flush out blood 
and restore physiological condition prior to tissue collection and storage. Unlike SHAM group, hearts in LAD 











Masson trichrome staining was used as a conventional method to establish a solid histological evidence of the 










Figure 3.1 Extracted SHAM and LAD hearts. a. A representative SHAM heart in Langendorff perfusion. b. A cross-section of 
SHAM heart at the end of perfusion. c. LAD heart in Langendorff perfusion, asterisk indicates position of surgical knot. d. 







Figure 3.2 Representative section of Masson’s Trichrome staining of LAD heart. Transverse section of a representative 
LAD coronary artery ligated heart stained with Masson’s trichrome stain. Collagen dense scar, located in the infarcted 




     3.3.1.1 Effect of LAD coronary artery ligation on distribution of cardiac fibrosis  
 
For detailed microscopic examination, three distinct areas from LAD hearts (infarct, border zone and remote) 
were selected based on Masson trichrome stain (figure 3.3). Four weeks post infarction, the infarct area 
demonstrates a pattern of compact fibrosis, characterised by its collagen dense disruption and scarcity of 
cardiomyocytes. In the border zone, however, cardiomyocytes were interspersed with blue collagen septa (i.e., 
diffuse fibrosis). Remote area shows bundles of cardiomyocytes with little to no fibrosis. This stain was also used 
to quantify the percentage of fibrous tissue in both groups from multiple cardiac sections as shown in figure 3.4. 
























Figure3.3 Masson’s trichrome staining of infarct, border zone and remote areas. Three areas in the LAD heart were 
selected and demarcated using Masson’s trichrome stain into infarct (*), border zone (ƚ) and remote (∇). Central 















  3.3.1.2 Effect of LAD coronary artery ligation on elastin deposition and arteriolar wall thickness 
 
EVG staining was used to identify elastin fibres (purple), collagen (red) in contrast to cardiomyocytes, which are 
stained in orange, as seen in figure 3.5. In control hearts, elastin is found in the elastic layer that connects intima 
to media in small arteries and arterioles. The outer layer (adventitia) is surrounded by a collagen rich matrix with 
occasional fibroblasts. However, infarct areas 4 weeks after LAD coronary artery ligation appear to include 
widespread discrete of elastin fibres bundles, in addition to collagen. Border zone exhibits interspersed collagen 
(diffuse fibrosis) with elastic fibres confined to the wall of arterioles, whilst no similar pattern was observed in 
the remote area.  
EVG stain was used to detect differences in the arterial wall thickness of medium to small arterioles (20-200 
micron in diameter) in infarcted area of LAD group against the control. There was significant increase in the ratio 
of total arteriolar wall area to total arteriolar area in LAD group, indicating an increased thickening of arteriolar 























Figure 3.4 Percentage of fibrosis in control and LAD groups. Quantification of cardiac fibrosis was performed from 
serial cross-section from LAD and control groups. Data were analysed using unpaired student’s t-test and presented 







































Figure 3.5 Representative EVG staining of control and LAD heart sections. a. Control heart, b. remote area, c. border 
zone and d. infarct area. Elastin is stained in purple (white asterisks in a), collagen in red (blue arrow in c), and 


































Figure 3.6 Percentage of arteriolar wall area to total arteriolar area. Percentage of artery wall area to total artery 
area was measured for each group, 3-4 fields were examined for each heart. Data were analysed using unpaired 














  3.3.1.3 Effect of LAD coronary artery ligation on cardiac cellular infiltration 
 
Haematoxylin &Eosin staining is used to differentiate the eosinophilic cytoplasm, which is stained in dark pink, 
from nuclei (blue) as shown in figure 3.7.  Massive cellular infiltration is observed in the collagen dense matrix 
in infarct area of LAD hearts, and to a lesser extent, in the border zone. Control hearts show clear bundles of 






















Figure 3.7 Representative H&E staining of control and LAD heart sections. a. control heart, b. remote area, c. border zone 
and d. infarct area. Cytoplasm is stained in dark pink, collagen in light pink (asterisks in c and d), and nuclei in blue (blue 







  3.3.2 Effect of LAD coronary artery ligation on rodent cardiac ultrastructure  
 
Transmission electron microscopy imagining (FEI TecnaiTM 12) was used to analyse structural differences 
observed in the infarct area of LAD hearts compared to SHAM hearts, 4 weeks after procedure. Measurements 
of mitochondrial morphology, distribution, cristae density and sarcomere length, along with characterisation 
and detection of the various elements of the interstitial architecture were performed.  
Figures 3.8- 3.10 are representative examples of infarcted areas taken from LAD heart. Numerous fibroblasts, 
and few myofibroblast, as well as endothelial cells, are scattered in the collagen-rich matrix. Telopodes, 



















Figure 3.8 TEM micrograph from a representative LAD ligated left ventricle. E. endothelial 


































Figure 3.9 A and B: Distribution of matrix cellular components in between cardiomyocytes in from representative LAD hearts.  



































    
 
Figure 3.10 TEM micrographs of white blood cell, telocyte and fibroblasts in LAD ligated left ventricle. E. endothelial cell, 
MyF myofibroblast, Fb, fibroblast, Tp, telopode, WBC, white blood cell. Blue arrow heads pointed to stress fibers in 







3.3.2.1 Mitochondrial cristae density, subpopulation distribution and morphometry 
 
Based on their location and distribution, there are three subpopulations of mitochondria in cardiomyocytes: 
Interfibrillar (IF), subsarcolemmal (SS) and perinuclear (PN). First, cardiomyocytes total area was measured for 
each group (figure 3.11A), and then the distribution of each subpopulation was measured and compared for 
both groups, as shown in figure 3.11B. Cardiomyocytes in LAD group had slightly insignificant increase in total 
area. Interfibrillar mitochondrial distribution tend to be decreased in LAD group (p > 0.05), and other 





















































































Figure 3.11 Mitochondrial distribution in rats A) Average cardiomyocyte area in each group, 3-4 fields containing 
longitudinal cardiomyocytes were examined for each heart. B) Percentage of mitochondrial subpopulations areas to total 
cardiomyocytes area. Mitochondrial subpopulation area that occupies selected area within cardiomyocyte was measured, 
and the ratio was calculated to total cardiomyocyte area. Data are presented as mean ± SEM, and analysed using unpaired  






Mitochondrial cristae density, which is inversely correlated to the ratio of intercristae space to the 
mitochondrion area, reflects the degree of cristae separation and mitochondrial swelling, was analysed for each 
group. In LAD group, there was significant increase in ratio of intercristae space area to total mitochondrial area 











In addition to subpopulation distribution and cristae density analysis, morphometric measurements for all 
mitochondrial subpopulations were measured for each group, followed by a comparison of each subtype 
between the two groups. 
              3.3.2.1.1 Mitochondrial subpopulations morphometry in SHAM group 
 
Perinuclear and subsarcolemmal mitochondria showed a significant decrease in length when compared to 
interfibrillar counterpart (PN p = 0.028, SS p = 0.017 vs. IF). Similarly, subsarcolemmal mitochondria were also 
significantly decreased in size (p = 0.049 vs. IF). The perimeter and roundness of perinuclear mitochondria were 
significantly decreased compared to interfibrillar mitochondria. However, the remaining mitochondrial 







Figure 3.12 Mitochondrial density in SHAM and LAD group. Bars charts represent the ratio of intercristae area to 
total mitochondrion area in each group. Data are presented as mean ± SEM and analysed using unpaired t-test. 
Images were analysed using ImageJ software through automatic threshold level detection for each mitochondrial 
(green filter, within blue border, covers intercristae area).  n =5, 3-4 fields were examined for each heart, total 














































        3.3.2.1.2 Mitochondrial subpopulations morphometry in LAD group 
 
In LAD hearts, perinuclear mitochondria exhibited only significant changes in circularity and aspect ratio 
compared to interfibrillar mitochondria as seen in figure 3.14. This subtype had increased in circularity but 
decreased in aspect ratio. Unlike SHAM group, length and other morphometric measurement did not change 


























































IF SS PNC D 
Figure 3.13 Mitochondrial morphometry of SHAM group. A) Length, width, and perimeter B) Area by size and 
multiplication (L*W) C) Aspect ratio, roundness, and D) Circularity. Data are presented as mean ± SEM, and analysed 
using one-way ANOVA followed by the Bonferroni and Games-Howell post-hoc tests. *  p < 0.05 vs. IF. n=5, 3-4 fields 
were examined for each heart. Total mitochondrial count = 200 (IF), 198 (SS) and 180 (PN). IF interfibrillar, PN perinuclear 















































Interfibrillar mitochondria of LAD hearts had a significant increase in aspect ratio (L:W) when compared to SHAM 
group (p = 0.024). IF mitochondria in LAD group appeared more rounded and decreased in size, however, these 
changes were not statistically significant. Other morphometric measurements did not significantly differ 














Figure 3.14 Mitochondrial morphometry of LAD group. A) Length, width, and perimeter B) Area by size and 
multiplication (L*W) C) Aspect ratio, roundness, and D) Circularity. Data are presented as mean ± SEM, and 
analysed using one-way ANOVA followed by the Bonferroni and Games-Howell post-hoc tests. * p < 0.05 vs. IF. 
n=5, 3-4 fields were examined for each heart. Total mitochondrial count = 200 (IF), 189 (SS) and 192 (SS). IF 






















































































Perinuclear mitochondria morphometric measurements showed a slight increase in area and roundness in LAD 
group compared to SHAM, however, these changes were not significantly different between the two groups as 
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Figure 3.15 Interfibrillar mitochondrial morphometry of SHAM and LAD groups. A) Length, width, and perimeter B) 
Area by size and multiplication (L*W) C) Aspect ratio, roundness, and circularity. Data are presented as mean ± SEM, 
and analysed using unpaired student’s t-test. n=5, 3-4 fields were examined for each heart. Total mitochondrial 




































Similarly, morphometric measurements of subsarcolemmal mitochondria were not significantly different 















































Figure 3.16 Perinuclear mitochondrial morphometry of SHAM and LAD groups. A) Length, width, and 
perimeter B) Area by size and multiplication (L*W) C) Aspect ratio, roundness, and circularity. Data are 
presented as mean ± SEM, and analysed using unpaired student’s t-test, n=5, 3-4 fields were examined for 




























3.3.2.2 Sarcomere length  
 
Diastolic sarcomere length (measured from one end of the sarcomere to the other) did not significantly vary 























Figure 3.18 Sarcomere length in SHAM and LAD hearts. Data presented as mean ± SEM. Representative EM images of 
sarcomere length measurements in SHAM (A) and LAD group (B) with sarcomere length defined (yellow arrows). Data 







































Figure 3.17 Subsarcolemmal mitochondrial morphometry of SHAM and LAD groups. A) Length, width, and 
perimeter B) Area by size and multiplication (L*W) C) Aspect ratio, roundness, and circularity. Data are 
presented as mean ± SEM, and analysed using unpaired student’s t-test. n=5, 3-4 fields were examined for 
















   3.3.3 Effect of LAD coronary artery ligation on rodent cardiac proteins  
 
     3.3.3.1 Total proteins 
 
In total, 4786 proteins were detectable in both LAD and SHAM groups, of which, 321 proteins were significantly 
changed 4 weeks after LAD coronary artery ligation (p value < 0.05). Figure 3.19 shows a volcano plot for total 
proteins. There were 114 significantly different protein that had increased expression with LAD coronary artery 
ligation (FC > 1.3), compared to 69 proteins with decreased fold change (FC < 0.8).  




















p value < 0.05






A breakdown of total proteins classification into molecular and biological functions in addition to proteins class 
using Panther Database classification system is shown in figure 3.20. Expression heatmap of significantly 
different proteins (p value < 0.05) between SHAM and LAD groups was generated using heatmapper online tool 




Figure 3.19 Logarithmic (volcano) plot of fold change of total proteins identified in LAD group compared to 
SHAM. P- value calculated using unpaired student’s t-test. Reference lines indicate fold change < 0.8 or >1.3 on 
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Figure 3.20 Classification of total proteins between SHAM and LAD groups using the PANTHER classification system. 















































































Figure 3.21 Expression heatmap of significantly different proteins (p <0.05) between SHAM and LAD groups. Heatmap 
was created using online tool (http://www.heatmapper.ca/expression/). n = 5, total significant proteins count = 321. 
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Significantly different proteins were further categorised into high or low expression (fold change 
(LAD/SHAM) >1.3 or < 0.8, respectively). Panther database classification system was also used to breakdown 
protein of high and low categories according to molecular and biological functions, and protein class. Figure 3.22 
shows these reported categories of significantly different proteins characterised by substantial decreased or 
increased fold change. Highly expressed proteins were predominantly involved in binding and catalytic activities.  
Proteins with low expression were classified mainly as catalytic, followed by binding and transporter activities. 
Interestingly, metabolites interconversion enzymes constitute a substantial class in proteins significantly 
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Figure 3.22 Classification of significantly different proteins between SHAM and LAD groups using the PANTHER classification 
system. Proteins are classified according to increased and decreased expression into molecular function (A) and biological 






          3.3.3.1.1 Mitochondrial proteins  
 
A total of 357 mitochondrial proteins were detected and shown in a volcano plot (figure 3.23). Approximately 
4% (n=14) of mitochondrial proteins had significant difference (p- value < 0.05) between SHAM and LAD groups.  
 


















p value < 0.05





These mitochondrial proteins are presented in figure 3.24. Highly expressed mitochondrial proteins involved in 
mitochondrial electron transport chain (Cytochrome c oxidase subunit 6A1, Atypical kinase COQ8B), and amino 
acids metabolism (Ornithine aminotransferase, Glutaminase kidney isoform). Proteins related to fatty acids 
metabolism (Long-chain specific acyl-CoA dehydrogenase, Short/branched chain-specific acyl-CoA 






Figure 3.23 Logarithmic (volcano) plot of fold change for total mitochondrial proteins identified in LAD group 
compared to SHAM. P- value calculated using unpaired student’s t-test. Reference lines indicate fold change < 0.8 




       
3.3.3.1.2 Kinase proteins 
 
Nine protein kinases were increased in LAD group such as protein kinase C and tyrosine protein kinase, while 
three kinase proteins were downregulated (figure 3.25). These were pantothenate kinase 1 (coenzyme A 
biosynthesis), adenylate kinase isoenzyme 1 (De novo purine biosynthesis), and creatine kinase M-type 











































Figure 3.25 Protein kinases. D3ZZH6; Mitogen-activated protein kinase kinase kinase 5, G3V9W5; Phosphatidylinositol 5-
phosphate 4-kinase type-2 gamma, D3ZWD3; Pantothenate kinase 1, F1LS98; Protein kinase C, G3V9W2; Tyrosine-protein kinase, 
O08662; Phosphatidylinositol 4-kinase alpha, Q99M64 ; Phosphatidylinositol 4-kinase type 2-alpha, A0A0G2K3A0; 
Serine/threonine-protein kinase WNK1, P54645; 5'-AMP-activated protein kinase catalytic subunit alpha-1, Q7TT49; 
Serine/threonine-protein kinase MRCK beta, P39069; Adenylate kinase isoenzyme 1, A0A0G2JSP8; Creatine kinase M-type. Data 






















*** * * * * * *
* * *
**
Figure 3.24 Mitochondrial proteins. P14604; Enoyl-CoA hydratase, Q4G064; 2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, 
Q5U1Z8; Protein preY, A0A0A0MY00; Short/branched chain-specific acyl-CoA dehydrogenase, D3ZY50; ATP synthase 
mitochondrial F1 complex assembly factor 1, D3ZMR9; Mitochondrial ribosomal protein L21, P29117; Peptidyl-prolyl cis-trans 
isomerase F, G3V7L0; Adrenodoxin, P12007; Isovaleryl-CoA dehydrogenase, P15650; Long-chain specific acyl-CoA dehydrogenase, 
P10818; Cytochrome c oxidase subunit 6A1, Q6AY19; Atypical kinase COQ8B, P13264; Glutaminase kidney isoform, Q5U2R4; 
Mitochondrial ribonuclease P protein 1, F1LMZ4; Ribosome-releasing factor 2, P04182; Ornithine aminotransferase. Data were 





    3.3.3.1.3 Phosphatase proteins 
 
Only inositol monophosphatase 2 and serine/threonine-protein phosphatase 2B catalytic subunit beta isoform 
and were significantly different between LAD group and SHAM (figure 3.26). The later plays an important role in 









    3.3.3.1.4 Oxidoreductase proteins 
 
Figure 3.27 shows the oxidases and reductases proteins that significantly changed four weeks after LAD coronary 
artery ligation. Aldehyde oxidase 3, which is involved in superoxide generation, was almost doubled in LAD group 
(FC = 2.2), whereas methionine sulfoxide reductase B3, which reduces oxidised methionine, was significantly 
































Figure 3.26 Protein Phosphatases. P20651; Serine/threonine-protein phosphatase 2B catalytic subunit beta 




























Figure 3.27 Oxidoreductase proteins. D4A650; Methionine sulfoxide reductase B3, P10818; Cytochrome c oxidase subunit 
6A1, mitochondrial, Q5QE80; Aldehyde oxidase 3, P00388; NADPH-cytochrome P450 reductase, Q6P7R8; Very-long-chain 








    3.3.3.1.5 Antioxidant related proteins 
 
Significantly different antioxidant proteins such as superoxide dismutase [Cu-Zn] and glutathione peroxidase 
were decreased in LAD hearts compared to SHAM as seen in figure 3.28. Other major antioxidants proteins like 
catalase (not shown), were not differentially changed between the two groups. 
     3.3.3.1.6 Inflammation related proteins 
 
Proteins involved in various inflammatory pathways, such as T cell activation (CD48 antigen), response to 
chemotaxis (lymphocyte specific 1, isoform CRA_a), macrophage and monocytes activation, (macrophage 
activation 2 like, CD163 antigen), and mast cell activation (tryptase), were all significantly upregulated in LAD 





























* * * * *
Figure 3.28 Antioxidant related proteins. P04041; Glutathione peroxidase 1, F1LQI1; Hydroxyacyl glutathione hydrolase, 
P07632; Superoxide dismutase [Cu-Zn], P08009; Glutathione S-transferase Yb-3, B0BNE5; S-formylglutathione hydrolase. 

































Figure 3.29 Inflammation related proteins. P10252, CD48 antigen, M0RDF8; Macrophage activation 2 like, Q5FVQ6; 
Interferon-gamma-inducible GTPase Ifgga3 protein, D3Z9U2; CD163 antigen, G3V8E5; Tryptase, Q4QQV6; Lymphocyte 
specific 1, isoform CRA a, Q31256; MHC class I RT1.Au heavy chain, A0A0G2JVZ6; Integrin subunit alpha V. Data were 
analysed using unpaired t-test. * p < 0.05, n=5 
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    3.3.3.1.7 Ions transport proteins  
 
Three ions transport proteins were significantly upregulated 4 weeks after LAD coronary artery ligation as shown 
in figure 3.30. Calcium channel voltage-dependent, alpha 2/delta subunit 2 and voltage-dependent L-type 
calcium channel subunit alpha mediates Ca2+ entry to the cell to further calcium release from the sarcoplasmic 
reticulum during EC coupling, while sodium/potassium-transporting ATPase subunit beta-3 is an integral 








        
3.3.3.1.8 Extracellular matrix proteins  
 
Several extracellular proteins were either upregulated or downregulated four weeks after LAD coronary artery 
ligation as listed in figure 3.31. Although many collagen subunits/chains were identified with increased fold 
change, none were statistically significant. However, other matrix proteins such fibronectin 1, heparan sulfate 
proteoglycan 2, in addition to ECM enzymes like cathepsin S, and metalloproteinase inhibitor 2 were significantly 
changed LAD group. There is a significant increase of cathepsin S, a protease that degrades matrix proteins, 
including heparan sulfate proteoglycan 2, that had decreased expression in LAD group. Nevertheless, 
metalloproteinase inhibitor 2 acts by regulating the activity of several MMPs is increased four weeks in the 







Figure 3.30 Ion transport proteins. F1M9X7; Calcium channel voltage-dependent, alpha 2/delta subunit 2, 
F1LNB7; Voltage-dependent L-type calcium channel subunit alpha, Q63377; Sodium/potassium-transporting 































3.3.3.1.9 Cytoskeletal proteins  
 
Except for Myomesin 3 and Tubulin polymerization-promoting protein, all significantly different cytoskeletal 
proteins were upregulated in LAD group compared to SHAM. Such proteins included tubulin alpha chain, a major 
component of microtubules, and cytoskeleton-associated protein 4, as shown in figure 3.32. Fold change of 
























Figure 3.31 ECM proteins. A0A0G2JTX7; Collagen type VI alpha 5 chain, B0BNM1; NAD(P)HX epimerase, O08591; heparan sulfate 
proteoglycan 2, Q8K3R4; adiponectin C1Q and collagen domain containing, Q80Z29; nicotinamide phosphoribosyltransferase, Q5RKI0; WD 
repeat domain 1, F1M6Q3; Collagen type IV alpha 2 chain, A0A0G2JV12; Collagen type XV alpha 1 chain, F1LR02; Collagen type XVIII alpha 
1 chain, F1LSV0; Semaphorin 4B, F1MA59; Collagen type IV alpha 1 chain, O88201; C-type lectin domain containing 11A, P30121; 
Metalloproteinase inhibitor 2, A0A096P6L8; fibronectin 1, Q53AQ4; transmembrane and ubiquitin like domain containing 1, A0A0G2KAN1; 
Collagen alpha-2(I) chain, Q02765; Cathepsin S, F1LNH3; Collagen type VI alpha 2 chain, P13941; Collagen alpha-1(III) chain, D3ZUL3; 
Collagen type VI alpha 1 chain, D3ZL10; Collagen type VI alpha 6 chain, D3ZZT9; Collagen type XIV alpha 1 chain, P02454; Collagen alpha-
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3.3.3.1.10 Z disc and junctional proteins  
 
Five z disc related proteins were identified and significantly increased four weeks in LAD group (figure 3.33). 
Spectrin alpha chain non-erythrocytic 1, or alpha II-spectrin, which is localised to z disc in cardiomyocytes, but 
also found in cardiac fibroblasts, was almost doubled in LAD group in comparison to SHAM (FC=1.9). However, 


































Figure 3.33 Z disc and junctional proteins. D3ZC56; Dystonin, Q6IRK8; Spectrin alpha chain, non-erythrocytic 1, 
M0R4H5; PDZ and LIM domain protein 4, D4A702; Synaptopodin-2, Q5VJM4; Cardiac titin fetal N2BA PEVK isoform 









Figure 3.32 Cytoskeletal proteins. D4A228; Myomesin 3, P63170; Dynein light chain 1, cytoplasmic, P0C5W1; 
Microtubule-associated protein 1S, A0A0G2K2D6; Tubulin polymerization-promoting protein, F1LUM5; Tubulin 
alpha chain, M0R9X8; Cytoplasmic dynein 1 heavy chain 1, G3V7G0; Cytoplasmic dynein 1 light intermediate 
chain 1, F1LNF0; Myosin heavy chain 14, D3ZH41; Cytoskeleton-associated protein 4, P31977; Ezrin. Data were 






































3.3.3.1.11 Metabolism proteins and enzymes 
 
All significantly different proteins involved in cardiac metabolism were decreased in LAD groups (figure 3.34). 
These proteins are part of several metabolic pathways, including glycolysis (pyruvate kinase PKM, 
glyceraldehyde-3-phosphate dehydrogenases), fructose metabolism (fructose-bisphosphate aldolase A), as well 
as amino acids (kynurenine-oxoglutarate transaminase 3, branched chain amino acid aminotransferase) and 













































Figure 3.34 Metabolism proteins and enzymes. A0A0G2K1F2, Acetyl-CoA carboxylase beta, P07483; Fatty acid-binding 
protein, heart, Q58FK9; Kynurenine-oxoglutarate transaminase 3, G3V8U8; Branched-chain-amino-acid 
aminotransferase, P11980; Pyruvate kinase PKM, F1M8P6; Glyceraldehyde-3-phosphate dehydrogenase SV=2, P05065; 
Fructose-bisphosphate aldolase A, P13221; Aspartate aminotransferase, cytoplasmic, A0A0G2K7M1; Glyceraldehyde-3-
phosphate dehydrogenase SV=1, P04797; Glyceraldehyde-3-phosphate dehydrogenase SV=3, P48500; Triosephosphate 
isomerase, P05065 Fructose-bisphosphate aldolase A, P16290; Phosphoglycerate mutase 2, D3ZMR9; Mitochondrial 
ribosomal protein L21, P14604; Enoyl-CoA hydratase, mitochondrial, D3ZZN3; Acetyl-coenzyme A synthetase. Data were 
analysed using unpaired student’s t-test. * p < 0.05, ** p < 0.01, n=5 
* ** * * ** * ** * * * * * * * * * 
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3.3.3.2 Pathway analysis 
 
The proteome output was further analysed using Ingenuity Pathway Analysis software IPA (Qiagen, Germany). 
Instead of proteins selection that is based on their shared functional or structural similarities, IPA software 
provides in depth assessment of data to identify main signalling pathways that were significantly different four 
weeks after LAD coronary artery ligation in rats. Figure 3.35 shows the top three signalling pathways that were 
changed based on the p value and fold change of components for each pathway. This is indicated by z score, a 
statistical measure reflecting the match between the expected relationship direction and the observed gene 
expression. These pathways are protein kinase A signalling, G beta gamma and phospholipase C signalling 













Figures 3.36-3.38 are illustrations of these signalling pathways, with fold change of the significantly different 






Figure 3.35 Top signalling pathways in LAD and SHAM proteome output. y- axis shows level of significance for each 
pathway (red horizontal line represents threshold, corresponding to p < 0.05). The direction of change in colour, 
represents z-score; positive scores represent relatively higher results in LAD group. Figure is reproduced from Ingenuity 


























Figure 3.36 Protein kinase A signalling pathway (A) pathway illustration, and fold change of component proteins in 
(B). Q6YDN7; cell division cycle 26, A0A0G2JZ01; EYA transcriptional coactivator and phosphatase 3, O35353; G 
protein subunit beta 4, P15865; histone cluster 1, H1e, P20651; protein phosphatase 3 catalytic subunit beta, F1LS98; 




























































Figure 3.37 G beta gamma signalling pathway (A) pathway illustration, and fold change of component proteins (B). 
D3ZWQ8; Rho guanine nucleotide exchange factor 6, F1M9X7; Calcium channel, voltage-dependent, alpha 2/delta 
subunit 2, O35353; Guanine nucleotide-binding protein subunit beta-4, F1LS98; Protein kinase C. Data were analysed 



































Figure 3.38 PLC signalling pathway (A) pathway illustration, and fold change of component proteins in (B). 
D3ZWQ8; Rho guanine nucleotide exchange factor 6, O35353; Guanine nucleotide-binding protein subunit beta-4, 
P14423; Phospholipase A2, membrane associated, P20651; Serine/threonine-protein phosphatase 2B catalytic 
































3.3.3.3 Effect of LAD coronary artery ligation on cardiac phosphoproteins 
 
A total of 990 phosphoproteins were detected in LAD and SHAM groups, of which 210 were significantly different 














These phosphoproteins, which were different in LAD compared to SHAM, are mainly involved in the molecular 



















Figure 3.40 Molecular function of significantly different phosphoproteins. Panther Go-Slim molecular function of 
significant phosphoproteins. (p < 0.05) using protein accession numbers. Phosphoproteins count=210  
Figure 3.39 Logarithmic (volcano) plot of fold change for total detected phosphosites in LAD group compared to SHAM. 
Reference perpendicular dotted red lines indicate fold change < 0.8 or >1.3. Horizontal dotted red line indicates 
statistical significance at p- value < 0.05 as calculated using unpaired student’s t-test. FC: fold change. n=5. Total 


















log2 fold change (LAD/SHAM)
p < 0.05




A selection of significantly different phosphorylation sites (serine and threonine) is shown in table 3.1. There is 
an increased phosphorylation of phosphosites in cellular signalling proteins, including Heat Shock Protein 90 
alpha, catenin alpha 1, in addition to ion transporters, i.e., L-type Ca+2 channel subunit alpha 2 and ryanodine 
receptor 2. These effects are also seen in sarcomere structural proteins such as Myosin-binding protein C, 
cardiac-type and z-disc related proteins, for example, myomesin 2, obscurin, vinculin and nexilin, as well as tight 
junction proteins (tight junction protein 2, tensin 2). 
Table 3.1 Changes in phosphoproteins in LAD and SHAM groups (p <0.05). Data were analysed using unpaired student’s t-














calcium channel subunit alpha 
Q71QJ6 S1700 1.3 0.03 
Ryanodine receptor 2 B0LPN4 S2358 1.3 0.02 
Sodium/potassium-transporting 
ATPase subunit alpha-1 
P06685 S40 1.3 0.03 
Sodium/hydrogen exchanger 1 P26431 S790 1.5 0.045 
Sodium channel protein A0A0G2JWG8 S224 1.6 0.02 
Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 








































Structural proteins (cont.) 
Tight junction protein 2 Q3ZB99 S1132 1.4 0.01 
Tensin 2 M0R671 S1086 1.5 0.04 
Spectrin β chain A0A0G2K8W9 S2132 1.3  
Taxilin beta A0A0G2K2T1 S477 1.3 0.04 
Synaptopodin D3ZZ68 S596 1.5 0.02 
Syntrophin, basic 1 D3ZWC6 T215 1.4 0.03 
Pinin, desmosome-associated 
protein 
D3ZAY8 S100 1.8 0.01 
Obscurin, cytoskeletal 
calmodulin and titin-interacting 
RhoGEF 
A0A0G2JUP3 S6445 1.6 0.01 
Nexilin (Fragment) C5H4P9 S80 1.4 0.03 
Myosin-binding protein C, 
cardiac-type 
P56741 S427 1.9 0.04 
Desmin P48675 S28 1.7 0.045 
Myomesin 2 G3V7K1 S76 1.4 0.02 
Myosin regulatory light chain 2, 
ventricular/cardiac muscle 
isoform 
P08733 S15 2 0.03 
Microtubule-associated protein 
1B 
F1LRL9 S904 1.4 0.04 




















Structural proteins (cont.) 
A-kinase anchor protein 12 Q5QD51 S350 2.2 0.03 
A-kinase anchor protein 13 F1M3G7 S765 1.4 0.03 







Heat shock protein HSP 90-
alpha 
P82995 S263 1.5 0.04 
Catenin (Cadherin associated 
protein), alpha 1 




D3ZRM0 S559 1.8 0.04 
ATP synthase subunit beta G3V6D3 S415 1.5 0.02 
Striated muscle-specific 
serine/threonine-protein kinase 
Q63638 S1177 1.4 0.04 
SRSF protein kinase 3 A0A0G2KAH6 S73 1.4 0.04 
Inositol-trisphosphate 3-kinase 
B 
P42335 S202 1.6 0.03 












Cyclin Y F1MA89 S73 1.5 0.04 
Cell cycle and apoptosis 
regulator 2 
F1LM55 S298 2.1 0.04 
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3.3.4 Effect of LAD coronary artery ligation on cardiac energetics 
 
All cellular metabolites were measured using HPLC apparatus from apical, right and left atrial tissues of LAD and 
SHAM hearts 4 weeks after surgical procedure, data were compared regionally between the two groups.  
3.3.4.1 Apical energetic profile 
 
Table 3.2 lists different metabolites levels as taken from apical region in LAD and SHAM groups. In general, 
metabolites levels were slightly decreased in LAD group. However, none of these metabolites were significantly 
different compared to SHAM. 
Table 3.2 Apical energy metabolites in LAD and SHAM hearts. Data are presented as mean ± SEM. Data were analysed using 
















Phosphorylation ratios of guanosine and adenine metabolites were calculated and showed no significant 
difference in phosphorylation potential between the two groups. Adenine metabolites pool (summation of ATP, 
ADP, and AMP levels), and energy charge ([ATP+0.5*ADP]/total adenine pool) were slightly decreased in LAD 
group, however, this change was not statically significant (figure 3.41)  
Metabolite SHAM (nmol/mg) LAD (nmol/mg) p value 
GTP 0.12 ± 0.01 0.13 ± 0.04 0.75 
GDP 0.11 ± 0.03 0.10 ± 0.01 0.70 
GMP 0.06 ± 0.02 0.05 ± 0.02 0.64 
IMP 0.22 ± 0.13 0.10 ± 0.03 0.11 
ATP 1.45 ± 0.25 1.25 ± 0.43 0.51 
ADP 1.43 ± 0.28 1.31 ± 0.36 0.81 
Hypoxanthine 0.2 ± 0.02 0.2 ± 0.07 0.59 
Xanthine 0.07± 0.01 0.07± 0.02 0.99 
AMP 1.38 ± 0.31 1.14 ± 0.19 0.74 
B-NAD 0.47 ± 0.10 0.41 ± 0.08 0.75 
Inosine 0.31 ± 0.14 0.39 ± 0.14 0.73 













3.3.4.2 Right atrium energetics profile 
 
Right atrial metabolites levels in LAD and SHAM groups are listed in table 3.3. Levels of B-NAD and guanosine 
metabolites were generally higher in LAD group, whereas inosine was decreased. However, no statistically 
significant difference was noted. 
Table 3.3 Right atrial energy metabolites in LAD and SHAM hearts. Data are presented as mean ± SEM, and analysed using 












Metabolite SHAM (nmol/mg) LAD (nmol/mg) p value 
GTP 0.09 ± 0.02 0.38 ± 0.33 0.47 
GDP 0.09 ± 0.01 0.43± 0.36 0.43 
GMP 0.04 ± 0.01 1.52 ± 0.90 0.33 
ATP 1.07 ± 0.26 1.03 ± 0.7 0.07 
ADP 1.02 ± 0.09 1.60 ± 1.02 0.14 
AMP 0.81 ± 0.08 0.69 ± 0.22 0.41 
B-NAD 0.42 ± 0.09 0.80 ± 0.57 0.56 
Inosine 0.24 ± 0.09 0.12 ± 0.07 0.43 



















Figure 3.41 Phosphorylation potential, energy charge, and adenine metabolites pool of apex in LAD and SHAM 






















However, there was a reduction in energy charge, total adenine pool and phosphorylation potential in LAD group 














3.3.4.3 Left atrium energetics profile 
 
Table 3.4 includes all left atrial energy metabolites levels from LAD and SHAM groups. Similar to right atrial 
profile, there was no significant difference between the two groups. Nevertheless, phosphorylation potential 
and energy charge were slightly increased in LAD group (figure 3.43).  
Table 3.4 Left atrial energy metabolites in LAD and SHAM groups. Data are presented as mean ± SEM, and were analysed 
using unpaired student’s t-test. n = 5 
Metabolite SHAM (nmol/mg) LAD (nmol/mg) p value 
GTP 0.14 ± 0.03 0.14 ± 0.06 0.91 
GDP 0.17 ± 0.06 0.10 ± 0.04 0.42 
GMP 0.06 ± 0.01 0.10 ± 0.08 0.71 
IMP 0.33 ± 0.13 0.39 ± 0.31 0.87 




















Figure 3.42 Phosphorylation potential, energy charge, and adenine metabolites pool of right atrium in LAD and 



















































SHAM (nmol/mg) LAD (nmol/mg) p value 
ADP 1.48 ± 0.39 1.45 ± 0.76 0.98 
Hypoxanthine 0.19 ± 0.02 0.31 ± 0.17 0.56 
AMP 2.08 ± 0.93 1.17 ± 0.76 0.47 
B-NAD 0.68 ± 0.18 0.47 ± 0.24 0.52 
Inosine 0.50 ± 0.15 0.60 ± 0.41 0.82 

























Figure 3.43 Phosphorylation potential, energy charge, and adenine metabolites pool of left atrium in LAD and 






















3.3.5 Effect of LAD coronary artery ligation on cardiac metabolites  
 
Using 1H-NMR spectral analysis of PCA extracted cardiac tissues from rat apical region, 16 metabolites were 
detected in both groups as seen in figure 3.44. Excluding cardiac energetics, these metabolites included amino 
acids, glucose, lactate, and lipids. However, none of these metabolites were statically significant between SHAM 























Figure 3.44 Rat apical cardiac metabolites. Metabolites in cardiac extract samples as collected from apex for LAD and 










































3.3.6 Effect of LAD coronary artery ligation on blood metabolites 
 
1H- NMR spectroscopy analysis was used to measure blood metabolites of LAD group before surgery (baseline) 
and four weeks after LAD coronary artery ligation. There were 24 metabolites that were annotated from NMR 
spectra (figures 3.45). These included TCA cycle intermediates, ketone bodies, amino acids and carbohydrates 
as seen in figure 3.46. However, only arginine and acetone were found to be statistically significantly different 




































Figure 3.45 Rat blood metabolites. Metabolites in blood samples collected at baseline level (BL) and after 4 weeks LAD 
































































Figure 3.46 (above and below) Rat blood metabolites (cont.). Metabolites in blood samples collected at baseline 
level (BL) and after 4 weeks LAD coronary artery ligation. Data are presented as mean ± SEM and were analysed 

























































3.3.6.1 Spiked-in experiment 
 
Spike-in experiment of arginine and acetone were done using 1H-NMR spectroscopy and buffers for both 
metabolites that were mixed to a pooled rat plasma. Addition of a certain metabolite to the pooled plasma must 
result in an enhanced signal at the exact frequency (ppm). However, acetone spiking resulted in one clear peak 
proved to exist in the samples (figure 3.47), while the spectra did not align perfectly with spiked arginine, 
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Figure 3.47 1H-NMR spectra for acetone spiked-in experiment. Spectra shown for 1.25 mM acetone in PBS buffer (in 
red), pooled rat plasma (purple) and rat plasma mixed with acetone (green).  
  
2 mM arginine in PBS buffer 
Rat serum in PBS buffer 
Rat serum with 2 mM 
arginine in PBS buffer 
Figure 3.48 1H-NMR spectra for arginine spiked-in experiment. Spectrum of rat plasma is shown in red, 2mM arginine 




3.4 Discussion  
 
In this work, a rodent model of in-vivo permanent LAD coronary artery ligation in adult heart was used to 
investigate post ischaemic cardiac remodelling, four weeks after the infarction. Key findings in this chapter are 
concluded as the following: 
• Post ischaemic cardiac remodelling is associated with distinctive pattens of fibrosis and structural 
disorganisation of extracellular matrix. 
• Remodelling was associated with significant changes in mitochondrial morphometry and density and 
structural integrity.  
• Decrease in antioxidant related cardiac proteins, and metabolic enzymes related to fatty acid and amino 
acids metabolic pathways.  
• Upregulation of cellular calcium handling proteins were significantly upregulated and modified by 
phosphorylation (as in post translational modification) in remodelled hearts. 
• Post ischaemic cardiac remodelling is associated with differential expression of certain cytoskeletal, 
ECM and z disc and junctional proteins, in addition to increased phosphorylation at multiple 
phosphorylation sites.   
• Key signalling pathways activities include protein kinase A, Phospholipase C (PLC), and Gamma G beta 
protein signalling pathways. 















3.4.1 Post ischaemic cardiac remodelling is associated with disruption to ECM structure and proteins 
 
Infracted areas in LAD hearts sections revealed patten of compact fibrosis, in which the collagen is deposited in 
a large dense area with a scarcity of cardiomyocytes, while in the border zone, collagen distribution appears 
rather diffuse, i.e., septa of collagen intersperse living cardiomyocytes (figure 3.3). Some of these features have 
been described in human myocardium post MI (Rog-Zielinska, Norris et al. 2016). Moreover, as seen in electron 
micrographs, the infarcted area is heavily populated with nonmyocytes, such as fibroblasts (and myofibroblast), 
endothelial cells, telocytes, and macrophages, etc. all of which are crucial for ongoing infract remodelling and 
matrix reorganisation (Sun and Weber 2000, Fomovsky and Holmes 2010).  
Tissue fibrosis is driven by fibroblasts which mediate tissue-repair, angiogenesis and biological responses that 
result in scar formation (Rog-Zielinska, Norris et al. 2016). Fibroblasts were noted in various stages of 
differentiation and activation (figures 3.8 -3.10). In response to tissue injury and TGF-β release, fibroblasts 
become activated and differentiate into myofibroblasts that are extensively involved in continuous de novo 
synthesis of fibrillar  collagen (type III and I) and degradation (Fu, Khalil et al. 2018), as well as deposition of ECM 
components such as proteoglycans, glycoproteins (Czubryt 2012), and as identified in our work, cathpesin S and 
heparan sulfate, and in addition to activation of angiogenesis and release proinflammatory cytokines (Lindner, 
Zietsch et al. 2014).  
Electron micrographs showed infiltrating immune cells such as macrophages into ECM (figures 3.9 and 3.10). 
Proteomics data showed that proteins involved in immune response activation were all increased in LAD group, 
even after four weeks of cardiac injury. One of these proteins is tryptase, which is contained in mast cells, 
therefore, it is as a marker for mast cell activation (Vanderslice, Ballinger et al. 1990). Tryptase, which is 
increased significantly in LAD group, triggers in-vitro rat cardiac fibroblasts proliferation and conversion to 
myofibroblast phenotype, favouring collagen deposition (Janicki, Brower et al. 2015) In this regards, there has 
been an evolving evidence demonstrating that cardiac mast cell plays a substantial role in adverse remodelling 
and several cardiovascular disorders (Janicki, Brower et al. 2015). Nevertheless, Chancy et. al showed that 
cardiac mast cells, which store and release biologically active substances and mediators such as tumour necrosis 
factor-α (TNF-α) and proteases like chymase and tryptase, are involved in MMPs activation in volume-
overloaded hearts (Brower, Chancey et al. 2002). Whether mast cells predominately mediate pro-inflammatory 
or pro-proliferative response in the ischaemic myocardium is not yet fully understood.  
 
In addition, CD 48 antigen, increased in LAD group, is involved in both innate and adaptive immune responses, 
such as granulocyte and lymphocytes activation and proliferation, through its interaction with CD244 receptor 
on cytotoxic T cell as well as Natural Killer cells(NK)(McArdel, Terhorst et al. 2016). Experimental small and large 
animal models provided evidence for both T and B lymphocytes infiltrate into the infarct zone following acute 
MI (Yan, Anzai et al. 2013). For example, cytotoxic T lymphocytes (CD8) increased one week following ischaemia, 
and when collected from rats subjected to acute MI, they had a deleterious effect on healthy cardiomyocytes 




Nonetheless, telocytes, characterised by their small cell body and thin long telopodes (10-30 um) (Bei, Wang et 
al. 2015), are involved in neovascularization and tissue regeneration (Zhao, Liao et al. 2014). In the myocardium, 
telocytes are believed to form cardiac network of interstitial cells with cardiomyocytes through cellular 
junctions, this helps mediating intercellular signalling (Gherghiceanu and Popescu 2012). Recent evidence argues 
that cardiac telocytes may play an important role in the maintenance of the structural and functional integrity 
of the myocardium (Nour, Sarhan et al. 2017). Our work data showed different alterations compared to Zhao et. 
al, who documented undetectable levels of telocytes in the infarcted area 28 days post MI in murine heart (Zhao, 
Chen et al. 2013). We have identified several telocytes that were in close proximity to cardiomyocytes in EM 
images of the infract area (figures 3.8 -3.10). This could be explained by the species-related differences, since 
mice achieve scar maturity faster than rats, in addition to extensive and large transmural infract after LAD 
ligation (Yang, Liu et al. 2002), or alternatively the stage at which telocytes are examined. In our work, it is 
evident that the infracted area has remaining cellular elements from late proliferative phase, hence the 
quantification of telocytes at later stage of remodelling could possibly result in massive decrease in telocytes 
density in the myocardium, as most cells undergo apoptosis to leave collagen rich scar.  Interestingly, telocytes 
in LAD group were marked by cytoplasmic vacuolation and shrinkage of their telopodes, suggesting continuous 
degeneration and cell stress (figure 3.10), similar findings were observed by Richter et. al in failing human 
myocardium (Richter and Kostin 2015).  
Finally, remodelling of arteriolar wall was evident with post ischaemic remodelling, in which the ratio of wall 
area to total area was increased (figure 3.6). This could be explained by disruption of endothelial cells 
and excessive vascular smooth muscle cells proliferation and turnover in tunica media, possibly as a result 
of inflammation, ROS release and induction of hypoxia signalling pathway in VSMC leading to vascular 
remodelling (Zhuge, Zhang et al. 2020). 
3.4.2 Changes in mitochondrial morphology and molecular content and metabolism 
 
This work has provided evidence of disruption to mitochondrial morphology, proteome and function which is 
maintained 4 weeks after cardiac injury.  These changes are selective and linked to different mitochondrial 
subpopulations. Interfibrillar mitochondria had a significantly increased aspect ratio (length to width) in LAD 
hearts compared to SHAM, i.e., appeared more elongated, which indicates a tendency towards mitochondrial 
fusion. Work by Sun et al. showed that mitochondria tend towards fusion in isolated rat heart after short periods 
of hypoxia (3-5 min) (Sun, Dhalla et al. 1969). Likewise, others have observed marked elongation of interfibrillar 
mitochondria in patients with ischaemic cardiomyopathies (Tandler, Dunlap et al. 2002, Kanzaki, Terasaki et al. 
2010). It is possible that mitochondrial fusion could emerge as an adaptive pro survival mechanism to mitigate 
cellular stress and damage and increase the oxidative phosphorylation capacity and to compensate for partially 
damaged mitochondria (Tondera, Grandemange et al. 2009, Youle and van der Bliek 2012). Mitochondria in 
cardiomyocytes are spatially distributed into three main subpopulations; interfibrillar subpopulation serve to 
provide ATP necessary for myofibril contraction, while subsarcolemmal and perinuclear subpopulation provide 
the needed energy for sarcolemmal ion pumps and nucleus, respectively (Hollander, Thapa et al. 2014). While 
mitochondrial subpopulation distribution did not significantly vary between the two groups, mitochondrial 
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cristae density, however, was significantly decreased in LAD hearts (figure 3.12). This is shown as a separation 
of  intercristae spaces, and these changes are linked to the disruptive metabolic status of the mitochondria 
(Logan 2006).   
As detected in proteomic data from the rodent model, several mitochondrial proteins that were diminished are 
related to ATP synthesis and ECT (figure 3.24). Moreover, LAD hearts were decreased in key mitochondrial 
enzymes involved in amino acids and fatty acids metabolism. For instance, branched chain amino acid 
aminotransferase 2 (BCAT2), which catalyses reversible transamination reaction of branched chain amino acids 
BCAA (valine, leucine and isoleucine) to produce branched chain keto acids (Holeček 2018).  Defect in BCAA 
catabolism was found in failing hearts of mice and patients, which alters cardiac contractile function and redox 
homeostasis (Sun, Olson et al. 2016, Uddin, Zhang et al. 2019). Moreover, impairment of fatty acids oxidation, 
through reduction of the pathway rate limiting enzyme acetyl-CoA carboxylase beta (ACACB) and mitochondrial 
enoyl-CoA hydratase (ECHS1), indicate a loss of the metabolic flexibility in heart failure (Neubauer 2007, Karwi, 
Uddin et al. 2018), which results in a drop of mitochondrial oxidation rates by 30-40% (Fillmore, Mori et al. 2014). 
This reduction in oxidation rate is associated with decrease in fatty acids and glucose metabolism, which is 
inefficient in energy production needed for contraction and ionic homeostasis. 
 
Moreover, oxidative stress mediates mitochondrial damage through increased production of ROS, and/or 
decreased antioxidant defence mechanisms. In this regard, our work has shown significant decrease of 
antioxidant enzymes levels in LAD hearts, for instance, glutathione peroxidase 1 (GSHPx-1), superoxide 
dismutase SOD [Cu-Zn] and several other glutathione s-transferases/hydrolases. Glutathione peroxidase 1 
(GSHPx-1) reduces lipid hydroperoxides, while superoxide dismutase [Cu-Zn] catalyses the conversion of 
superoxide radicals into molecular oxygen or hydrogen peroxide (Krishnamurthy 2012). Other studies have also 
provided evidence of progressive decrease in SOD and GSHPx activities in the infarcted myocardium, followed 
by the non-infarcted region in rodents (Sun 2009). The depletion of antioxidant enzymes content in infarcted 
hearts can indirectly reflect the continuous state of oxidative stress, which leads to extensive proteins and lipid 
peroxidation, and cellular damage. This is also consistent with the continuous presence of debris including 
evidence of macrophages and leukocyte in electron micrographs of LAD hearts (figure 3.9-3.10). 
 
Additionally, blood acetone, the smallest of ketone bodies that is formed by spontaneous decarboxylation of 
acetoacetate in mitochondria (Sass 2012), was significantly increased four weeks after LAD coronary artery 
ligation as concluded from NMR results. While data regarding metabolic profiling of animal models with post 
ischaemic cardiac remodelling are still lacking, there have been reported evidence concerning ketone bodies in 
clinical studies of patients with heart failure. Both Du Z and Tenori L et. al showed modulation of ketone bodies 
metabolism and reported marked increase in acetone and β-hydroxybutyrate levels in blood of HF patients with 
mildly to severely reduced EF in comparison to healthy control (Tenori, Hu et al. 2013, Du, Shen et al. 2014). At 
the level of heart itself, a study showed that myocardium maintains ketone bodies extraction in heart failure 
(Janardhan, Chen et al. 2011),  while other studies concluded that in diseases, such as hypertrophic and dilated 
cardiomyopathies, ketone bodies utilisation is elevated (Cotter, Schugar et al. 2013). 
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3.4.3 Sarcomere proteins with post ischaemic cardiac remodelling  
 
Sarcomere length is one the main determinants of cardiac contractile strength, based on Frank-Starling 
relationship, it directly affects the contraction and relaxation of myofibrils, and eventually cardiac function.   
The sarcomere length, as measured using EM imaging four weeks after LAD coronary artery ligation, was slightly 
elongated in LAD group but did not significantly change compared to SHAM hearts. Nonetheless, passive 
myocardial stiffening, which determines stretching, is affected by expression of titin isoforms (Neagoe, Kulke et 
al. 2002). Titin, a giant protein which connects z disc to M line, is normally present in N2B isoform, but during 
ischaemia, an increase of N2BA isoform expression, which is also seen in rats proteomic data, is linked to reduced 
sarcomere stiffness and increased compliance (Warren, Jordan et al. 2003). Differences in sarcomere length 
after ischaemia are also time dependant, as shown by Crozatier et al, in which sarcomere length was increased 
15 minutes after ischaemia, as measured from the infarct area of open-chest LAD coronary artery ligated canine 
heart, due to overstretching from rapid loss of cardiomyocytes. Moreover, there was a prominent time 
dependant variation in sarcomere lengths as measured 45 minutes to 2 hours afterwards (Crozatier, Ashraf et 
al. 1977).  
However, z disc, which is found at the border between two adjacent sarcomeres, is not only involved in 
maintaining the structural integrity of sarcomere, but it also plays an active role in cell signalling in 
cardiomyocytes (Knöll, Buyandelger et al. 2011). Proteomics data from LAD and SHAM groups demonstrated 
differential overexpression of many structural elements in z disc such spectrin alpha chain, non-erythrocytic 1, 
PDZ and LIM domain protein 4, Synaptopodin-2. However, little is known about the effect of ischaemia and 
chronic remodelling on z-disc structures. For instance, synaptopodin-2 regulates intracellular signalling between 
z disc and nucleus in cardiomyocytes, along with other proteins like A-kinase anchoring protein (AKAP), 
Calcineurin and CaMKII (Faul, Dhume et al. 2007). While PDZ-LIM domain protein interacts with α-actinin 
proteins and Protein Kinase C to mediate its translocation to z disc (Zheng, Cheng et al. 2010, Maturana, 
Nakagawa et al. 2011). All these results demonstrate the dynamic response of z disc that could be implicated in 
pathophysiology of post ischaemic remodelling. 
Not only proteins expression that changes with post ischaemic cardiac remodelling, but also protein post-
translational modification (including phosphorylation), results in alteration and vast diversity of proteins 
activities. Whether these changes occur acutely and continue for four weeks after cardiac injury, or manifest 
only at later stage of cardiac remodelling is unknown.  These included A-kinase anchoring protein (AKAP)-12 
(pS350), Spectrin β chain (pS2132), Heat Shock Protein (HSP) α (pS263), catenin-α1 (pT660) and nexilin (pS80). 
Catenin-α1 is located in intercalated discs in cardiomyocytes and plays an important role in anchoring 
cytoskeleton to sarcolemma (Jamora and Fuchs 2002). Interestingly, phosphorylation of threonine phospho-
linker in actin-binding domain of this protein promotes intercellular adhesions in drosophila, mice and human 
cells (Escobar, Desai et al. 2015). Moreover, AKAP-12, a cytoskeletal scaffold protein that is involved in signal 
transduction of PKC and PKA. Upon its phosphorylation by PKC, AKAP-12 translocates from plasma membrane 
to mediate actin cytoskeleton reorganization (Akakura and Gelman 2012). Nevertheless, how these responses 
are linked to post ischaemic remodelling is still to be elucidated. 
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3.4.3 Effect of post ischaemic remodelling on cellular calcium handling proteins 
  
Defective calcium homeostasis is a distinguished feature of heart failure, which results in disruption to cardiac 
contraction and relaxation and LV function. Some calcium handling protein such as calcium channel voltage-
dependent, alpha 2/delta subunit 2 and voltage-dependent L-type calcium channel subunit alpha were 
upregulated in LAD group, whereas sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) and 
Ryanodine receptor 2 (RyR2) were subjected to increased phosphorylation. In particular, there was increased 
phosphorylation of SERCA2 in LAD group at several phosphorylation sites, including serine 38, which is shown to 
increase Vmax of calcium transport by Ca2+/calmodulin-dependent protein kinase CaMK (Toyofuku, Curotto 
Kurzydlowski et al. 1994). Other unique unreported sites were T376 and S663. However, RyR2 had increased 
phosphorylation at S2358. It is known that with increased adrenergic stimulation during heart failure, there is 
increased phosphorylation of RyR2 by several kinases, such as PKA, at different phosphorylation sites, including 
S2809 and S2030 (Jiang, Lokuta et al. 2002, Xiao, Jiang et al. 2005). It is important to take in consideration that 
slight variations in phosphorylation sites are species dependant. Nonetheless, hyperphosphorylation of RyR2 
enhances its Ca2+ sensitivity, which may lead to increased diastolic sarcoplasmic reticulum calcium leak (Bers 
2006), and with loss of synchronous sarcoplasmic reticulum Ca2+ release, this consequently triggers cardiac 
arrhythmia as seen in rabbit HF model rabbit using coronary artery ligation (Fowler, Wang et al. 2020). However, 
data regarding effects of these posttranslational modification on cardiac contractility and performance are still 
limited. 
3.4.4 PKC signalling in post ischaemic cardiac remodelling  
 
IPA analysis highlighted the role of three main signalling pathway in post ischaemic cardiac remodelling in rodent 
model. All of these pathways included PKC to initiate downstream signalling for multiple cellular targets. PKC, 
specifically subunit alpha, exerts regulatory effects on cardiac contractility and hypertrophic response (Dorn and 
Force 2005, Steinberg 2012), and it modulates cardiac response in IRI (Kang, Zhang et al. 2010) . PKC mediated 
activation of PKA through adenylate cyclase results in phosphorylation of many proteins such as myosin light 
chain kinase (MLCK), leading to cytoskeletal regulation and titin, which ultimately reduce myofibrillar passive 
tension (Krüger and Linke 2006). PKC activation in G beta gamma signalling pathway activates extracellular 
signal–regulated kinase1/2 (ERK1/2), which promotes cardiac hypertrophy and growth (Braz, Bueno et al. 2002). 
Moreover, PKC mediates pathological maladaptive hypertrophy via activation of calcineurin, which mediates 
dephosphorylation of nuclear factor of activated T cells (NFAT), allowing its translocation to nucleus to activate 
transcription of hypertrophic response genes (Dorn and Force 2005)  as seen PLC pathway (figure 3.38).   
 
In summary, using a rat model of sustained ischaemia after permanent LAD coronary artery ligation, this work 
highlighted, amongst several changes, the complicity of mitochondrial morphological disruption as evident by 
decreased cristae density, in addition to oxidative stress, through decreased expression of antioxidant related 
proteins in post ischaemic cardiac remodelling. Moreover, z disc proteins appear to play significant role in 
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pathophysiological processes following acute sustained myocardial injury, as they provide not only structural 



















































Chapter 4  
Post ischaemic cardiac remodelling in porcine 
















4.1 Introduction  
 
The study in chapter 3 focused on cardiac remodelling after acute MI in rodent model. Rodent hearts are 
excellent for initial investigations given their low cost and their longevity. Nonetheless, rodents do not easily 
develop coronary disease, and they have different action potential profile and heart rate reaching 450 bpm. 
Therefore, it is important to compare data obtained from rat with a clinically relevant large animal model. 
Although the dog was considered as the closest to human (e.g., similar collaterals), its use in cardiovascular 
clinical studies has markedly reduced largely due to ethical issues. 
The use of porcine model in cardiovascular research has gained wide acclaim due to the anatomical and 
physiological similarities between human and pig hearts (Spannbauer, Traxler et al. 2019). This great advantage 
facilitated the translation of numerous therapeutic interventions and devices from small animal models to 
patients. Nonetheless, high costs, labour intensive care, and the lack of developed collateral coronary circulation 
in pigs remain major limitations that challenge the use of this model as a substitute to human heart to study 
ischaemic heart diseases (Seiler, Stoller et al. 2013). In contrast to humans, who have the most advanced 
coronary collateral function after the guinea pig, the pig has the least advanced collateral function in comparison 
to all other relevant models of mammals (Seiler, Stoller et al. 2013). Furthermore, the high rate of mortality due 
to fatal arrhythmias in pigs during surgical induction of ischaemia and/or reperfusion is an issue for many 
research centres (Spannbauer, Traxler et al. 2019). Despite this, the porcine model of cardiovascular disease 
remains important for translating interventions from rodents to clinical practice. In general,  in-vivo large animal 
models are divided into open or closed chest models (Kumar, Kasala et al. 2016). Percutaneous left anterior 
descending coronary artery occlusion in pigs is a popular model for studying heart failure after acute MI, and is 
used largely for investigating therapeutic interventions (Laguens, Cabeza Meckert et al. 2002, Champagne, Su et 
al. 2003, Jansen of Lorkeers, Gho et al. 2015, Malka, Meerkin et al. 2015, Collantes, Pelacho et al. 2017).  
Studies investigating heart failure following MI tend to focus on one aspect of functional, structural and signalling 
changes with remodelling, and there is lack of studies that monitor other aspects of remodelling in an integrated 
manner. Therefore, this work aims to extend knowledge about cardiac remodelling following acute MI in a large 
animal model. Based on that, we decided to investigate molecular, cellular, histological changes in porcine model 
of post ischaemic cardiac remodelling four weeks after IRI. This model is currently being used in Bristol to test 
therapeutic interventions that can reduce injury and mitigate the severity of heart failure. In view of the 
complexity of remodelling (see different phases in section 1.4), improved knowledge will assist in interpreting 
outcome and in identifying pathways that can be targeted to reduce the detrimental effects of remodelling 








The procedures and methods used in this chapter are fully described in detail in materials and methods chapter 
(chapter 2).  
4.2.1 Experimental procedure 
 
In summary, animal procedures were undertaken at the University of Bristol Translational Biomedical Research 
Centre (TBRC) in accordance with the United Kingdom Animal (Scientific Procedures) Act, 1986 (under PPL 
7008975). Female Yorkshire pigs weighing 58-64 kg (n = 4) underwent closed-chest balloon catheter inflation to 
occlude the left anterior descending (LAD) coronary artery for 60 minutes, the mean pressure of occlusion was 
10.6 atmospheric pressure (atm). This was followed by balloon deflation and recovery. The intervention was 
performed at the TBRC and carried out by Dr Tom Johnson and assisted by Dr. Domenico Bruno. As a precaution 
to decrease the possibility of lethal ventricular arrhythmia, both amiodarone and magnesium (300 mg and 8 mg, 
respectively over 4 hours) were administered at the time of MI induction through a central line. 
Cardiopulmonary resuscitation was performed in case of arrhythmia. Healthy adult pigs, which did not undergo 
any surgical intervention, were taken as a control group (n= 4). Cardiac imaging and cardiac troponin-I 
measurements were performed by the surgical team at selected time intervals (further explained in the 
appendix), after which pigs underwent termination, and cardiac tissues from the infarcted area of the left 
ventricle in addition to blood samples were collected. The left ventricular tissues were snap frozen in liquid 
nitrogen and stored at -80 °C. 
Blood collection was done at the baseline (before surgery), reperfusion, and 10, 20 ,30 minutes; 1, 4 and 24 
hours and at termination (4 weeks). Each sample was transferred into EDTA tube (BD Vacutainer, UK) and 
centrifuged at 1000 g at 4 °C for 10 minutes. The plasma was collected into Eppendorf tubes and stored at -80 °C 
freezers for cardiac troponin-I measurement and nuclear magnetic resonance experiments. 
Tissues collected from the left ventricle of control or LAD group (four weeks after intervention) were snap frozen 
in liquid nitrogen and stored at -80 °C freezers for proteins extraction. Chunks of left ventricle were also placed 
in 4% paraformaldehyde solution, kept at 4 °C for 24 hours, and sent for tissue processing the following day.  
4.2.2 Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) 
 
Left ventricular myocardial tissues from both groups (n= 4) were homogenised for protein extraction in RIPA 
buffer with protease and phosphatase inhibitors, followed by quantification using Bradford essay, and then the 
extracted samples were sent for Proteomics facility at University of Bristol, to be analysed using Liquid 
Chromatography Tandem Mass Spectrometry (LC-MS/MS) to detect changes in proteins and phosphoproteins 





4.2.3 High Performance Liquid Chromatography (HPLC) 
 
Left ventricular, right and left atrial tissues from both groups (n= 4) were crushed with pestle and mortar for 
metabolites extraction using PCA and neutralised with K2CO3. The tissue extract was sent for HPLC analysis to 
determine cardiac energetics in left ventricle, left and right atria from each group as described in section (2.4.2). 
4.2.4 Nuclear Magnetic Resonance (NMR) 
 
Blood samples taken from pigs (4 weeks after LAD coronary artery occlusion and control) were collected into 
EDTA tubes, centrifuged at 1000 g for 10 minutes, and the plasma was transferred into Eppendorf tubes and 
stored in -80 °C freezer until later use. Plasma samples in addition to PCA extracted tissues were transferred to 
School of Chemistry, University of Bristol on dry ice for metabolites analysis using Nuclear Magnetic Resonance 
spectroscopy (NMR). Full method is described in section (2.4.3). 
4.2.5 Light Microscopy 
 
Tissues from porcine hearts were fixed using 4% paraformaldehyde solution and prepared for processing, 
embedding, and sectioning, and staining with H&E, EVG and Masson’s trichrome stains to study post ischaemic 
cardiac remodelling at gross structural level. Full details regarding these techniques are found in section (2.4.4). 
4.2.6 Electron Microscopy  
 
Left ventricular tissues from porcine hearts were fixed with 4% paraformaldehyde solution. Samples were sent 
for Wolfson Bioimaging facility for processing, EPON epoxy resin embedding, sectioning, and staining with uranyl 
acetate and lead citrate to study post ischaemic cardiac remodelling at ultrastructural structural level. Full details 











 4.3 Results 
 
4.3.1 Effect of 60-minute LAD coronary artery occlusion /reperfusion on gross porcine cardiac 
morphology 
 
Data regarding cardiac injury measurement and assessment of the porcine model following ischaemia 
reperfusion injury as used in this study are included in the appendix. This work was carried out by the TBRC team, 
which and includes CMR measurements (ejection fraction and infarct size) and cardiac troponin I (cTnI) results.  
 
4.3.1.1 Effect of 60-minute LAD coronary artery occlusion /reperfusion on cardiac fibrosis  
 
Masson trichrome staining was used to establish a histological evidence of the infarcted scarred myocardium, 
as observed in the septal area four weeks after LAD coronary artery balloon occlusion and reperfusion. There is 
an extensive deposition of collagen (in blue) in LAD group sections as seen figure 4.1. There was significant eight-
















Figure 4.1 Representative Masson’s trichrome staining of control and LAD cardiac sections. Sections were 
taken from the infarct in LAD group, and from left ventricle in control. Images were acquired with objective 
lens x40. Scale bar set to 100 microns. Extensive fibrosis (blue) can be seen perivascular as well as diffused in 
between myocytes bundles in all samples collected from LAD hearts. In contrast, there is markedly less 
















4.3.1.2 Effect of 60-minute LAD coronary artery occlusion /reperfusion on elastin deposition and arteriolar 
wall thickness 
 
Figure 4.3 shows EVG staining, which was used to identify elastin fibres (purple), collagen (red) in contrast to 
cardiomyocytes (orange). In addition to collagen, infarcted areas 4 weeks after LAD coronary artery occlusion 
and reperfusion appear to have widespread distribution of elastin in the perivascular space. Moreover, there 
was a significant increase in ratio of arteriolar wall area to total arteriolar area in LAD group compared to control 





























Figure 4.2 Percentage of fibrous tissue in control and LAD groups. Quantification of cardiac fibrosis was performed in 
the infarct area (% of area of fibrosis to total acquired field) in LAD group and corresponding LV area in control using 
Masson’s trichrome stain. Data were analysed using unpaired student’s t-test and presented as mean percentages 






























Figure 4.3 EVG staining of control and LAD heart sections.  Elastin is stained in purple (blue arrow), collagen in red (white 






































Figure 4.4 Percentage of porcine arteriolar wall area to total arteriolar area. Quantification was performed in EVG stained 
sections. Data are presented as mean percentages (SEM), and analysed using unpaired student’s t-test. ** p < 0.01, n = 4, 
3-4 fields were examined for each heart. 
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4.3.1.3 Effect of LAD coronary artery occlusion on cardiac cellular infiltration 
 
Haematoxylin and eosin staining (as shown in figure 4.5) showed various interstitial infiltration of connective 
















4.3.2 Effect of 60-minute LAD coronary artery occlusion /reperfusion on porcine cardiac ultrastructure  
 
Transmission electron microscopy imagining (FEI TecnaiTM 12) was used to analyse ultrastructural differences 
observed in the infarct area of LAD hearts 4 weeks after balloon LAD artery occlusion and reperfusion compared 
to control. Figures 3.6 and 3.7 are examples of infarcted areas taken from LAD heart.  
Marked disruption to cardiomyocytes is noted in samples from the infract area of LAD group. Many telocytes in 
LAD group are characterised by cytoplasmic vacuolations and telopodes shrinkage. Moreover, there are 
numerous fibroblasts, endothelial and immune cells in the collagen dense matrix as seen in figures 4.6 and 4.7). 
In addition, measurements of porcine mitochondrial cristae density, subpopulation distribution and morphology 
and sarcomere length, along with characterisation and detection of the various elements of the interstitial 
architecture were performed.    
LAD Control 
Figure 4.5 H&E staining of control and LAD heart sections. Cytoplasm is stained in dark pink, collagen in 
































Figure 4.6 TEM micrograph from the infarct of LAD group. E. endothelial cell, cl. Collagen, Fb fibroblast, 



































Figure 4.7 (A and B) TEM micrographs from the infarct of LAD group. E. endothelial cell, RBC, red blood cell, 






4.3.2.1 Mitochondrial subpopulation distribution, cristae density, and morphometry 
 
Cardiomyocytes area was measured for control and LAD groups (figure 4.8 A) and the distribution of each 
subpopulation was measured for each group and compared, as shown in figure 4.8 B. Cardiomyocytes area in 
LAD group was slightly increased (p > 0.05). However, there was significant decrease in interfibrillar 



















































































Figure 4.8 A and B Cardiomyocytes area and mitochondrial subpopulation distribution A) Average cardiomyocyte area in 
each group. B) Percentage of mitochondrial subpopulation area to total cardiomyocytes area. Data are presented as mean ± 
SEM. Data were analysed using unpaired t-test. n=4, 3-4 fields were examined for each sample. IF interfibrillar, PN 





The ratio of intercristae space area to total mitochondrial area, which reflects mitochondrial cristae density, was 













4.3.2.1.1 Mitochondrial subpopulations morphometry in Control group 
 
In general, interfibrillar mitochondria appeared longer and with increased area and aspect ratio, however, no 






















































Figure 4.9 Mitochondrial density in control and LAD groups. Bar chart represents the average ratio of intercristae 
space area to total mitochondrion area in each group. Data are presented as mean ± SEM and analysed using 
unpaired student’s t-test. Images were analysed using ImageJ software through automatic threshold level detection 
for each mitochondrial (green filter inside white border covers intercristae area).  n=4, 3-4 fields were examined for 





















4.3.2.1.2 Mitochondrial subpopulations morphometry in LAD group 
 
In LAD hearts, perinuclear mitochondria showed significant decrease in length and perimeter compared to 
interfibrillar mitochondria as seen in figure 4.11. This subtype had increased in circularity coupled with a 
decrease in aspect ratio. Unlike control group, length and other morphometric measurements did not change 




























Figure 4.10 Mitochondrial morphometric measurement of control group. A) Length, width and perimeter B) Area by 
size and multiplication (L*W) C) Aspect ratio, roundness, and circularity. Data are presented as mean ± SEM, and were 
analysed using one-way ANOVA followed by the Bonferroni and Games-Howell post-hoc tests. SS subsarcolemmal, IF 





















































Interfibrillar mitochondria of LAD hearts had increased length, perimeter and area, however, none of these 









































Figure 4.11 Mitochondrial morphometric measurements of LAD group. A) Length, width and perimeter B) Area by size and 
multiplication (L*W) C) Aspect ratio, roundness, and circularity. Data are presented as mean ± SEM. Data were analysed using 
one-way ANOVA followed by the Bonferroni and Games-Howell post-hoc tests. * = p < 0.05, **= p <0.01. SS subsarcolemmal, 








































Perinuclear mitochondria morphometric measurements showed slight decrease in area and roundness in LAD 
group compared to control, however, these changes were not significantly different between the two groups as 









Aspect Ratio (L:W Ratio) Roundness Circularity
Control LAD
Figure 4.12 Interfibrillar mitochondrial morphometric measurements of control and LAD groups. A) Length, width and 
perimeter B) Area by size and multiplication (L*W) C) Aspect ratio, roundness, and circularity. Data are presented as 
































































Similarly, morphometric measurements of subsarcolemmal mitochondria were not significantly different 








































Form Factor Roundness Circularity
Control Infarct
Figure 4.13 Perinuclear mitochondrial morphometry of control and LAD group. A) Length, width and perimeter B) Area by 
size and multiplication (L*W) C) Aspect ratio, roundness, and circularity. Data are presented as mean ± SEM, and analysed 































4.3.2.2 Diastolic sarcomere length 
 
Diastolic sarcomere length (measured from from one end of sarcomere to the other) did not significantly vary 
between control (1.4 ± 0.2 µm) and LAD group (1.6 ± 0.1 µm) as illustrated in figure 4.15. Sarcomere length 



















Figure 4.15 Sarcomere length in control and LAD porcine hearts. Data presented as mean ± SEM, and analysed using 
unpaired student’s t-test.  Measurement of 200 sarcomere from each group (50 per sample) were taken, n=4. 
Representative EM images of sarcomere length measurements in control (A) and LAD group (B) with sarcomere length 







































Figure 4.14 Subsarcolemmal mitochondrial morphometric measurements of control and LAD group. A) Length, width, and 
perimeter B) Area by size and multiplication (L*W) C) Aspect ratio, roundness, and circularity. Data are presented as mean 

















4.3.3 Effect of 60-minute LAD coronary artery occlusion /reperfusion on porcine cardiac proteomics 
 
4.3.3.1 Total proteins 
 
In total, 5661 proteins were detected in both LAD and control groups. Of which, 909 proteins were significantly 
changed 4 weeks after LAD coronary artery occlusion and reperfusion (p value < 0.05). Figure 4.16 is a volcano 
plot for total identified proteins. There were 272 significantly different protein that had increase in expression 
(FC > 1.3) in LAD group, compared to 538 proteins with decreased fold change (FC < 0.8).  


















p value < 0.05




A breakdown of total proteins classification into molecular and biological functions in addition to proteins class, 
using Panther Database classification system, is shown in figure 4.17. Expression heatmap of significantly 
different proteins (p value < 0.05) between control and LAD groups was generated using Rstudio (PBC, USA) as 







Figure 4.16 Logarithmic (volcano) plot of fold change for total proteins identified in LAD and control group. p- value 
calculated using unpaired student’s t-test. Reference lines indicate fold change < 0.8 or >1.3 on the x- axis, and p- value 
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Figure 4.17 Classification of total proteins identified in control and LAD groups using the PANTHER classification 

























Significantly different proteins were further categorised into high or low expression (fold change 
(LAD/Control) >1.3 or < 0.8, respectively). Panther database classification system was also used to breakdown 
protein of high and low expression into categories based on molecular functions and biological processes, and 
protein classes. Highly expressed proteins were predominantly involved in binding and catalytic activities.  
Proteins with low expression were mainly classified as catalytic, followed by binding and transporter activities. 
Interestingly, metabolites interconversion enzymes constitute a substantial class in significantly decreased 
proteins four weeks after LAD coronary artery occlusion and reperfusion (figure 4.19). 
Figure 4.18 Expression heatmap of significantly different proteins (p <0.05) from porcine proteomics 
output. Heatmap was created using Rstudio software. n=4, total significant protein count=909. L; LAD 
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Figure 4.19 Classification of significantly different proteins identified from porcine proteomics output using the 
PANTHER classification system. Proteins are classified according to increased (n=272) and decreased (n= 538) expression 






4.3.3.1.1 Mitochondrial Proteins 
 
A total of 403 mitochondrial proteins were detected and shown as a Volcano plot (figure 4.20). Approximately 
44.6% (n = 180) of mitochondrial proteins had significant difference (p- value < 0.05) between control and LAD 
groups. Most of these proteins were decreased in LAD group. 




















p value < 0.05




4.3.3.1.2 Kinase proteins  
 
Figure 4.21 shows all the significantly increased (figure 4.21 A) and decreased (4.21 B) kinases proteins in control 
and LAD groups. Amongst notable kinases are glycogen synthase kinase 3 (GSK-3), adenylate Kinase Isoenzyme 







Figure 4.20 Logarithmic (volcano) plot of fold change for total mitochondrial proteins identified in LAD group 
compared to control. p- value calculated using unpaired student’s t-test. Reference lines indicate abundance ratio 














































Figure 4.21 A and B Protein kinases. I3LNH4; Ca2+/Calmodulin-Dep Prot Kinase Type 1D, A0A286ZWQ7; Ser/Thr-Prot 
Kinase DCLK1, A0A286ZV07; L-Fucose Kinase, M3VH47 Casein Kinase 1, Delta Tv1, M3VH59; Phosphatidylinositol-4-
Phosphate 3-Kinase, Cat Sub Type 2 Alpha, A0A286ZLF6; Ser/Thr-Prot Kinase N2, F1RSN7; AARF Domain-Containing 
Kinase 5, A0A287BD11; Ser/Thr-Prot Kinase SMG1, A0A287AL02; Non-Specific Ser/Thr-Prot Kinase, A0A287B2T4; 
Ser/Thr Prot Kinase Nek3, P06732; Creatine Kinase M-Type, A0A287B0J6; Activated CDC42 Kinase 1, F1S006; 
Fructosamine-3-Kinasee, B7U6F4; Ser/Thr Protein Kinase MST4, A0A286ZZN4; GSK-3 Alpha, G9BWQ2; Non-Specific 
Ser/Thr Prot Kinase, F1S2Q4; Ser/Thr Prot Kinase Nek9, F1SEZ4; MAP Kinase-Activated Prot Kinase 2, A0A287A7K4; 
Ribokinase, D2D0E0; Choline/Ethanolamine Kinase, F1RIR7; [3-Methyl-2-Oxobutanoate Dehydrogenase [Lipoamide]] 
Kinase, Mito, B8XSJ0; Acylglycerol Kinase, A0A287BSA1; [Pyruvate Dehydrogenase (Acetyl-Transferring)] Kinase Isozyme 
2, Mito , A0A286ZPF5 Mitogen-Activated Protein Kinase, A0A286ZQ79; Adenylate Kinase Isoenzyme 1, Q2HYU1; 
Mitochondrial Creatine Kinase 2. Data were analysed using unpaired student’s t-test. * p < 0.05, ** p < 0.01, n=4 









































4.3.3.1.3 Phosphatase proteins  
 
Majority of significantly different phosphatases were downregulated in LAD group (figure 4.22). However, 
inactive dual specificity phosphatase 27 (involved in oxidative stress response) and receptor-type Tyrosine-
Protein Phosphatase C (T and B cells activation) were increased in LAD group. 
4.3.3.1.4 ATP synthesis proteins 
 
Various mitochondrial ATP synthase subunits and assembly factors were significantly decreased 4 weeks after 
LAD coronary artery occlusion and reperfusion as seen in figure 4.23.  
 
Figure 4.22 Protein Phosphatases. A0A287BEF3; Receptor-Type Tyrosine-Protein Phosphatase ETA, I3L6E7; 
Phosphoethanolamine/Phosphocholine Phosphatase, A0A287B391 ; Mg-Dep Phosphatase 1, I3LS97 ; Pseudouridine-
5'-Phosphatase, F1S9H9 LMW Phosphotyrosine Protein Phosphatase, F1S252 ; Inactive Dual Specificity Phosphatase 
27, A0A287A9D0 ; Receptor-Type Tyrosine-Protein Phosphatase C. Data were analysed using unpaired student’s  t-test. 





























Figure 4.23 ATP synthesis proteins. I3LAB4; ATP Synthase Mitochondrial F1 Complex Assembly Factor 2, Q95312; ATP 
Synthase Subunit Delta, Mitochondrial, A0A287ACT4; ATP Synthase Subunit G 2, Mitochondrial-Related, A0A287A725; 
ATP Synthase Subunit, A0A286ZYM6; ATP Synthase F(0) Complex Subunit B1, Mitochondrial, A0A287B0C3; ATP Synthase 
Subunit D, Mitochondrial, Q9MYT8; ATP Synthase Subunit E, Mitochondrial, A0A287ATH3; ATP Synthase F(0) Complex 
Subunit C1, Mitochondrial, A0A286ZYL7; ATP Synthase Subunit Delta, Mitochondrial, K7GLT8; ATP Synthase Subunit Beta. 



























4.3.3.1.5 Ions transport proteins 
 
Figure 4.24 lists ion transporters (e.g., Na+/K+ transporting ATPase Sub Β-1) and calcium handling proteins (e.g., 
phospholamban and SERCA2), all of which were significantly decreased in LAD group compared to control.  
 
4.3.3.1.6 Antioxidant related proteins 
 
Significantly different antioxidant proteins such as thioredoxin Reductase 2 and glutathione reductase were 
reduced in LAD hearts compared to control as seen in figure 4.25.  
 
 
Figure 4.25 Antioxidant related proteins. A0A287BQ74; Thioredoxin Reductase 2, Mito, F1RX66; Glutathione Reductase, 
A0A0K1LY40; Peptide-Methionine (R)-S-Oxide Reductase, F1SKJ2; Thioredoxin, Mito. Data were analysed using unpaired 
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Figure 4.24 Ion transporters. P05027; Na/K-Transporting ATPase Sub Beta-1, A0A287AVV2; Voltage Dependent Anion-
Selective Channel Protein 1, F1S2F6; Voltage dependent anion-selective Channel Protein 2, P11607; 
Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2, P61013; Cardiac Phospholamban, A0A287APK5; Calcium-
Transporting ATPase, A0A287BIE3; Voltage-dependent L-type Calcium Channel subunit Beta-2, A0A287AB87; Voltage-























4.3.3.1.7 Oxidoreductase proteins 
 
Figure 4.26 shows the oxidases and reductases proteins that significantly changed four weeks after LAD ligation. 
Except for NADPH-Cytochrome P450 Reductase, and Ubiquinol-Cytochrome-C Reductase Complex Assembly 
Factor 3, all the proteins in this class were significantly decreased in LAD hearts. Notably, NADH-Ubiquinone 
Oxidoreductase 75 KDA subunit, which forms the largest subunit of complex I of ETC was decreased significantly 
in LAD group.  
 
 
4.3.3.1.8 Metabolism proteins and enzymes 
 
Almost all significantly different proteins involved in cardiac metabolism were decreased in LAD groups (figure 
4.27). These proteins are part of several metabolic pathways, including glycolysis (acetyltransferase, component 
of Pyruvate DH Complex), as well as amino acids (branched chain amino acid aminotransferase) and fatty acids 
metabolism (Malonyl-CoA-Acyl Carrier Protein Transacylase, Acyl Coenzyme A Synthetase Long-Chain 1, Very 
Long-Chain Specific Acyl-CoA DH and Very-Long-Chain (3r)-3-Hydroxyacyl-CoA Dehydratase). 
 
 
Figure 4.26 Oxidoreductase proteins. A0A287ASY8; NADPH:AdrenodoxinOxidoreductase, Mito, A0A287BLV7; NADH-
Ubiquinone Oxidoreductase 75 KDA Sub, Mito , D3K5L2; Ubiquinol-Cytochrome C Reductase Complex Chaperone, 
A0A287BPZ9; Oxidoreductase-Like Domain-Containing Protein 1, F1SFY5; Oxidoreductase HTATIP2, F1SN58; 
Sulfide:Quinone Oxidoreductase, Mito, A0A0K1LY40; Peptide-Methionine (R)-S-Oxide Reductase, F1SSI2; 
DH/Reductase Sdr Family Member 7, F1RX66; Glutathione Reductase, A0A287BQ74; Thioredoxin Reductase 2, Mito, 
A0A287BPI1; Electron Transfer Flavoprotein-Ubiquinone Oxidoreductase, Mito, F1S1B9; DH/Reductase Sdr Family 
Member 11, A0A286ZXA3; NADPH-Cytochrome P450 Reductase, A0A287BK40; Ubiquinol-Cytochrome-C Reductase 
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Figure 4.27 Metabolism proteins and enzymes. A0A287B6S5; Alpha-Enolase, F1SNZ7; Succinate--CoA Ligase [Adp/Gdp-
Forming] Subunit Alpha, Mito ,Q6B339; Acyl Coenzyme A Synthetase Long-Chain 1 (Fragment), K9IW70; Acetyltransferase 
Component Of Pyruvate DH Complex, A0A286ZZN4; Glycogen Synthase Kinase-3 Alpha, A0A287BA23; Acetyl-Coenzyme A 
Synthetase, F1SBJ3; Arginine-Hydroxylase Ndufaf5, Mito, F1S3H1; Methylmalonate-Semialdehyde DH [Acylating], Mito, 
F1RM74; Glyceraldehyde-3-Phosphate Dehydrogenase, P42174; Glutamate Dehydrogenase 1, Mito (Fragments), I3LCN1; 
Gamma-Enolase, A0A287BER5; Branched-Chain-Amino-Acid Aminotransferase, I3LP02; Acetyl-CoA Acetyltransferase, 
Mito, P16276; Aconitate Hydratase, Mito, I3LQA1; Aldehyde Dehydrogenase Family 8 Member A1, F1ST43; Very Long-
Chain Specific Acyl-CoA DH, Mito, A0A287BAF3; Adenylosuccinate Synthetase Isozyme 1, K7GP28; 3-Hydroxyacyl-Coa DH 
Type-2, P00348; Hydroxyacyl-Coenzyme A DH, Mito, F1SJK6; Very-Long-Chain (3r)-3-Hydroxyacyl-CoA Dehydratase, 
F1SBH1; D-Aminoacyl-tRNA Deacylase, I3LUR5; Acyl-CoA DH Family Member 9, Mito, F1SEN2; Glutamate Dehydrogenase 
1, Mito, D0G0B3; Acetyl-Coenzyme A Acyltransferase 2, Q1G1K7; Isocitrate Dehydrogenase [NAD] Sub  Mito, P41566; 
Isocitrate Dehydrogenase [NAD] Sub Gamma, Mito (Fragments), K7GPJ4; Acyl-Coenzyme A Thioesterase 9, Mito, 
A0A286ZQY6; Isocitrate Dehydrogenase [NAD] Sub, Mito, F8UWD3; Alpha-L-Fucosidase, I3LP41; Malate Dehydrogenase, 
K7GQG9; Malonyl-CoA-Acyl Carrier Protein Transacylase, Mito, F1RJH8; Argininosuccinate Lyase, A0A287A8Y8; Short-
Chain-Specific Acyl-CoA DH, Mito, F1SRC5; Aconitate Hydratase, Mito, A0A287BSA1; [Pyruvate Dehydrogenase (Acetyl-
Transferring)] Kinase Isozyme 2, Mito, B8XSJ0; Acylglycerol Kinase, F1SK00; Isocitrate Dehydrogenase [NADP], P00889; 
Citrate Synthase, Mito, B8XTR3; 1-Acylglycerol-3-P O-Acyltransferase 5, P08059; Glucose-6-Phosphate Isomerase, 
























































Fold change (LAD/Control) 
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4.3.3.1.9 Collagen subunits and chains 
 
Several collagen types and chains were identified in porcine proteomics output, nonetheless, only five were 
significantly increased in LAD group. These included procollagen (proCol) α-1(V), Col α-1(I) Chain, Col α-1(XIV) 
Chain, proCol α-2(V) and Col α-1(III) Chain, as shown in figure 4.28. 
4.3.3.1.10 Z disc proteins 
  
Z disc proteins such as plectin and filamin C were identified and significantly increased four weeks after LAD 
coronary artery occlusion and reperfusion (figure 4.29). However, calsarcin 1 (myozenin 2) and neubulette were 








































** * * 
Figure 4.28 Collagen subtypes and chains. A0A287AFT5; Col α-1(Xv) Chain, A0A287BQN5; Col α-1(XVIII) Chain, M3V819; Col, 
Type IV, α-1, Q95JA3; Col Type I α-1 (Fragment), A0A287A0A6; Col Type VI α-6 Chain , I3LUR7 Col α-3(VI) Chain, I3LQ84 Col 
Type VI α-2 Chain, F1RLL9; Col α-2(Iv) Chain, Q1T7A8; Type VI Col α-1 Chain (Fragment), Q59IP3; ProCol α-1(V), A0A287A1S6; 
Col α-1(I) Chain, K7GT00 Col α-1(XIV) Chain, Q59IP2; ProCol α-2(V), F1RYI8 Col α-1(III) Chain, F1RQI0; Col α-1(XII) Chain. Data 






























4.3.3.1.11 Inflammation related proteins  
 
Inflammation related proteins were significantly upregulated in LAD group compared to control as seen in figure 
4.30. Such proteins are involved in T and B cells activation (Receptor-Type Tyrosine-Protein Phosphatase C).  
Others such as cardiotrophin-1 (figure 4.31), which is involved in cardioprotection during ischaemia and 














Figure 4.30 Inflammation related proteins. A0A287A9D0; Receptor-Type Tyrosine-Protein Phosphatase C, F1SEZ4; MAP 
Kinase-activated Protein Kinase 2, F1S475; 1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Gamma, 
A7XUJ6; TNF Receptor-Associated Factor 6, A0A287AZQ5; Tumor Necrosis Factor Alpha-Induced Protein 2, 
A0A286ZPF5; Mitogen-activated protein kinase, F1S475; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase ɣ, 
F1SEZ4; MAP kinase-activated protein kinase 2. Data were analysed using unpaired student’s  t-test. * p < 0.05, ** p < 



































Figure 4.31 Average cardiotrophin-1 abundance in control and LAD group. Data are presented as mean (±SEM), and 



































4.3.3.2 Pathway analysis 
 
The proteomics output was further analysed using Ingenuity Pathway Analysis software IPA (Qiagen, Germany). 
Instead of proteins selection that is focused on functional or structural similarities, IPA software provides in 
depth assessment of data to identify main signalling pathways that were significantly different, four weeks after 
LAD coronary artery occlusion and reperfusion in porcine model. Figure 4.32 shows the top three signalling 
pathways that were changed based on their z scores, which included epithelial adherens junction signalling, 















Figure 4.32 Selected top functional categories comparing LAD and control groups proteome. Threshold line represents 
significance value (y- axis) and direction of change in colour, represents z-score; negative scores are relatively higher 





Figure 4.33 Epithelial adherens junction. ACTA1; actin alpha 1, skeletal muscle, ACTA2; actin alpha 2, smooth muscle, 
ACTG1; actin gamma 1, ACTN2; actinin alpha 2, ACTN4; actinin alpha 4, ACTR2; actin related protein 2, AKT1; AKT 
serine threonine kinase 1, AKT2; AKT serine threonine kinase 2, ARPC3; actin related protein 23 complex subunit 3, 
ARPC4; actin related protein 23 complex subunit 4, ARPC1B; actin related protein 23 complex subunit 1B, MYH2;  
myosin heavy chain 2, MYH3; myosin heavy chain 3, MYH7; myosin heavy chain 7, MYH9; myosin heavy chain 9, 
MYH13;  myosin heavy chain 13, MYH14; myosin heavy chain 14, MYL3; myosin light chain 3, RALB; RAS like proto-




























































Figure 4.34 Actin cytoskeleton signalling. ACTA1; actin alpha 1, skeletal muscle, ACTA2; actin alpha 2, smooth 
muscle, ACTG1; actin gamma 1, ACTN2; actinin alpha 2, ACTN4; actinin alpha 4, ACTR2; actin related protein 2, 
ARPC3; actin related protein 23 complex subunit 3, ARPC4; actin related protein 23 complex subunit 4, ARPC1B; 
actin related protein 23 complex subunit 1B, DOCK1; dedicator of cytokinesis 1, GSN; gelsolin, MYH2; myosin heavy 
chain 2, MYH3; myosin heavy chain 3, MYH7; myosin heavy chain 7, MYH9; myosin heavy chain 9, MYH13; myosin 
heavy chain 13, MYH14; myosin heavy chain 14, MYL3; myosin light chain 3, PIK3C2A; phosphatidylinositol-4-
























































Figure 4.35 Integrin signalling proteins. ACTA1; actin alpha 1, skeletal muscle, ACTA2; actin alpha 2, smooth muscle, 
ACTG1; actin gamma 1, ACTN2; actinin alpha 2, ACTN4; actinin alpha 4, ACTR2; actin related protein 2, AKT1; AKT 
serinethreonine kinase 1, AKT2; AKT serinethreonine kinase 2, ARPC3; actin related protein 23 complex subunit 3, 
ARPC4; actin related protein 23 complex subunit 4, ARPC1B; actin related protein 23 complex subunit 1B, ASAP1; ArfGAP 
with SH3 domain, ankyrin repeat and PH domain 1, DOCK1; dedicator of cytokinesis 1, GSN; gelsolin, PIK3C2A; 
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha, PLCG2; phospholipase C gamma 2, RALB; RAS 
like proto-oncogene B, RAPGEF1; Rap guanine nucleotide exchange factor 1, TNK2; tyrosine kinase non receptor 2, * p 






















4.3.3.3 Effect of 60-minute LAD coronary artery occlusion /reperfusion on cardiac phosphoproteins 
 
A total of 1153 phosphoproteins were detected in LAD and control groups, of which 66 were significantly 
different (p < 0.05). Phosphosites of total detected phosphoproteins are shown in figure 4.36. 


















p value < 0.05




Phosphoproteins that are statistically different (p <0.05) were mainly involved in molecular binding activity, 
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translation regulator activity (GO:0045182)  
Figure 4.37 Molecular function of significantly different phosphoproteins. Panther Go-Slim molecular function of 
significant phosphoproteins. (p < 0.05) using protein accession numbers. n=4, phosphoproteins count=66  
Figure 4.36 Logarithmic (volcano) plot of fold change for total detected phosphosites in porcine phosphoproteome. 
Reference perpendicular dotted red lines indicate fold change < 0.8 or >1.3 on y-axis. Horizontal dotted red line 
indicates statistical significance at p- value < 0.05. FC: fold change. n=4, total phosphosite count=1153 
166 
 
 Selected significantly different phosphorylation sites (serine, threonine and tyrosine) are listed in table 4.1. 
There is an increased phosphorylation of phosphosites of cellular signalling proteins, including Heat Shock 
Protein 90 β, catenin α 1, as well as ion transporters, such as sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 (SERCA2). These effects are also seen in sarcomere structural proteins including spectrin β chain and 
Z-disc related proteins (PDZ and LIM domain protein 1) as well as tight junction proteins (gap junction protein).  
Table 4.1 Changes in phosphoproteins in control and LAD groups (p <0.05). Data were analysed using unpaired student t-













Sodium/hydrogen exchanger F1STQ3 S799 2.3 0.013 
Calcium voltage-gated channel 
auxiliary subunit β 2 
A0A287ANL1 T221 0.6 0.011 
Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 
























Tropomyosin β chain A0A287AN33 S283 2.3 0.007 
Cardiac muscle α actin 1 B6VNT8 T55 2.8 0.011 





S387 2.3 0.017 
S538 4.4 0.004 
Myosin heavy chain 8; MYH8 F1SS62 S1203 1.8 0.010 
Actin, α skeletal muscle P68137 Y242 2.4 0.027 
Fibrillin-1 F1SN67 S2702 1.5 0.030 




S2341 1.6 0.044 





S306 2.1 0.03 
S85 2.2 0.04 



















S1203 1.9 0.02 
S1144 3.4 0.03 
Synemin A0A287B3V0 S418 2.5 0.02 





S342 1.6 0.04 
S385 1.6 0.04 
   





S911 2.0 0.04 
S1363 2.1 0.03 
T1310 2.6 0.04 
S1103 2.6 0.03 







S759 2.0 0.03 
T641 2.5 0.04 
S2169 2.7 0.02 
S1597 3.1 0.01 
S698 5.7 0.04 
Signalling proteins 
Catenin α 1 (CTNNA1) F1RGJ2 T838 1.9 0.048 
Heat shock protein family A 
(HSP70) member 12B 
F1S8C1 S29 2.7 0.047 










A-kinase anchoring protein 12 A0A287BE06 S1494 3.5 0.029 
Nuclear factor 1 A0A287AQ42 S301 2.3 0.03 
Histone deacetylase; HDAC6 I3LEZ7 T936 1.6 0.019 
Enzymes 





S561 1.8 0.041 
S562 2.5 0.005 
S473 2.4 0.016 




S502 3.1 0.011 














Signalling proteins (cont.) 




S1513 2.3 0.036 
T1563 2.8 0.004 
Glyceraldehyde-3-phosphate 
dehydrogenase 
P00355 T182 0.4 0.00 
Calpastatin F6PU32 S208 0.6 0.03 
Serine/threonine protein 
kinase MST4 
B7U6F4 S300 0.4 0.03 
6-phosphofructokinase A0A286ZZL7 S795 2.6 0.01 
ADP/ATP translocase 3 A0A287AVQ0 T84 0.3 0.01 




S398 2.4 0.03 





S145 1.9 0.02 

















4.3.4 Effect of 60-minute LAD coronary artery occlusion /reperfusion on porcine cardiac energetics 
 
All cellular metabolites were measured using HPLC from control and LAD groups from left ventricular (or infarct), 
as well as right and left atrial tissues 4 weeks after LAD coronary artery occlusion and reperfusion. The data were 
compared regionally between the two groups.  
4.3.4.1 Left ventricular energetics profile 
 
Table 4.2 lists different metabolites levels taken from infarct region from LAD group and left ventricle from the 
control. None of these metabolites were significantly different. 
Table 4.2 Energy metabolites of control (LV) and LAD (infarct) groups. Data are presented as mean ± SEM and analysed using 











Total adenine metabolites pool was significantly increased in LAD group, mainly due to an increase in AMP and 
ADP content (nearly doubled). Nonetheless, phosphorylation ratios of guanosine and adenine metabolites were 
calculated and showed no significant difference in phosphorylation potential. Energy charge was slightly 












GTP 0.09 ± 0.03 0.10 ± 0.03 0.87 
GDP 0.05 ± 0.02 0.12 ± 0.04 0.16 
GMP 0.02 ± 0.01 0.04 ± 0.01 0.26 
IMP 0.03 ± 0.00 0.09 ± 0.03 0.17 
ATP 1.54 ± 0.62 1.65 ± 0.89 0.93 
ADP 0.95 ± 0.17 2.17 ± 0.78 0.22 
Hypoxanthine 0.30 ± 0.12 0.05 ± 0.01 0.13 
AMP 0.44 ± 0.16 0.97 ± 0.48 0.34 
B-NAD 0.48 ± 0.02 0.55 ± 0.14 0.64 
Inosine 1.52 ± 0.50 0.20 ± 0.06 0.08 















4.3.4.2 Right atrium energetics profile 
 
Right atrial metabolites levels from LAD and control groups are listed in table 4.3. Similarly, none of these 
metabolites levels were significantly different was noted. 
Table 4.3 Right atrium (RA) energy metabolites in control and LAD groups. Data are presented as mean ± SEM and analysed 

















GTP 0.09 ± 0.03 0.10 ± 0.02 0.95 
GDP 0.06 ± 0.03 0.03 ± 0.01 0.55 
GMP 0.03 ± 0.01 0.02 ± 0.00 0.50 
IMP 0.03 ± 0.02 0.02 ± 0.01 0.52 
ATP 0.59 ± 0.27 1.11 ± 0.19 0.20 
ADP 0.91 ± 0.48 0.62 ± 0.09 0.62 
HYPO 0.31 ± 0.11 0.12 ± 0.01 0.23 
AMP 0.49 ± 0.24 0.28 ± 0.02 0.48 
B-NAD 0.23 ± 0.07 0.21 ± 0.04 0.79 
Inosine 0.78 ± 0.23 0.52 ± 0.17 0.42 


























Figure 4.38 Phosphorylation potential, energy charge, and adenine metabolites pool of LAD (infarct) and control 

















There were increase of ATP to ADP and AMP ratios, respectively in LAD group compared to control as seen in 















4.3.4.3 Left atrium energetics profile 
 
Table 4.4 includes left atrial metabolites levels from LAD and control groups. Only hypoxanthine and AMP levels 
were significantly reduced in LAD group.  
Nevertheless, energy charge and GTP/GDP, ATP/ADP and ATP/AMP ratios were significantly increased in LAD 



































GTP/GDP GTP/GMP ATP/ADP ATP/AMP
Control LAD
Figure 4.39 Phosphorylation potential, energy charge, and adenine metabolites pool of right atrium in LAD and control 
















Table 4.4 Left atrium (LA) energy metabolites in control and LAD groups. Data are presented as mean ± SEM and analysed 

































GTP 0.11 ± 0.00 0.12 ± 0.01 0.39 
GDP 0.03 ± 0.00 0.02 ± 0.00 0.07 
GMP 0.01 ± 0.00 0.01 ± 0.00 0.12 
IMP 0.03 ± 0.01 0.03 ± 0.01 0.84 
ATP 1.51 ± 0.19 1.99 ± 0.14 0.11 
ADP 0.54 ± 0.03 0.40 ± 0.04 0.05 
Hyoxanthine 0.19 ± 0.02 0.01 ± 0.00 0.00 
AMP 0.19 ± 0.01 0.10 ± 0.02 0.02 
B-NAD 0.27 ± 0.00 0.28 ± 0.03 0.90 
Inosine 0.60 ± 0.12 0.22 ± 0.09 0.07 



































Figure 4.40 Phosphorylation potential, energy charge, and adenine metabolites pool of left atrium in LAD and 
















4.3.5 Effect of 60-minute LAD coronary artery occlusion /reperfusion on porcine cardiac metabolites 
 
Using 1H-NMR spectral analysis of PCA extracted porcine cardiac tissues from left ventricle in the control and 
the infarct in LAD group, 16 metabolites were detected as seen in figure 4.41. These metabolites included amino 























Figure 4.41 Porcine cardiac metabolites. Metabolites in cardiac extracts as collected from control and LAD group 4 weeks 
after LAD coronary artery occlusion and reperfusion. Data were corrected per mg of wet tissue weight and presented as 







































4.3.6 Effect of 60-minute LAD coronary artery occlusion /reperfusion on porcine blood metabolites 
 
1H- NMR spectroscopy analysis was also used to measure blood metabolites 4 weeks after LAD occlusion and 
reperfusion and compared to control. In total, 24 metabolites were annotated from NMR spectra as seen in 
figure (4.42). Certain significantly different metabolites included TCA cycle intermediates, ketone bodies, amino 
acids and carbohydrates. Taurine was significantly decreased in blood from LAD group, while ketone bodies such 






























Figure 4.42 (A and B) Porcine blood metabolites. Metabolites detected in blood samples as collected from control and LAD 
group 4 weeks after LAD coronary artery occlusion and reperfusion. Data are presented as mean ± SEM and analysed using 











































A porcine model of in vivo 60-minute LAD coronary artery occlusion and reperfusion was used to investigate 
post ischaemic cardiac remodelling, four weeks after the infarction. The main findings are concluded as the 
following: 
• Post ischaemic cardiac remodelling is associated with distinctive pattens of cardiac extracellular matrix 
fibrosis and structural disorganisation. 
• Remodelling is associated with significant changes in morphometry, cristae density and subpopulation 
distribution of the mitochondria.  
• Remodelling is associated with decreased ATP synthesis, antioxidant related cardiac proteins, fatty acid, 
and amino acids metabolic pathways. 
• Calcium handling proteins were decreased with post ischaemic cardiac remodelling. 
• There is increase in extracellular, structural, junctional and cytoskeletal proteins following post 
ischaemic cardiac remodelling in porcine heart. 
• Main signalling pathways identified with post ischaemic cardiac remodelling in porcine model were actin 
cytoskeleton, integrin and tight junction signalling pathways.  
• Remodelling is associated with increased levels of ketone bodies and selected amino acids in porcine 

















4.4.1 Disruption and remodelling of ECM during post MI cardiac remodelling 
 
LAD porcine hearts sections taken from the infarct area four weeks after ischaemia reperfusion revealed patten 
of extensive fibrosis (eightfold increase) due to collagen deposition (figure 4.2). The infarct area is also rich in 
noncardiomyocytes, as seen in light and electron micrographs, which included fibroblasts (and myofibroblast), 
endothelial cells, telocytes, macrophages, and infiltrating leukocytes, etc. These types of cells indicate ongoing 
infract remodelling and scar reorganisation.  
The effect of ischaemia reperfusion injury on coronary arteriolar wall thickness were marked by the substantial 
increase in the ratio of wall area to the total arteriolar area (figure 4.4). These arterioles (20-200 micron in 
diameter) play a major role in coronary resistance and blood flow regulation (Fedele, Severino et al. 2013), which 
contribute later to microcirculation dysfunction and deterioration of myocardial performance. The increased 
ROS production, with decreased NOS release, along with synthesis and release of proinflammatory mediators, 
and the shear stress from disruption of myocardial organisation consequently induce growth and hypertrophy 
of vascular smooth muscle cells SMC in tunica media (Severino, Amato et al. 2020). There is also increased in 
angiogenesis at this stage of cardiac remodelling, as most of the changes that occurs in coronary vasculature is 
secondary to endothelial dysfunction, which leads to release of vasoactive substances (such as endothlin-
1)(Böhm and Pernow 2007). The increased wall thickness is an indirect measure of increased wall stress and 
regional myocardial intramural pressure, leading consequently to vascular remodelling (Choy and Kassab 2009). 
Moreover, the intercellular interaction between telocytes and other cell types such as endothelial cells and stem 
cells appears to be involved in mediating angiogenic response and cardiac recovery post MI (Banciu, Cretoiu et 
al. 2017, Liao, Chen et al. 2021). As seen in the infarct area of LAD hearts, telocytes were characteristically similar 
to their counterpart in patients with heart failure, in which ultrastructural alterations such as telopodes 
shrinkage and shortening, and cytoplasmic vacuolisation were the most prominent features, indicating incessant 
cellular stress and disruption to their function (Cretoiu, Cretoiu et al. 2013, Galrinho, Manole et al. 2016).  
Several inflammatory cells such as macrophages and infiltrating leukocytes were seen in EM images of LAD pigs, 
while little to none observed in the control. At this stage of late proliferative phase, fibroblasts are extensively 
present in ECM, and activated myofibroblast are mediating matrix proteins and collagen synthesis. In healthy 
adult heart, the predominant types of collagen are type I (> 50% of total collagen), followed by type III (10–45%) 
(Eghbali and Weber 1990). In our work, subunits of collagen that were significantly as identified by the proteome 
output (figure 4.28). These included procollagen type V (α-1/2), collagen type I (α-1), collagen type III (α-1), and 
interestingly type XIV (α-1). Based on their mechanical properties, each subtype of collagen has different effect 
on scar characteristics. Work done by Asgari and Rusu et al. showed that deposition of type III and V collagen in 
between the stiff type I collagen appears to decrease the level of stiffness in the infract region at the end of 
proliferative phase (2-3 weeks), and therefore reduce the level of stretching on exerted on cardiomyocytes 
(Asgari, Latifi et al. 2017, Rusu, Hilse et al. 2019). Procollagen V α-1 and 2 chains, which are normally upregulated 
in developing hearts (Frangogiannis 2019), were also increased in post MI cardiac remodelling in porcine hearts 
(Barallobre-Barreiro, Didangelos et al. 2012) and in pressure overloaded myocardium in rats (Honda, Goto et al. 
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1993). It has been shown that procollagen V is linked to collagen fibril assembly and diameter in the myocardium 
(Lincoln, Florer et al. 2006). Little data is available regarding the role of collagen type XIV (α-1) during scar 
formation. This suntype is involved in organisation and integrating bundles of collagen, in addition to cellular 
adhesion to extracellular matrix, through its binding to CD44 on cell surface, and signal transduction through 
cytoskeleton via ankyrin protein (Schuppan, Cantaluppi et al. 1990, Ehnis, Dieterich et al. 1996, Bauer, Dieterich 
et al. 1997) .  
4.4.2 Disruption to mitochondrial structure and molecular content in parallel with decrease in 
energetics in post MI hearts 
 
Cardiac tissues collected from infarct area were used to monitor energetics and morphological, and molecular 
changes in the mitochondria. Morphometric measurements of different mitochondrial subpopulations did not 
reveal marked differences between the two groups, although, the measured areas of IF and SS mitochondria 
appeared larger in LAD group, possibly due to imminent swelling. There was also marked decrease in interfibrillar 
mitochondrial distribution in LAD porcine hearts compared to control (figure 4.8), which could be attributed to 
the imbalance between the energy demands and mitochondrial biogenesis as observed in decompensated HF 
(Rosca and Hoppel 2010). Although it is expected to observe a drop in cardiac performance (e.g. EF) in response 
to inadequate energy supply due to decreased IF subpopulation, the pigs used in this study had increased cardiac 
muscle mass, which could potentially compensate for cardiac death and loss in the infarct area (as seen in 
appendix). Nevertheless, mitochondrial cristae density, which reflects the degree of cristae separation, was 
decreased significantly in LAD group, indicating a decrease in mitochondrial respiratory rate, and therefore 
function (Rosca and Hoppel 2013). Similar findings were reported in patients with dilated and hypertrophic 
cardiomyopathies (Baandrup, Florio et al. 1981), as well as dogs with chronic ischaemic heart failure (Sharov, 
Goussev et al. 1998). This disruption to cristae is known to disrupt ability of mitochondria to produce ATP, which 
is evident in proteomic output of mitochondrial proteins, as most of these proteins had decreased expression in 
LAD group (figure 4.23). Mitochondrial ATP synthesis ability is known to diminish acutely after ischaemia 
reperfusion injury (Kuznetsov, Javadov et al. 2019), yet a persistent decrease in ATP synthesis proteins (subunits 
of F0/F1 complex) and creatine kinase-M type four weeks after IRI reflects the ongoing mitochondrial 
incapability to meet the energy demands. Similar findings were reported by Bienk et al who reported a decrease 
in mitochondrial ECT proteins such as complexes III and IV , 7 days after reperfusion in the ischaemic zone in the 
myocardium (Binek, Fernández-Jiménez et al. 2017).  
These defects in oxidative phosphorylation and ETC expose mitochondria to increased level of oxidative stress 
weeks after infarction. In this regard, antioxidant related proteins, as identified in this work, were significantly 
decreased in LAD pigs. For instance, both thioredoxin reductase 2 and glutathione reductase maintain redox 
balance in cells through reduction of the oxidised thioredoxin and glutathione, respectively (Biterova, Turanov 
et al. 2005, Deponte 2013), These findings reflect a continuous chronic state of oxidative stress after ischaemia 
reperfusion injury.  
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Moreover, there was impairment of mitochondrial fatty acids oxidation (decrease in enzymes such as acetyl-
coenzyme A synthetase and acetyl-coenzyme A acyltransferase 2). In heart failure, it is known that there is a 30-
40% decrease in ATP levels (Beer, Seyfarth et al. 2002) in addition to shift towards foetal metabolism, which is 
characterised by decreased mitochondrial oxidative capacity and increased dependence on glucose oxidation 
(Fillmore, Mori et al. 2014). Consequently, as the heart becomes less reliant on fatty acids oxidation due to 
mitochondrial remodelling, and with progressive decrease in glucose oxidation possibly due to insulin resistance 
(Riehle and Abel 2016), other metabolites such as ketone bodies are utilised to compensate for increasingly 
metabolic demands during heart failure, since heart is an omnivore and would extract substrates that are 
present at high concentration. As concluded from NMR results, ketone bodies such as acetoacetate and acetone 
were both elevated in porcine blood four weeks after ischaemia reperfusion injury. Similar findings were seen 
in patients with ischaemic heart disease, in which levels of acetone in breath was used as marker of severity of 
heart failure (Marcondes-Braga, Gutz et al. 2012). However, whether this increase of ketone bodies reflects a 
decrease in cardiac utilisation and extraction and/or increased systemic production is yet to be determined. 
Porcine blood metabolic profiling also showed a marked decrease in taurine in LAD group, while its level 
increased significantly in LAD cardiac tissue extracts. Taurine, a β-amino acid that is found in high levels in heart 
and muscle tissues, has many physiological roles including membrane stabilisation, regulation of Ca2+ sensitivity 
and contractile functions (Schaffer, Jong et al. 2010). Taurine is considered as one of the major osmolytes in 
cardiac tissue and it is involved in regulating sodium efflux through the action of sodium dependant taurine 
transporter (Suleiman, Rodrigo et al. 1992). Decrease in taurine suggests that this amino acid has been used by 
Na+ to exit the myocytes, since regulation of Na+ is important as Na+ /Ca2+ exchanger can be a source of Ca2+-
loading and cardiomyocyte death. Therefore, cardiomyocyte ability to regulate Ca2+ levels can be help in 
cardiomyocytes protection from death by apoptosis (Lewis, Littlejohns et al. 2014). Taurine has been shown to 
exert cardioprotective effects during IRI, as it decreases the levels of oxidative stress and the impact of ROS on 
mPTP opening (Schaffer, Jong et al. 2014). Additionally, taurine is involved in activation of Akt-dependent 
signalling, which results in inhibition of pores formation via PKC-ε activation, all of which are crucial for survival 
signalling (Takatani, Takahashi et al. 2004).    
Another amino acid, methionine (a sulphur containing amino acid) was markedly elevated in LAD group. This 
essential amino acid is involved in several metabolic processes, for example, thioredoxin and glutathione 
synthesis as well as proteins and polyamine metabolism (Dhar, Lysne et al. 2018). Since methionine is involved 
in diverse metabolic processes, it is therefore quite difficult to attribute this change to a single metabolic 
pathway. However, proteomics data from porcine model showed a significant decrease in mitochondrial 
thioredoxin and peptide-methionine (R)-S-oxide reductase. The latter is an oxidoreductase enzyme which plays 
a significant protective role from oxidative stress damage, caused by reactive oxygen species, through a 
reversible reaction to reduce the oxidized methionine to methionine using thioredoxin (Kantorow, Lee et al. 
2012). It is possible that the sustained oxidative stress and mitochondrial damage in LAD pigs might be the 
reason behind the reduced expression of these antioxidant proteins and the increased systemic methionine. A 
study by Hakuno et. al showed a positive correlation between elevated plasma amino acids levels such as 
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methionine and HF parameters (such as EF, Blood Natriuretic Peptide, etc) in patients with stage II heart failure 
(Hakuno, Hamba et al. 2015).  
Interestingly, taurine and methionine metabolism are linked through transulphuration pathway. Methionine is 
converted to homocysteine, which could be further metabolised by cystathionine β-synthase into cystathionine 
and later cysteine and taurine. Taurine could be also be synthesised from cysteine by the actions of 
cysteinesulfinic acid decarboxylase (CSD) and hypotaurine dehydrogenase (Hayes and Sturman 1981). Thus, an 
increase in methionine and a reduction in taurine level might be suggestive of a defect in this metabolic pathway 
during post ischaemic cardiac remodelling.  
 
4.4.3 Altered actin cytoskeletal proteins and possible role in cardiomyocytes survival signalling 
 
Measurement of sarcomeres in porcine hearts following post ischaemic cardiac remodelling did not detect 
significant differences in length. Similar finding was reported in patients with compensated and decompensated 
heart failure, in which sarcomere length was not markedly changed compared to hemodynamically normal LV 
function group, and did not correlate with heart failure severity (Rackley, Dalldorf et al. 1970). This could be 
explained by compensatory cardiac hypertrophy following ischaemia reperfusion injury, which is associated with 
increased number of sarcomeres (parallel addition) rather than elongation of sarcomere length (Mann and 
Bristow 2005). Maintenance of sarcomere structure is also linked to modifications in key sarcomere proteins 
such as titin, which spans the entire length of sarcomere, and mediates passive resistance through its extensible 
regions such as N2B subunit (Hanft, Korte et al. 2007), this protein was notably increased in LAD cardiac 
proteome.   
Proteomics study showed overexpression of several structural elements in z disc such as α-actinin-2, Cap Z 
subunits and desmin. It is known that dilated and hypertrophic cardiomyopathies are linked to abnormalities in 
z disc proteins (Yin, Ren et al. 2015). Desmin, for example, was elevated in failing myocardium due to dilated 
cardiomyopathy (Heling, Zimmermann et al. 2000). Interestingly, this protein was also hyperphosphorylated in 
LAD pigs at different phosphorylation sites, including phosphosite S31. This phosphosite was shown to promote 
desmin aggregation in ischaemic HF patients and mice model of pressure-overload induced HF (Rainer Peter, 
Dong et al. 2018). Additionally, overexpression of CapZ β subunits in a transgenic mice resulted in hypertrophic 
cardiomyopathy and distorted sarcomere architecture (Sequeira, Nijenkamp et al. 2014). However, some of z 
disc associated signalling proteins were decreased in LAD pigs. These included calsarcin-1, which normally 
represses calcineurin (a Ca2+-dependant phosphatase that is involved in cardiac hypertrophic signals)in 
cardiomyocytes (Posch, Thiemann et al. 2008). 
Many of cellular signal transduction in cardiomyocytes occurs in costamere and z disc through interaction with 
several ECM proteins as seen in figure 4.43. (Borg, Goldsmith et al. 2000). As seen in porcine proteome output 
analysis using IPA software, the role of epithelial adherens junction, actin cytoskeleton reorganisation and 
integrin signalling provide novel aspects to understand post ischaemic remodelling in the myocardium four 
180 
 
weeks after IRI.  The downstream cellular effect of these pathways involved in cytoskeletal rearrangement, actin 
polymerisation and stabilisation in addition to activation of PI3K/AKT signalling, which might be involved in 
cellular hypertrophy and survival in the heart (Sugden 2003). Gelsolin, another protein highly expressed in in 
integrin and actin cytoskeleton signalling pathways, is implicated in progression towards heart failure through 
its involvement in apoptosis mediated singling (Li, Shi et al. 2009). Inhibition of gelsolin through PI3K signalling 
appears to be protective from adverse remodelling (Patel, Zhabyeyev et al. 2018).  
 
Figure 4.43 Illustration of cardiac z disc proteins. PDZ-1LIM; one-PDZ and one-LIM domain protein, MYOZ2; myozenin 2 
(carsarin 1); MLP/CRP3; muscle-specific LIM protein/cysteine-rich protein 3, Cn; calcineurin, FHL2; four-and-a-half LIM 
protein, 2PDZ-3LIM; one-PDZ and three-LIM domain protein, MAPRs; muscle ankyrin repeat proteins, MURFs; muscle-
specific ring-finger proteins. From (Hoshijima 2006)  
4.4.4 Disruption to EC coupling, ionic cyclic proteins, and functional impairment 
 
Sarcoplasmic reticulum calcium uptake and cardiac contractile function are affected by SERCA2 expression levels 
in the heart (Periasamy and Huke 2001). The abnormal Ca2+ cycling, and decreased SR calcium content are 
observed with decreased expression of SERCA2. As measured from proteomic output, SERCA2 and its regulatory 
proteins, such as phospholamban were all downregulated in LAD group. Clinical and experimental studies have 
shown that deficient calcium uptake by SR is associated with decreased SERCA2a levels, which leads to impaired 
contractility as observed in heart failure (Kawase and Hajjar 2008, Lipskaia, Chemaly et al. 2010). Additionally, 
phosphoproteomics analysis showed 2.5-fold increase in SERCA2 phosphorylation at two novel consecutive sites 
(S50 and 51), however, the role of post translational modification on these sites and its effect SERCA2 activity 
are yet to be determined.  
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In summary, work on porcine model identified significant changes to mitochondria cristae density and 
interfibrillar distribution, in addition to identification of novel subtypes of collagen such as collagen XIV that 
were increased in ECM four weeks post IRI. Antioxidant related proteins and ATP synthesis proteins were 
decreased with post ischaemic cardiac remodelling, while cytoskeleton and z disc area appear to be heavily 
involved in cardiac response post MI, through upregulation and increased phosphorylation of certain proteins. 
Metabolomics data showed, amongst others, a decrease in taurine levels in blood with increased cardiac content. 
Certain aspects in this work are similar to rat model of permanent LAD coronary artery ligation, while others are 























































  5.1 Key similarities and differences between rodent and porcine model of cardiac injury 
 
Studies using animal models of coronary artery disease have massively contributed in the expansion of 
understanding to pathophysiological mechanisms that are implicated in myocardial injury and repair or 
protection, in addition to identification of several cellular targets such as inflammation, ROS, mitochondrial 
damage and calcium overload (Chorro, Such-Belenguer et al. 2009). Yet, little is known regarding long term 
manifestation of post ischaemic cardiac remodelling leading to heart failure across different species used in 
cardiovascular research at multiple cellular and systemic levels.  
 
This chapter presents the main features of post ischaemic cardiac remodelling in rodent and porcine models, 
focusing on key similarities and differences four weeks after myocardial injury. Although there are major 
distinctions between rats and pigs with regards to modality of cardiac injury, age and species-specific cardiac 
healing periods (i.e., being faster in small animals), the goal of this comparison is to highlight potential targets 
that seem to be involved in cardiac remodelling in hearts subjected to myocardial injury in two invaluable 
models. Based on these shared features, further experimental work could be performed to assess their 
significance in clinically relevant settings. However, there must be careful interpretation and comparison of data 
presented in chapters 3 and 4 as the aim is to provide distinct assessment of cardiac remodeling in two disparate 
experimental models. As explained in chapter 3, rodents are the first step used to study pathophysiology of 
cardiac disease and evaluate therapeutic interventions, due to a variety of reasons including cost and longevity, 
whereas the pig model is closer to human structurally and physiologically and has solid translational potential.   
 
It is important to consider the fundamental differences between the two models, as listed in table 5.1. In 
addition to differences in cardiac structure, the mode of cardiac injury induction, i.e., reperfusion injury, was 
only introduced in porcine model but not in rats, as permanent ligation of the LAD coronary artery occurred. 
Moreover, the area used for proteomic, metabolomic and energetic analyses in rats was taken from the apical 
region, distal to the site of injury, whereas in pigs, the myocardial tissues were taken from the infarcted area. 
Since scars post MI mature faster in small animals like rodent in comparison to pigs, therefore deriving results 
from the exact same area in rodent heart could falsely include collagen-rich, hypcelleularised myocardial tissue 
that could potentially interfere with proteomics and NMR outputs. Furthermore, it is important to note that the 











Table 5.1 Main differences between rodent and porcine hearts. 
 
 
Structural remodelling in rodent and porcine models of cardiac injury 
Structural remodelling in rodent and porcine models four weeks after cardiac injury showed cellular changes 
that were characterised by disruption of ECM architecture, in addition to presence of several infiltrating 
noncardiomyocytes such as fibroblasts and telcoytes, as observed in EM images. Both models showed disruption 
to mitochondrial cristae density, by which there was increased ratio of intercristea area to the total 
mitochondrion area, which indicates disruption to mitochondrial respiration and function four weeks after injury. 
Similar findings of decreased mitochondrial matrix density were observed in canine model of chronic heart 
failure and clinically in patients with hypertrophic cardiomyopathies (Baandrup, Florio et al. 1981, Sharov, 
Goussev et al. 1998, Rosca and Hoppel 2013). Table 5.2 lists comparisons of key structural and ultrastructural 







Rodent heart Porcine heart References 
Heart rate (beats per 
minute) 




pressure (mm Hg) 
124 > 90 researchservices.umn.edu 
(Gangwar, Kumar et al. 
2014) 
Collateral blood flow  More advanced collateral 





(Seiler, Stoller et al. 2013) 
Action potential Short action potential, 
lacks a plateau phase. 
Similar to human action 
potential. 
(de Boer and Stengl 2017) 
Coronary circulation Different from humans, 
e.g., Left Coronary Artery 
(LCA) has few branches. 
Analogous to humans. (h-Ici, Jeuthe et al. 2015) 
Calcium cycling Calcium removal is less 
dependent on Na+/Ca2+-
exchanger activity 
Calcium cycling shares 
similar characterises to 
humans.   
(Hasenfuss 1998) 




Table 5.2 Comparison of structural and ultrastructural measurements as taken from infarcted and left ventricular 
myocardium in rodent and porcine models of cardiac injury 4 weeks after intervention (Rat: LAD coronary artery ligation, 
pigs: LAD coronary artery occlusion and reperfusion). Direction of change reflects measurement in LAD group compared to 












Molecular remodelling in rodent and porcine models of cardiac injury 
Although there are differences in proteome outputs between the two species, there were, however, selected 
categories in which proteins could be classified and compared amongst rats and pigs. Molecular alterations in 
rodent and porcine models reflected the state of mitochondrial dysfunction, as both models 
exhibited significant degree of mitochondrial damage. For examples, proteins involved in mitochondrial ATP 
synthesis and respiration were diminished. It has been shown that the inability of mitochondria to meet energy 
demands during remodelling leads to disease progression towards heart failure, known as energy starvation 
hypothesis (Zhou and Tian 2018). ATP synthesis machinery in mitochondria is disrupted by decrease in 
expression of ATP synthase subunits and cofactors.  Pigs had several components the ATP synthesis machinery 
down regulated unlike the rat, which only had on significantly downregulated component (ATP synthase 
mitochondrial F1 assembly factor). Moreover, antioxidant related proteins were decreased 
reflects dysregulation in redox homeostasis and increased oxidative stress four weeks after injury.   
Molecular remodeling involved many of structural proteins that were overexpressed in LAD group in rats and 
pigs. These proteins are located at several location such as z-disc and cytoskeleton. For example, spectrin α 
chain, non-erthrocytic 1 (encoded by SPTAN1), which is found in z disc and sarcolemma, is upregulated with 
cardiac injury. Gap junction proteins (connexins) are critical in intercellular connection and synchronized cardiac 
contraction, and as shown in rats and pigs proteome outputs, it had decreased expression four weeks after 
cardiac injury. This comparison emphasises on the role of z-disc and costamere area, as it is not only restricted 
 
Rodent model Porcine model 
Gross structural measurements (LM) 
Cardiac fibrosis ↑ ↑ 
Arteriolar wall thickness ↑ ↑ 
Ultrastructural measurements (EM) 
Cardiomyocyte area  ━ ━ 
Mitochondrial cristae density ↑ ↑ 
Mitochondrial subpopulation 
distribution 




↑ in aspect ratio 
(length/width) 
━ 
Sarcomere length ━ ━ 
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as structural components of sarcomeres, but rather a location for cellular signalling, which might be related 
to cardiac contractility and performance, as many of z-disc proteins translocate to cytoskeleton in response to 
pathological stressor (Frank and Frey 2011). 
Finally, there was increased phosphorylation at different phosphorylation sites in rodent and porcine data While 
there are several phosphoproteins exhibited increased phosphorylation, only selected phosphoproteins were 
shared in both models. These included catenin α, HSP 90, AKAP12 and nexilin/nebulette. Table 5.3 summarises 
key changes between rodent and porcine models.  
Table 5.3 Comparison of proteomic and phosphprotemics selected data, as taken from infarcted and left ventricular 
myocardium in rodent and porcine models of cardiac injury 4 weeks after intervention (Rat: LAD coronary artery ligation, 
pigs: LAD coronary artery occlusion and reperfusion). Direction of change reflects measurement in LAD group compared to 









Rodent model Porcine model 
Proteomics (with proteins examples) 
ATP synthesis proteins ↓ (ATP synthase F1 complex 
assembly factor 1) 
↓↓ (ATP Synthase F(0) Complex 
Subunit B1) 
Antioxidant related proteins ↓ (glutathione peroxidase 1) ↓↓ (Thioredoxin Reductase 2) 
Z disc proteins ↑↑ (Spectrin alpha chain, non-
erythrocytic 1) 
↑ (Plectin) 
Ion transport proteins ↑ (Voltage dependent L type calcium 
channel subunit alpha) 
↓ (Voltage dependent L type 
Calcium Channel subunit Beta 2) 
Phosphoproteomics (with phosphosites examples) 
Calcium cycling  ↑ (Ryanodine receptor 2, S1700) ↑ (SERCA2, S50&S51) 
Structural proteins ↑ (Tight junction protein 2, S1132) ↑ (Tensin-1, S911, S1363,T1310) 
Signalling proteins ↑ (Heat shock protein HSP 90-alpha, 
S263) 




Metabolic remodelling in rodent and porcine models of cardiac injury 
As presented in table 5.4, metabolomics analysis using NMR spectroscopy revealed significant increase in blood 
acetone level in rats (compared to baseline levels) and pigs (in comparison to control). In addition, blood from 
porcine LAD group had increased level of acetoacetate (another ketone body). Despite differences and timing in 
collection, ketone bodies, where significantly increased in blood samples in both models. 
Ketone bodies metabolism in post ischaemic cardiac remodelling needs to be further explored in animal models, 
since it is extremely difficult to separate patients with CAD from underlying metabolic syndrome that could 
potentially ameliorate systemic production and utilisation of ketone bodies. Furthermore, another metabolite 
which is taurine only decreased in blood from porcine LAD group and elevated in porcine cardiac extract. Rodent 
taurine levels in blood and cardiac extract were not significantly change. As for cardiac energetics, only porcine 
LAD group had significant increase in total adenine pool, due to increased AMP levels.  
Table 5.4 Selected blood and cardiac metabolomics, and cardiac energetics measurements in rodent and porcine models of 
cardiac injury 4 weeks after intervention (Rat: LAD coronary artery ligation, pigs: LAD coronary artery occlusion and 
reperfusion). Direction of change reflects metabolites/energetics abundance in LAD group compared to control (or SHAM). 







Rodent model  Porcine model  
Metabolomics (NMR) 
Metabolite Blood Cardiac extract  Blood Cardiac extract  
Taurine ━ ━ ↓ ↑ 
Lactate ━ ━ ND ↓ 





ND Acetoacetate ━ ↑ 
Arginine ↑ ━ 
Left ventricular/apical energetics (HPLC) 
Energy charge ━ ━ 





Post ischaemic cardiac remodelling following acute infarction is associated with alterations at the molecular, 
metabolic, and structural levels. In this work, animal models of cardiac injury following acute myocardial 
infarction were adopted using in vivo LAD coronary artery ligation in rodents, and balloon occlusion (inflation) 
and deflation in LAD coronary artery porcine hearts. Histological, proteomics, and metabolomic studies, in the 
myocardium and blood, were performed to detect permutations that are associated with post ischaemic cardiac 
remodelling in those models.  
In the rodent model of chronic sustained ischaemia, there was significant decrease in cardiac antioxidant 
proteins in the as well as fatty acids and amino acids metabolism enzymes. While calcium handling proteins were 
significantly upregulated. Key signalling pathways identified in this model involved Protein Kinase A, 
Phospholipase C (PLC), and Gamma G beta protein signalling pathways. Metabolomics analysis showed 
accumulation of blood acetone four weeks after cardiac injury. Cardiac morphometric analysis showed increase 
in mitochondrial cristae separation, in addition to aspect ratio of interfibrillar mitochondria in infarct group, but 
no significant changes in sarcomere length was noted in comparison to SHAM group.  
In the porcine model of ischaemia reperfusion injury, there was significant decrease in cardiac ATP synthesis, 
antioxidant cardiac proteins, fatty acid, and amino acids metabolic proteins. Main signalling pathways identified 
with post ischaemic cardiac remodelling in this model were actin cytoskeleton, integrin and tight junction 
signalling pathways. Metabolomics analysis revealed increased ketone bodies levels in porcine blood four weeks 
after the cardiac injury, and taurine in porcine cardiac extracts. Morphometric analysis showed decreased 
interfibrillar mitochondrial distribution, increase in mitochondrial cristae separation in the infarcted group, but 
no detected differences with regards to sarcomere length.  
Translational aspects 
As presented in this work, ketone bodies such as acetone and acetoacetate were identified markedly in blood 
following myocardial injury. Therefore, blood ketone bodies could be targeted as potential biomarker in CAD 
patients and correlated to adverse cardiac remodeling. Nonetheless, cardioprotective effects of taurine and 
whether a decreased in blood taurine subjects those patients to increased risk of heart failure remain critical 
aspects for further investigation.  
As discussed in previous chapters, it is known that z disc and cytoskeleton are massively changed with dilated 
and hypertrophic cardiomyopathies, however, the role of ischaemia and ischaemia reperfusion injury in 
modulating cytoskeletal rearrangement, modification of z disc proteins expression or phosphorylation in 
patients with HF failure (with reduced or preserved ejection fraction), remains relatively unknown. The main 
signaling pathways in rodent and porcine models provided different perspective to identify potential targets in 








Probably the most notable limitation present in this work is the inability to apply the same surgical procedures 
to both models. The rodent model involved chronic cardiac remodelling following sustained ischaemic injury (as 
in coronary artery ligation) with no reperfusion (permanent ligation). In both models, the cardiac injury was 
done on healthy hearts with no apparent systemic vascular or metabolic diseases, which excludes the cellular 
and molecular changes due to diseased coronary vasculature, as seen in progressive atherosclerotic plaque 
build-up in CAD patients. In rodent model, however, the cardiac injury did not precisely reflect the 
pathophysiological mechanisms of post-MI remodelling attributed to ischaemia reperfusion injury, as the 
procedure only included chronic sustained ischaemic insult without reperfusion.  
Infarct healing is also different between small animals like mice and rats compared to large models. There are 
inconsistencies reported in literature with regards to the exact point by which scar maturity is thought to occur, 
as different phases of cardiac remodelling overlap over time after injury. In mice, scar healing is thought to be 
complete 21 days post MI, while in rats it averages around 3 weeks, and later (6 weeks onwards) in porcine and 
canine models (Jugdutt, Joljart et al. 1996, Yang, Liu et al. 2002, Wu, Yin et al. 2011, Houser, Margulies et al. 
2012, Aronsen, Espe et al. 2017). Therefore, 4 weeks in rodent and porcine models are related to chronic stages 
of cardiac remodelling (late proliferative and early maturation). Ideally, assessment of cardiac remodelling at 
different stages would assist in better understanding and characterisation of pathophysiological mechanisms 
involved.    
Sex differences between species is also a limitation, since male Wistar rats were only used in the rodent model 
of cardiac injury, it was not possible to assess the variation in cardiac remodelling in females compared to male 
rats. Additionally, it should be taken in consideration that male rats were compared against female pigs in 
selected molecular and metabolic aspects. It is known that susceptibility to cardiovascular disease in human is 
lower in females, which is a similarity that is shared across other species as well (Patten 2007). 
 
Tissue collection  
It was an obstacle to obtain all blood and cardiac tissues from a single set of rats, so many were outsourced from 
separate group of LAD rats following same surgical procedure, and these were compared against either their 
baseline levels (blood metabolomics) or healthy control (cardiac tissues for light microscopy). OCT embedding 
of cardiac tissues was not the best option to study the structure of cardiac tissue as desired, since processing 
(sectioning and staining) resulted occasionally in samples loss, inadequate stain uptake, thus there has been 
several troubleshooting efforts to obtain best quality of images. 
Sample size and characteristics  
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This study used the minimum required number of animals (n=5 in rats, and 4 in pigs, per group) in accordance 
with the 3 R’s rule (Refinement, Reduction and Replacement). However, increased sample size that facilitate 
collection of tissues over days or weeks for both models, in addition to implementation of diseased experimental 
models (e.g., atherosclerosis or diabetes) or with co-morbidities to investigate the vulnerability to IRI and 
cardioplegic arrest, and test cardioprotective interventions would assist in detection of early changes in 
biomarkers that could predict adverse cardiac remodelling after extended periods. 
NMR spectroscopy 
NMR intrinsic insensitivity is a major issue and drawback to this technique, in which many of the metabolites 
were not detected or distinguished from other noise in the spectra. Unlike other methods such as gas or mass 
spectroscopy. Despite this, there are continuous efforts to enhance the technique sensitivity to detect wide 
range of metabolites. Metabolomics identification and annotation were challenging task since little or 
underdeveloped databases are available for those species, unlike human metabolome. 
Proteomics 
With porcine proteome, the lack of available databases with completed and integrated porcine proteome 
database made it difficult to characterise several proteins without relying on human database as reference. 
Therefore, proteomics results were generated based on human proteome, a step which is necessarily performed 
to decrease the number of uncharacterized proteins in porcine data, even though there are advances in porcine 
gene entries, they are not yet fully completed. Phosphorylation sites databases are not also fully developed for 
porcine phosphoproteome. 
Electron Microscopy  
Due to inability to perfuse a porcine heart with EM fixative, cardiac samples that were sent for EM processing 
and embedding have been fixed with conventional fixation. It resulted to samples loss in many cases or a 
decrease in contract sometimes. 
Covid-19 impact 
This work should have included patients data, as a project grant was given to metabolomics study to assess 
metabolomic profile in STEMI patients and compare these results with pigs and rat. However, since the 
pandemic, ethical approval was halted as non-covid related clinical trials were stopped during pandemic.  
5.4 Future direction 
Based on data from this work, it is planned to continue metabolomics study on patients with coronary artery 
disease to detect metabolic profiles after MI and during cardiac remodelling. Moreover, for porcine and rodent 
models, future work would be inclusive to molecular and metabolic profiles from borderzone 
and nonischaemic areas of the heart and compare it accordingly with infarcted region in both models. 
Additionally, measurement of certain proteins such as collagen XIV and z disc proteins using Western Blot from 
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infarcted areas in rodent and porcine hearts to validate their significance in post ischaemic cardiac remodelling. 
Taurine and ketone bodies levels will be assessed at their baseline levels and after myocardial injury, to monitor 
their fluctuations in blood and cardiac tissues. Moreover, collection of blood samples at several time points to 
ensure the detection of early blood metabolites that are altered in accordance with functional parameters and 
cardiac enzymes release. A comparative study could be also drawn using ex-vivo Langendorff perfusion of whole 
rat heart to identify acute changes at selected time points that are manifested at the functional and molecular 
levels following ischaemia reperfusion injury and/or sustained ischaemia by LAD coronary artery ligation or 
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1- CMR measurement in porcine model 
Cardiac imaging was taken 2 days and 4 weeks after surgery using multi-slice cine CMR (Siemen Healthcare 
Limited, Magnetom 3T PRISMA, Erlangen Germany) at the Translational Biomedical Research Centre in 
University of Bristol. Thirty images throughout the cardiac cycle were obtained. Cardiac contours were 
manually drawn and analysed by Dr. E Sammut using software package CVI42 (Calgary, Canada, V5.6.6). 
Full width half maximum (FWHM) method was used to measure myocardial scar weight in grams. This 
technique follows an initial region that extends to include pixels with a signal intensity greater of 50% of a 
user selected point. Then, the maximum intensity (MX) expected in the initial region is computationally 
calculated. Consequently, the infarcted area is measured as the total area that presents with more than 
50% of the initial region’s maximum intensity (Area infarcted= MX* 0.5). 
 Pigs undergoing closed-chest balloon LAD catheter inflation for 60 minutes and deflation had on average 21 
grams of the infarct (using CMR) two days after surgery, and 8.5 grams at termination after weeks (Figure 10). 
No major difference in the percentage of left ventricular ejection fraction was observed (Δ %EF = 9.67%) as 



























Day 2 Week 4
Figure A.1 Time-dependent changes in infarct size in pigs. Bar chart demonstrating infarct size (g) in pigs 2 
















Day 2 Week 4
Figure A.2 Change in ejection fraction in pigs after IRI. Bar chart demonstrating the percentage of Left Ventricular 




2- Cardiac Troponin I measurement  
Cardiac troponin-I (c-TnI) assay was measured by Mr. D Lopez using an ultra-sensitive pig cardiac troponin 
enzyme-linked immunosorbent assay (CTNI-9-US Life Diagnostics, PA). Samples were diluted following 
manufacturer instruction and each of the plasma sample was analysed in duplicates.  
This method uses a rabbit anti-TnI polyclonal antibody for the solid phase on the microfilter plate that binds to 
the Troponin-I in the sample. When a goat anti-cTnI peptide specific polyclonal antibody conjugated to 
horseradish peroxidase (HRP) is added to the plate, Troponin I becomes sandwiched between the two antibodies. 
Detection of cTnI concentration is achieved through the addition of Tetramethylbenzidine (TMB reagent) which 
binds to HRP, resulting in the development of a blue colour, which is later stopped by a stop solution (HCl), 
turning the reaction into yellow. Absorbance is then read at 450 nm using a 96-microplate reader (Opsys MR™, 
DYNEX Technologies, Inc. VA) and the concentration is derived from the standard curve. 
High sensitivity cardiac Troponin I measurement from plasma samples showed peaked levels at four hours after 




































LAD 1 LAD 2 LAD 3 LAD 4
Figure A.3 Cardiac injury following acute MI. Serial Troponin I measurements taken at baseline 
(before ischaemia), at reperfusion and selected time intervals. 
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Sufficient pump function of the heart is essential to ensure delivery of oxygenated blood to heart muscle and to 
other organs.  
Severe coronary artery disease results in acute reduction of blood (ischaemia) to the heart, which, if not treated 
promptly can lead to death of heart muscle cells (infarction). However, re-introducing blood to an ischaemic 
area (via the placement of stents in coronary arteries called angioplasty) can further augment the ischaemic 
damage (reperfusion injury). Unlike other muscle types, cardiac muscle cannot generate new heart cells to 
replace the dead ones. Subsequently, the infarcted areas undergo gradual change involving metabolic, 
molecular and structural alterations which eventually can lead to a varying degree of impaired pumping function 
of the heart (heart failure). Heart failure leaves patients prone to dangerous heart rhythms, fluid overload, 
repeated hospital admissions and ultimately death. Therefore, it is important to understand the systemic and 
cardiac changes that are associated with remodelling into heart failure in order to identify early biomarkers of 
cardiac impairment so that appropriate therapeutic interventions can be designed. 
Recent work in Bristol using experimental models of heart failure (rodent & pig) following acute ischaemia have 
shown interesting changes in selected blood metabolites when measured immediately after infarction (before 
heart failure) and after the onset of heart failure. Work is underway to establish if the changes in any of these 
metabolites can predict the severity/incidence of heart failure. Furthermore, identifying metabolic pathways 
implicated in the development of heart failure will help in the design of targeted therapeutic interventions.  
We plan to extend the work on experimental models to patients with ST elevation myocardial infarction to 
identify metabolites that change from acute infarction to failure and correlate with the function of a failing heart. 
The information obtained from this exploratory focused study will be used to inform design of a future larger 
study. Blood samples will be collected to monitor metabolites and markers of cardiac injury and inflammation. 
Patients will also have an echocardiogram – an ultrasound which assesses the pumping of the heart - within 
48hrs of the heart attack and at 6-8 weeks according to standard care.    
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Background and rationale 
 
Coronary heart disease is the most common cause of myocardial infarction (MI). With modern treatments, most 
patients now survive the acute episode. However, a significant proportion of patients will develop heart failure 
post MI due to cell death and adverse myocardial remodelling. The British Heart Foundation estimate that there 
are currently approximately 900,000 people living with heart failure in the UK. This leads to a significant 
deterioration in quality of life, repeated admissions to hospital, increased incidence of arrhythmia and sudden 
cardiac death and high mortality rates.  
MI is typically a consequence of atherosclerosis where there is progressive narrowing of a coronary artery 
leading to a demand and supply imbalance which renders areas of the myocardium ischaemic. During ischaemia, 
sustained cardiomyocyte deprivation of oxygen and metabolites results in disruption of intracellular metabolic 
and ionic homeostasis, leading to calcium loading and cardiomyocyte death. Timely reperfusion of the ischaemic 
zone via primary percutaneous coronary intervention (PPCI) can salvage some of the myocardium but can cause 
reperfusion injury, and as cardiomyocytes are terminally differentiated, regeneration of infarcted tissue is 
limited. Damaged myocardium undergoes a state of cleaning and repair via apoptosis and the migration of 
inflammatory cells to the infarcted area [1].  The inflammatory response (systemic and innate) plays a central 
role in cardiac remodelling post MI. These inflammatory changes are also likely to be reflected in changes in 
blood metabolites. These may vary depending on the stage and severity of remodelling from acute 
(ischaemia/reperfusion) to chronic disease (heart failure). Remodelling involves a number of metabolic, 
molecular and cellular alterations [2, 3] which lead to fibrosis and ultimately impaired ability of the heart to 
meet its intensive functional demands [4].  
There is heterogeneity in the degree of adverse remodelling between patients, and there is currently no way of 
predicting which patients will be most affected.  
Although the mechanisms underlying acute ischaemia and reperfusion injury are well understood, we know little 
about the chronic processes leading to subsequent heart failure as a result of adverse remodelling.  Importantly, 
the link between acute injury and characteristics of heart failure is not known. Understanding and identifying the 
underlying triggers of heart failure after an ischaemic injury will help in design of therapeutic interventions. Since 
both acute injury and chronic remodelling involve metabolic alterations, metabolites are an emerging area of 
research to investigate the progression of heart failure and to guide therapeutic strategies [5, 6]. In particular 
these biomarkers are likely to improve heart failure prognostication [7] and early targeting of heart failure 
treatments.  
Recent clinical trials have investigated alterations in blood metabolome in cardiovascular diseases including 
hypertrophy, coronary disease, diabetic cardiomyopathy, heart failure, atrial fibrillation and cardiac 
resynchronization therapy [7-14]. Recent studies have also reported changes in the metabolome in ST-segment 
elevation myocardial infarction (STEMI) patients [15, 16]. However, little work has been done to investigate the 
changes in the metabolome following acute MI and during progression in heart failure [17]. Furthermore, most 
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studies tend to include a heterogenous population of patients (gender, age etc) with comorbidities which are 
known to have a metabolic impact (e.g. diabetes and kidney disease). Researchers at Bristol have recently 
developed experimental models (rodent and pig) of MI with subsequent remodelling and heart failure to address 
this issue. The large animal model of acute MI has been established by Dr Tom Johnson (the Principal 
Investigator) at the Translational Biomedical Research Centre, University of Bristol. In this porcine model, four 
weeks post in-vivo LAD balloon induced MI, structural, molecular (proteins and phosphoproteins), metabolic 
(circulatory metabolites levels in blood) profiles were observed. Key findings involved detrimental modulation 
of Z-disc and cytoskeletal proteins, reduction of mitochondrial and antioxidant enzymes, and elevation of blood 
ketone bodies and methionine and reduction of taurine (unpublished data). Moreover, similar changes observed 
in rats four weeks after acute LAD ligation, included increased phosphorylation of Z-disc proteins and an increase 
in blood acetone. Therefore, this exploratory study has been designed to see if these findings translate to a 
STEMI patient population. The porcine model of MI is based on a population of animals with healthy hearts, it is 
unclear if these changes will be observed in a population of patients with coronary artery disease.  
It is evident that there is a need to investigate changes in patients’ metabolites acutely post MI and also during 
remodelling into heart failure. This will allow discovery of any metabolomic alterations that correlate with 
cardiac impairment and maladaptation, and aid identification of molecular pathways that could be targeted to 
aid the design of therapeutic interventions. Given the issue of heterogeneity in patients, it is important that in 
the first instance a focused small group of patients are selected to monitor changes in cardiac function and blood 
metabolites following acute infarction and during remodelling into heart failure. The aim of this exploratory 
study to inform design of a future larger study. 
 
Aims 
This exploratory study aims to monitor alterations in cardiac function, blood metabolites and markers of cardiac 
injury and inflammation in a selected group of STEMI patients (n=30) both acutely post MI and following 
remodelling into heart failure.  
 
Hypothesis  
1- A distinct metabolomic profile will be observed in STEMI patients who develop severe left ventricular 
adverse remodelling compared to STEMI patients that do not develop adverse remodelling, compared 
to controls. 
 
2- A distinct profile of markers of inflammation / oxidative stress will correlate with the degree of left 
ventricular adverse remodelling in a group of STEMI patients, compared to a group of age-matched 




Assessment and risk  
Patients will only be included in the study if they meet the inclusion criteria, do not fulfil any of the exclusion 
criteria and once they are deemed clinically stable by their clinical team.   
 
Standard care of patients after with STEMI includes:  
- Blood samples taken at the time of primary percutaneous coronary intervention (PPCI) 
- Blood samples taken 24 to 48hrs following admission 
- Echocardiogram within 48hrs of admission 
- If significant left ventricular impairment, an echocardiogram 6-8 weeks following discharge from 
hospital 
- Clinic appointment 4-6 weeks following admission 
 
The only additional test required for this study will be 1 additional venepuncture taken at the time of the follow 
up clinic appointment 6-8 weeks following PPCI. 
 
Objectives 
1) Primary objective:  Observation of metabolomic profile acutely post MI and during remodelling into 
heart failure to identify ones that correlate with left ventricular negative remodelling.  
 
Sample size 
As this is an exploratory study to inform design of a future larger study, no formal power calculation has been 
performed. However, previous work within the group using a large animal model of MI and from relevant 




Inclusion criteria:  
1. Male patients  
2. Anterior STEMI (due to occlusion of left anterior descending artery (LAD))  





1. Congenital heart disease 
2. Pre-existing pacing device (pacemaker or ICD). 
3. Atrial fibrillation 
4. Bystander coronary disease requiring intervention  
5. Co-existent comorbidities such as diabetes, disease of the kidney, liver and peripheral vasculature, or 
chronic inflammatory conditions.  
 
Selection of control participants: 
1. Must not meet exclusion criteria mentioned above. 
2. No history of cardiac disease, therefore normal LV function will be assumed. They will not undergo 
echocardiography. 
 
Consent/ screening  
Potentially eligible patients will be identified by screening emergency STEMI admissions. All patients admitted 
with an anterior STEMI will have 1 extra blood sample taken at the time of the primary percutaneous coronary 
intervention (PPCI) which will be stored. 
Within 48hrs of their admission, a member of the research team will approach eligible patients providing them 
with a patient information leaflet containing full details of the study, discuss the study with them, and answer 
any questions they may have. Patients will be given as much time as necessary to consider their participation in 
the study. Informed consent will be obtained by a member of the research team. If patients are deemed to be 
ineligible or if they do not consent, the stored sample will be disposed of in accordance with local policy. 
 
Method 
As part of clinical routine care, STEMI patients attending the Bristol Heart Institute will be treated as follows:  
1. Upon arrival, blood tests will be performed to measure troponin T, C-reactive protein, full blood count, 
renal and liver function, clotting screen & lipid profile. 
2. At 24-48 hours post admission, blood will be collected again to measure injury and stress markers 
including troponin T, brain natriuretic peptide & C-reactive protein. 
3. Trans-thoracic echocardiogram at 24-48 hours post admission (following angioplasty and prior to 
discharge) 
4. Follow up appointment 4-6 weeks post discharge which will include a repeat trans-thoracic 




In addition to standard care described above, we propose to additional blood samples as follows:  
5. Additional 5ml blood taken on arrival (at time of standard venepuncture) 
6. Additional 5ml blood taken at 24-48 hours (at time of standard venepuncture) 
7. Additional 5ml blood taken at 4-6 week follow up appointment (additional venepuncture).  
 
Withdrawal criteria  
Patients will be consented prior to discharge, if they withdraw consent then their data will not be used, and all 
samples stored will be disposed of. 
 
Data storage and analysis 
Data will be collected and retained in accordance with the Data Protection Act 1998. 
 
Data will be pseudo-anonymised, stored on a secure NHS server as well as a secure University of Bristol server 
and will only be accessible to the research team.  
 
All other data collected will be pseudo-anonymised and held on a password protected database stored on a 
secure NHS server accessible only to the research team. 
 
A secure electronic ‘key’ with a unique participant identifier, and key personal identifiers (e.g. name, date of 
birth and NHS number) will be password protected and held on a secure NHS server. 
 
Study documents will be retained in a locked cabinet in a locked office in The Bristol Heart Institute, only 
accessible to the research team, during and after the trial has finished. All source documents will be retained for 
a period of five years following the end of the study.  
 
Statistical analysis will be performed by the group who have experience in analysing metabolomic data.  
 
Costs 




Safety Reporting  
Adverse events will be recorded and reported in accordance with University Hospitals Bristol’s Research Safety 
Reporting SOP.  
Adverse events will be recorded from the beginning of cardiac pacing until the end of the cardiac pacing 
procedure.  
An adverse event, is defined as serious if it: 
(a) results in death,  
(b) is life-threatening,  
(c) requires hospitalisation or prolongation of existing hospitalisation,  
(d) results in persistent or significant disability or incapacity,  
(e) consists of a congenital anomaly or birth defect. 
 
Monitoring and Audit 
 
The study will be monitored in accordance with University Hospitals Bristol’s Monitoring and Oversight of 
Research Activity SOP. All trial related documents will be made available on request for monitoring and audit by 
UH Bristol, the relevant Research Ethics Committee and any other licensing bodies as applicable. 
 
Quality Control 
Where applicable, a random sample of 10% of CRFs will be checked, by the trial Research Team or R&I monitor, 
against entries within the database and with the source data for quality purposes. The percentage checked will 
be increased if a significant error rate is found.  
 
Data Handling and Protection  
The database will be designed so as to protect patient information in line with the Data Protection Act 1998.  
Trial staff will ensure that the participants’ confidentiality is maintained through protective and secure handling 
and storage of patient information at the trial centres (as relevant). All documents will be stored securely and 
only accessible by trial staff and authorised personnel. Data will be collected and retained in accordance with 
the Data Protection Act 1998.  
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Storage of records 
Study documents (paper and electronic) will be retained in a secure location during and after the trial has 
finished. All essential documents, including patient records and other source documents will be retained for a 
period of 5 years following the end of the study. Where trial related information is documented in the hard copy 
medical records – those records will be identified by a ‘Do not destroy before dd/mm/yyyy’ label where date is 
5 years after the last patient last visit. Where electronic records are in use, trust policy will be followed. 
Indemnity  
This is an NHS-sponsored research study. For NHS sponsored research HSG(96)48 reference no. 2 refers. If there 
is negligent harm during the clinical trial when the NHS body owes a duty of care to the person harmed, NHS 
Indemnity covers NHS staff, medical academic staff with honorary contracts, and those conducting the trial. NHS 
Indemnity does not offer no-fault compensation and is unable to agree in advance to pay compensation for non-
negligent harm. Ex-gratia payments may be considered in the case of a claim. 
Authorisations 
The study will be performed subject to favourable opinion/ authorisation/permission or equivalent from all 
necessary regulatory and other bodies. This includes but is not limited to REC, MHRA, HRA, NHS trusts.  
Research Governance Statement 
This study will be conducted in accordance with:  
• International Conference for Harmonisation of Good Clinical Practice (ICH GCP) guidelines. 
• UK Policy Framework for Health and Social Care  
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